Synthesis and application of chiral dienes and chiral imidates as ligands for transition metal catalysis by Noël, Timothy
 Faculty of Sciences 
Department of Organic Chemistry 
Laboratory for Organic and Bioorganic Synthesis 
 
Synthesis and application of chiral dienes 
and chiral imidates as ligands for 
transition metal  catalysis 
 
 
 
 
 
 
Timothy Noël 
Dissertation in order to obtain the degree of Doctor of Science: Chemistry. 
Promoter: Prof. Dr. Johan Van der Eycken 
-2009- 
Faculty of Sciences 
Department of Organic Chemistry 
Laboratory for Organic and Bioorganic Synthesis 
Synthesis and application of chiral dienes 
and chiral imidates as ligands for 
transition metal  catalysis 
Ph.D. dissertation in order to obtain the degree of Doctor of Science: 
Chemistry 
by 
Timothy Noël 
Born 2 september 1982, Aalst. 
  
Promoter:    Prof. Dr. Johan Van der Eycken (Ghent University) 
Reading Commission:  Prof. Dr. Johan Van der Eycken (Ghent University)
Prof. Dr. Carsten Bolm (RWTH Aachen, Germany) 
    Prof. Dr. Erik Van der Eycken (K.U. Leuven) 
Members of the Jury: Prof. Dr. Katrien Strubbe (Chairman, Ghent University) 
    Prof. Dr. Johan Van der Eycken (Ghent University) 
Prof. Dr. Carsten Bolm (RWTH Aachen, Germany) 
    Prof. Dr. Erik Van der Eycken (K.U.L., Leuven) 
    Prof. Dr. Kourosch Abbaspour Tehrani (V.U.B., Brussel) 
    Prof. Dr. Pierre De Clercq (Ghent University) 
    Dr. Sam Verbrugghe (Ghent University) 
     
     
     
i 
CONTENTS 
CONTENTS i
ACKNOWLEDGEMENTS iii
ABBREVIATIONS v
1. INTRODUCTION 1
    1.1 Chirality 1
    1.2 Asymmetric Synthesis 4
    1.3 The Development of Enantioselective Transition Metal Catalysis 7
    1.4 Chiral Organic Ligands for Asymmetric Transition Metal Catalysis 11
    1.5 Asymmetric Synthesis on an Industrial Scale 14
    1.6 References 17
2. AIMS AND OUTLINE OF THIS THESIS 21
    References 24
3. CHIRAL DIENE LIGANDS 25
    3.1 Introduction 25
    3.2 The Metal-Olefin Bonding 26
    3.3 Chiral Olefin Ligands in Asymmetric Transition Metal Catalysis 30
    3.4 Definition of the Problem 40
    3.5 Synthesis of Bistriflate 41
         3.5.1 Synthesis of (1S,4S)-bicyclo[2.2.1]heptanes-2,5-dione 41
         3.5.2 Synthesis of (S,S)-bistriflate 42
    3.6 Synthesis of Norbornadiene Ligands via a Grignard Coupling 44
    3.7 Synthesis of Norbornadiene Ligands via a Shapiro Reaction 49
    3.8 Application of the Synthesized Chiral Norbornadiene Ligands 50
         3.8.1 Rhodium-catalyzed 1,4-additions 50
         3.8.2 The asymmetric synthesis of diarylmethanols via a rhodium- 
                  catalyzed 1,2-addition 59
    3.9 Further Developments 64
    3.10 Conclusions 65
    3.11 References 67
4. CHIRAL IMIDATE LIGANDS 72
    4.1 Introduction 72
    4.2 The Metal-Nitrogen Bonding 73
    4.3 Imidates 75
    4.4 Definition of the Problem 77
ii 
    4.5 Synthesis of Imidate Ligands 78
         4.5.1 Synthesis of 1,3-dihydro-iminoisobenzofuran hydrochloride  78
         4.5.2 Synthesis of a small imidate ligand library by condensation of 
                 imidate ligand precursor 4.18 with various chiral amines 80
         4.5.3 Synthesis of a copper complex of bisimidate 4.33 82
         4.5.4 Synthesis of substituted imidate precursors 83
         4.5.5 Synthesis of chlorine-substituted bisimidate ligands and their 
                 Corresponding copper(I) complexes 87
         4.5.6 Synthesis of mixed imidate-phosphane ligands 89
    4.6 Synthetic Applications of Imidates 91
         4.6.1 One-step synthesis of chiral oxazoline-alcohol ligands 91
         4.6.2 Synthesis of chiral imidazolidines 94
    4.7 Application of the Synthesized Chiral Imidate Ligands 96
         4.7.1 Copper(I)-catalyzed asymmetric aziridination 96
         4.7.2 Catalytic asymmetric organozinc additions to carbonyl compounds 103
                 4.7.2.1 Asymmetric 1,2-addition of diethylzinc to benzaldehyde in the
                            presence of chiral imidate ligands 105
                 4.7.2.2 Asymmetric 1,2-addition of diethylzinc to benzaldehyde in the
                            presence of chiral imidate- and oxazoline-alcohol ligands 107
         4.7.3 Asymmetric palladium-catalyzed allylic substitutions 110
    4.8 Conclusions 120
    4.9 References 123
5. SUMMARY AND FUTURE PERSPECTIVES 129
    References 136
6. EXPERIMENTAL SECTION 137
    References 191
7. NEDERLANDSE SAMENVATTING EN TOEKOMSTPERSPECTIEVEN 192
    Referenties 199
iii 
ACKNOWLEDGEMENTS 
After four years of laboratory work, I am delighted to present in this thesis the results 
of my research. Completing a Ph.D. was really a dream come true, and it has been a 
privilege to be paid to do something I really enjoy.  
A lot of people have contributed, in one way or another, to the writing of this thesis.  It 
is, however, impossible to list all these names without forgetting one. Therefore, I 
apologize in advance. 
First of all, I would like to thank my promoter Prof. Dr. Johan Van der Eycken who 
has given me the opportunity to prepare my Ph.D. in his laboratory. His continuous 
support  and the freedom he gave to pursue my research has contributed significantly 
to the success of my Ph.D. 
I would also like to acknowledge the support of Dr. Koen Vandyck, my supervisor in 
my predoctoral year. He gave me a lot of good advice, especially in the early stages 
of my Ph.D.  
To Sam Verbrugghe I would like to express my gratitude for his continuous support 
throughout the patenting process. I am very grateful that I was given the opportunity 
to be so closely involved in this procedure. I learned a great deal from the 
experience. 
A special word should also be directed to Engineer Jan Goeman, the handy-man of 
the S4 (a.k.a. the person who cannot say ‘no’). Without his presence, I am convinced 
that none of the equipment of the S4 would work. Thanks for all LC-MS recordings, 
chiral recordings and all other practical help.  
I would also like to thank my thesis students for their help with this work: Yilmaz 
Ozkilic, Elvan Er and Katrien Bert.  
I also appreciate the help of Dr. Koen Robeyns and Prof. Dr. Luc Van Meervelt for 
the quick recording of the X-ray structures, the various X-ray figures (which I was 
unable to produce) and the interesting talks.  
The recording of all the HRMS spectra was carried out by Stijn Claerhout and Prof. 
Dr. Erik Van der Eycken. I greatly appreciate their help in this.  
Inside the S4, several assisting technical personnel should be acknowledged. For the 
NMR facilities I would like to thank the team of Prof. Dr. José Martins, consisting of 
Katrien, Tim, Roland and George. To Davy Sinnaeve as well, who helped me 
significantly (although he said it was nothing) with one chiral NMR experiment , I 
express my gratitude. I also thank Marc for the EI Mass spectra, Veerle for ordering 
the chemicals, Tom and Freddy for the help with several administrative problems, 
Dirk, Hector, Tom and Paul for replacing solvent barrels, etc. 
iv 
I would like to show my sincere appreciation to Monica Sandor, Caroline Pieters and 
Merel Pieters for proof reading my publications and this manuscript.  
Off course, I would like to thank the lab colleagues for the nice time I had in the S4: 
Jelle (my squash partner and roommate on several symposia), Frederique (a.k.a. 
The Marco and il piccolo grande), Yaar and Zeki (for the nice dinners in the 
Sleepstraat), Ine, Pieter (for the talks about cycling), Sam (have you given back my 
10 ml flask yet?), Rosa (your laugh is legendary), Karel-Simon, Katrien, Jurgen, Leen 
(for the willingness to listen), An, Vincent, Gert, Michel and Simon. 
And last but certainly not least, I would like to thank my family and friends, especially 
my wife Merel and my parents. I cannot thank them enough for their continuous 
support in everything I do and the opportunities they gave me.  
Thanks to all of you! 
Timothy Noël 
September 2009 
v 
ABBREVIATIONS 
Acac Acetylacetonate  
Ac Acetyl  
APT Attached Proton Test 
APCI Atmospheric Pressure Chemical Ionization  
aq Aqueous  
Ar Aryl 
b Backdonation 
BINAP 2,2’-bis(diphenylphosphino)-1,1’-binaphthyl  
BINOL 1,1’-binaphthol 
Bn Benzyl 
bp Boiling point 
BSA N,O-bis-(trimethylsilyl)acetamide  
c- Cyclo-  
°C Temperature in degrees centigrade  
CALB Candida antarctica lipase B 
CDA Charge Decomposition Analysis  
COD 1,5-cyclooctadiene 
d Donation 
Dba Dibenzylidene acetone 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene  
DET Diethyl tartrate 
DIOP 4,5-bis(diphenylphosphinomethyl)-2,2-dimethyl-1,3-dioxolane  
DiPAMP Ethylene((o-anisyl)phenylphosphine) 
DIPEA Diisopropylethylamine  
DME Dimethoxyethane  
DMF N,N’-Dimethylformamide 
DMSO Dimethylsulfoxide 
dppf Bis-(diphenylphosphino)ferrocene  
dvds Divinyltetramethyldisiloxane 
% ee % Enantiomeric excess 
E Entgegen  
EI Electron Impact 
ES Electro Spray 
Et Ethyl  
Et2O Diethylether 
EtOAc Ethylacetate  
ETS Extended Transition State 
Equiv Equivalents 
FDA Food and Drug Administration 
GC Gas Chromatography 
h Hour (hours) 
HATR Horizontal Attenuated Total Reflectance  
hfc 3-(heptafluoropropyl-hydroxymethylene)-d-camphorate  
HPLC High Pressure Liquid Chromatography  
vi 
HRMS High Resolution Mass Spectroscopy  
HSQC Heteronuclear single quantum correlation spectroscopy  
i-Bu Isobutyl 
IR Infrared 
J Joule (= 0.2390 cal) 
KHMDS Potassium hexamethyldisilazide  
L Ligand 
LC Liquid Chromatography 
LDA Lithium diisopropylamide 
LHMDS Lithium hexamethyldisilazide 
M Metal 
Me Methyl 
MHz Megahertz 
MOP 2-(diphenylphosphino)-2’-methoxy-1,1’-binaphtyl  
mp Melting point 
MS Mass Spectroscopy 
MTBE Methyl Tertiary Butyl Ether 
n.a. Not applicable 
nbd Norbornadiene 
NBS N-bromosuccinimide 
n-BuLi n-Butyllithium (CH3CH2CH2CH2Li) 
n.c. No conversion 
n.d. Not determined 
NHC N-heterocyclic carbenes 
NMR Nuclear Magnetic Resonance 
n.r. No reaction 
Ph Phenyl 
PhINTS (N-(p-toluenesulfonyl)imino)phenyliodinane 
ppm Parts per million 
R rectus 
rac racemic 
Rf Ratio to front or retention factor  
R.T. Room temperature 
S sinister 
Sat. saturated 
Sec-BuLi sec-Butyllithium (CH3CHLiCH2CH3) 
SMB Simulated Moving Bed 
TADDOL , , ’, ’-tetraaryl-4,5-dimethoxy-1,3-dioxolane  
t-Bu Tertiary Butyl 
Tf (OTf) Triflate (trifluoromethylsulfonyl)  
Tfb tetrafluorobenzobarrelene 
THF Tetrahydrofuran 
TLC Thin Layer Chromatography 
TMANO Trimethylamine-N-oxide 
TMS Trimethylsilyl 
TMEDA N,N,N’,N’-tetramethylethylenediamine  
TON Turn Over Number 
TOF Turn Over Frequency 
Tris 2,4,6-triisopropylbenzenesulfonyl  
Ts Tosyl (p-toluenesulfonyl) 
vii 
XRD X-Ray Diffraction 
Z Zusammen 
 Cone Angle 
  
1 
1 
INTRODUCTION 
1.1 CHIRALITY 
“I call any geometrical figure, or group of points, chiral, and say it has chirality, if its 
image in a plane mirror, ideally realized cannot be brought to coincide with itself.” 
Lord Kelvin, Baltimore Lectures. 
The term “chiral” is used to describe an object that is non-superimposable on its 
mirror image. Lord Kelvin (William Thompson) introduced the term into science. The 
term “chirality” is derived from the Greek word for hand,  (/cheir/). Our hands are 
indeed an excellent macroscopic example of chirality. The two mirror images are 
called enantiomers. 
Examples of macroscopic chirality can be found all around us, from medieval spiral 
stairwells, right- or left-handed screws and propellers, the left-right asymmetry of 
internal organs with humans1, chiral snail shells2 to chiral bacterial-colony formation3
(Figure 1.1). 
Figure 1.1. Examples of macroscopic chirality, from left to right: (a) spiral stairwells, 
(b) chiral snail shells, (c) chiral bacterial-colony formation.
In sharp contrast with this macroscopical chirality, which is easy to observe, the 
discovery of molecular chirality lasted till the 19th century. The French physicist Biot 
Chapter 1. Introduction 
2
established that certain organic compounds rotated the plane of polarization of light. 
However, it was Pasteur who correlated this phenomenon with an asymmetric 
grouping of atoms within molecules. He investigated solutions of sodium ammonium 
tartrate which did not rotate the plane of polarized light. After crystallization of the 
solutes, he noticed that the crystals came out in two asymmetric forms. Sorting both 
forms by hand, he discovered that one form rotated polarized light clockwise while 
the other form rotated light counterclockwise. Kekulé found that carbon should have 
four valences. This finding together with the finding by van’t Hoff and Le Bel that 
these valences should be arranged in a tetrahedral fashion set the stage for the 
possibility of organic molecules to exist in mirror-image forms or enantiomers. 
L-amino acids
H2N COOH
R
O
HOH2C
HO
HO
OH
OH
D-glucose
Figure 1.2. Molecules in two mirror-image forms and chiral biologically active 
molecules.
Chiral molecules are present in the most fundamental processes of life. The sugars 
that constitute DNA and RNA possess a uniform stereochemical configuration. The 
proteins, encoded by these oligonucleotides, consist of chiral L-amino acids. 
Homochirality, reflecting the fact that biomolecules are built from chiral building 
blocks, is generally recognized as a fundamental property of life. The origin of this 
homochirality is, in spite of numerous theories, still unclear.4 Nature has in some 
cases taken advantage of its own homochirality through the use of post-translational 
reactions to convert L-amino acids into the corresponding D-enantiomers. The 
resulting peptides and proteins exhibit an enhanced stability towards enzymatic 
degradation.5
Since chirality is an integral part of all biological processes, enantiomers may differ 
both quantitatively and qualitatively in their biological activities.6 At one extreme, one 
enantiomer may be devoid of any biological activity; at the other extreme, both 
enantiomers may have qualitatively different biological activities. These 
stereoselective differences may arise not only from drug interactions at 
pharmacological receptors but also from pharmacokinetic events.7 This can express 
itself in a different taste8, smell, toxicity or therapeutic effect (Figure 1.3). The 
thalidomide tragedy of 1961 is one of the most famous examples where the two 
enantiomers have a totally different biological activity. Thalidomide was prescribed as 
a racemate for pregnant women as an antiemetic against morning sickness. Whereas 
the (R)-enantiomer had the desired activity, the (S)-enantiomer proved to be 
teratogenic. However, the tragedy could not have been avoided if only a single 
enantiomer would have been used and that for two reasons. Firstly, studies in rabbits 
showed that both enantiomers show equal teratogenic potency.9 Secondly, the chiral 
centre in thalidomide is unstable in acidic media and undergoes a rapid 
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racemization.10 But, this tragic example resulted in an increasing awareness of the 
stereoselectivity of drug action. In addition, since 1992 the Food and Drug 
Administration (FDA) policy states that in the development of a drug with a 
stereogenic center, both enantiomers should be evaluated in vivo at an early stage.11  
O O
(S)-carvone
Caraway odor
(R)-carvone
Spearmint odor
O NH
OH
(R)-propranolol
inactive
ONH
OH
(S)-propranolol
beta-blocker
NH
N
O
O O
O
(R)-thalidomide
antiemetic
NH
N
O
OO
O
(S)-thalidomide
teratogen
Figure 1.3. The different activities of enantiomers.
Till the mid-1950s, it was generally believed that all four fundamental forces of nature 
were perfectly symmetrical.12 At that time, there existed the so-called “thau-theta 
puzzle”. These two particles decayed differently while they should have similarly. This 
could only be explained under the assumption that one of their fundamental 
properties was not the same. In 1956, Yang and Lee published a paper where they 
considered that parity might be violated and that there could be an asymmetry in 
nuclear -decay.13 In this paper, several experiments were proposed to check 
whether parity is conserved in the weak interactions or not. One of these experiments 
involved the measurement of the -decay of cobalt-60 atoms. A few months later, it 
was shown that cobalt-60 nuclei, spinning in the same direction around the z-axis, 
underwent -decay and emitted more electrons in the –z direction than in the +z 
direction.14 This result is not invariant under a mirror reflection, indicating that the 
interaction responsible for the decay process, i.e. the weak interaction, does not 
conserve parity. After the parity violation was proven, also charge-parity violation (CP 
violation) was discovered.15 But, when time-reversal (T) is considered, it is still 
believed that CPT-symmetry is conserved. 
Parity violation leads to an energy difference between two enantiomers in the 10-12-
10-15 J/mol range. These subtle energy differences can, however, not explain the 
origin of homochirality in nature.16
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1.2 ASYMMETRIC SYNTHESIS 
A large amount of the pharmaceuticals and agrochemicals contain one or more 
stereogenic centers. Several possible approaches have been developed to access 
these enantioenriched compounds. 
A first possibility is the so-called chiral pool approach which starts from readily 
available chiral building blocks originated from nature, e.g. sugars, amino acids, 
terpenes, hydroxyacids and alkaloids. This method is commonly used in early phases 
of drug synthesis. Given the homochirality of nature, the opposite enantiomer is often 
difficult to obtain. An example is given in scheme 1.1, the synthesis of captopril, an 
ACE inhibitor, starts from L-proline. 
HN
COOH
L-proline
N
COOH
HS
O
captopril
Scheme 1.1. Synthesis of captopril starting from (L)-proline. 
A second possibility is the separation of the two enantiomers by means of a 
resolution step. This can be done via a classical resolution, i.e. a crystallization of 
diastereomeric adducts. Recently, a new and intriguing technique for obtaining a 
single enantiomer was reported.17 Solution-solid mixtures with a composition of 2-3% 
ee were magnetically stirred in the presence of glass beads. A soluble racemizator 
was added to this mixture. It appeared that the ee of the solid raised in function of the 
time until a solid of single chirality was obtained. This shows that a slight imbalance 
in enantioselectivity can lead to a single solid chiral state. Another possibility to 
separate two enantiomers is via chiral HPLC, where the enantiomers are separated 
over chiral stationary phase columns.18 Using simulated moving bed techniques 
(SMB), the chiral separation can be done continuously on an industrial scale.19
Although 50% of the material is the wrong enantiomer, resolution is still the most 
commonly used technique in industrial asymmetric syntheses. 
An interesting technique is a kinetic resolution. The two enantiomers show different 
reaction rates in a chemical reaction and if the difference is large enough, in theory, 
only one of the two is converted. An important extension is the dynamic kinetic 
resolution. Hereby the unwanted enantiomer racemizes in situ while the other 
enantiomer is constantly reacting away. Hence, conversions of 100% are 
theoretically possible. An interesting example of a dynamic kinetic resolution, where a 
biocatalyst (CALB) is combined with a metal racemisation catalyst, is shown in 
scheme 1.2.20
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O O
HPh
Ph
Ph
Ph
Ph
Ph
Ph
Ph
Ru Ru
H
OC CO
CO CO
R
OH
CALB
p-Cl-C6H4-OAc
toluene (0.25M) R
OAc
78-92% yield
>99% ee
R= aryl,
      alkyl
+ R
OH
Scheme 1.2. Dynamic kinetic resolution of secondary alcohols with a ruthenium 
racemisation-catalyst 
Another approach involves the use of chiral auxiliaries. In this strategy the prochiral 
substrate is attached to a chiral, non-racemic group, known as the chiral auxiliary, 
prior to reaction. The two possible products then become diastereoisomeric and thus 
only one could be formed in excess. Although the reactions are highly predictable 
and reliable, this method requires additional reaction and purification steps, and 
stoichiometric amounts of chiral auxiliary are necessary (Scheme 1.3).  
OH
O
F
HN
O
Ph
O
PivCl, Et3N, PhMe
80-85 °C
75%
N
O
F
O
O
Ph
N
O
F
O
O
PhNC
THF, -20°C
LHMDS
NaBH4
THF/H2O
100%
F
NC
OH
F
OH
NH
HN
N
O
H2N
PNP405
N
O
F
O
O
Ph
Li
80%
BrCH2CN
Scheme 1.3. Synthesis of PNP405 with (R)-4-phenyl-2-oxazolidinone as a chiral 
auxiliary. 
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However, the best way to introduce chirality is to use a chiral catalyst because only a 
small amount of highly valuable catalyst is required to obtain a large amount of chiral 
target product. There are three fundamentally different approaches to obtain 
enantiomerically pure compounds via catalysis.  
A first approach is biocatalysis. Nature uses chiral, non-racemic catalysts (enzymes) 
to carry out many enantioselective reactions. Although the induced enantioselectivity 
is often impressive, these biocatalysts have a very high substrate-specificity and their 
use in organic solvents is rather difficult. A notorious exception to this rule are 
hydrolases, like lipases and esterases. These problems can be partly overcome 
thanks to the tremendous advances recently made in the field of biocatalysis. This is 
due to the apparition of novel techniques such as directed evolution21, the use of 
enzymes in organic solvents22, etc. (Scheme 1.4). 
-O2C OHC OPO3
2-
O OH
+ -O2C OPO3
2-
O OH
OH
O
HO
OH OH
CO2
-
KDPG
aldolase Phosphatase
-O2C OHC OH
O OH
+ -O2C OH
O OH
OH
O
OH
novel KDPG
aldolase
CO2
-OH
OH
D-sugar
L-sugar
Directed
Evolution
Scheme 1.4. Access to both enantiomers of a sugar via enzymatic catalysis.
A second approach is the use of transition metal complexes. These complexes 
consist of a chiral organic ligand bound to a transition metal. The chiral ligand 
modifies the reactivity and selectivity of the metal center in such a way that only one 
of the two possible enantiomers is preferentially formed. The wide variety of chiral 
organic ligands that can be combined with several transition metals, makes this 
method the most versatile to use in asymmetric syntheses. An example of an 
industrial process with a chiral transition metal complex can be found in scheme 
1.5.23
OH OH
Ru(OOCCF3)2 /BINAP
20°C, 100 bar H 2
ee 97%
TON 50000; TOF 500 h-1
Scheme 1.5. Industrial synthesis of citronellol by Takasago.
Given the success of several asymmetric transition metal-catalyzed processes, e.g. 
the Sharpless asymmetric epoxidation, synthetic chemists can now devise strategies 
to prepare target structures based on chiral starting materials which are unavailable 
from nature. These unnatural starting materials are new cheap sources of 
enantiomerically pure products and they fulfill the same role as the products from the 
‘natural’ chiral pool. Therefore it was suggested to consider these products as 
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members of a ‘new’ chiral pool.24,25 An example is given in scheme 1.6, glycidol is 
synthesized via a Sharpless asymmetric epoxidation. This member of the ‘new’ chiral 
pool was used in the synthesis of (S)-propranolol.26
OH
O H
(S)-(-)-glycidol
ONH
OH
(S)-propranolol
beta-blocker
OH
Sharpless 
asymmetric 
epoxidation
Scheme 1.6. Synthesis of (S)-propranolol starting from (S)-(-)-glycidol.
Between the extremes of transition metal catalysis and biocatalysis, a third approach 
to the catalytic production of chiral compounds has emerged, i.e. 
organocatalysis.27,28,29 In sharp contrast with transition metal catalysis, the organic 
molecule itself functions as the catalyst. Proline, a chiral pool compound, is a 
classical example of an organocatalyst. It catalyzes aldol and related reactions by 
iminium or enamine pathways (Scheme 1.7).30  
O
H
O O OH
N
H
CO2H
L-proline
DMSO, r.t.
97% yield
96% ee
+
Scheme 1.7. Proline-catalyzed intermolecular aldol reaction. 
1.3 THE DEVELOPMENT OF ENANTIOSELECTIVE TRANSITION 
METAL CATALYSIS31
The principle of asymmetric catalysis is illustrated in figure 1.4.32,33 The initially used 
chiral precatalyst is activated into a catalyst via an induction process. This catalyst 
consists of a metal or a metal ion and a chiral organic ligand. The ligand stabilizes 
the metal and creates a chiral environment. The catalyst activates prochiral 
molecules A and B and reversibly forms an intermediate. The chiral environment 
around the metal is the origin of the chiral induction and, therefore, a chiral product 
AB is formed and the catalyst is regenerated. 
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Figure 1.4. The principle of asymmetric catalysis with chiral organometallic molecular 
catalysts. 
The first example of homogeneous asymmetric catalysis was performed by Natta in 
the polymerization of benzofuran with an AlCl3-phenylalanine catalyst. Optical activity 
was detected for the polymer. However, it is difficult to estimate the efficiency of the 
chiral induction process from an optical rotation of a polymer.34
The first example of asymmetric organometallic catalysis outside the field of polymer 
chemistry was the cyclopropanation of alkenes by Nozaki and Noyori in 1966.35 A 
chiral salen-copper catalyst gave selectivities up to 10% ee (Scheme 1.8). Although 
the selectivity was low, this result was a significant achievement and initiated further 
research in asymmetric catalysis. 
+   N2CHCO2Me
CO2Me
CO2Me
6% ee
10% ee
+
N
O
Cu
N
O
Ph
Ph
(1 mol%)
Scheme 1.8. Cu-catalyzed asymmetric cyclopropanation.
In that same year, Wilkinson performed the first homogeneous catalytic 
hydrogenation reaction with RhCl(PPh3)3 as a catalyst.
36 Stimulated by this finding, 
Horner et al.37 and Knowles et al.38 found, independently from one another, that the 
Chapter 1. Introduction 
9
use of a chiral phosphane ligand in the rhodium-catalyzed hydrogenation induced 
modest enantioselectivities into a prochiral alkene. In 1971, Kagan et al. synthesized 
the first C2-symmetrical diphosphane ligand, named DIOP.
39 The idea behind this 
was that a C2-symmetrical ligand would lead to a better defined transition state 
complex with, hopefully, a beneficial effect on the induced enantioselectivity. 
Enantioselectivities up to 88% ee were obtained with DIOP in the hydrogenation of 
enamides.  
Ph R
+ H2
[Rh] / Ph
P
Me
n-Bu
Ph R
Me H
R= Et           8% ee    (Horner et al.)
R= CO2H   15% ee    (Knowles et al.)
AcHN Ph
+ H2
[Rh] / DIOP
AcHN Ph
Et H
Me
88% ee
(Kagan et al.)
PPh2
PPh2
O
O
H
H
DIOP
Scheme 1.9. Pioneering work in the rhodium-catalyzed asymmetric hydrogenation.
Inspired by the work of Kagan et al., Knowles et al. developed the C2-symmetrical
DiPAMP.40 This diphoshane ligand combines the good chelating properties of a 
bidentate C2-symmetrical ligand and the good chirality inducing properties of a chiral 
phosphorous atom. This ligand was used in the asymmetric synthesis of L-DOPA at 
Monsanto and was the first example of an industrial asymmetric synthesis (Scheme 
1.10). 
CO2H
NHAc
MeO
AcO
+      H2
[Rh((R,R)-DiPAMP)COD]+BF4
-
100%
CO2H
NHAc
MeO
AcO
H3O
+
CO2H
NH2
HO
HO
L-DOPA
P P
Ph
Ph
OMe
MeO
(R,R)-DiPAMP
95% ee
Scheme 1.10. The Monsanto synthesis of L-DOPA using a catalytic asymmetric 
hydrogenation.
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In 1980, two significant breakthroughs in the field of asymmetric catalysis were 
published. The first one was the asymmetric epoxidation of allylic alcohols by 
Sharpless and Katsuki.41 This method allowed a great deal of flexibility within the 
structure of the substrate. However, there is one restriction: the presence of an allylic 
alcohol is necessary (Scheme 1.11). The second breakthrough was the preparation 
of BINAP by Noyori et al.42 This C2-symmetrical diphosphane is characterized by a 
full aromatic substitution and is known to have superior chirality recognition and 
induction abilities.43 Through the years BINAP has become one of the most versatile 
ligands known in asymmetric catalysis. E.g., BINAP is used as a ligand in the 
synthesis of naproxen, an analgesic and anti-inflammatory agent (Scheme 1.12).44  
R3R2
R1
OH
+      t-BuOOH
DET / Ti(Oi-Pr)4 R
3R2
R1
OH
O
> 95% ee
R3
R2
R1
OH
D-(-)-diethyl tartrate
L-(+)-diethyl tartrate
(natural)
(unnatural)
Scheme 1.11. Sharpless asymmetric epoxidation of allylic alcohols.
CO2H
MeO
CO2H
MeO
Naproxen
97% ee
+    H2
Ru(OAc)2(S)-BINAP
PPh2
PPh2
(S)-BINAP
Scheme 1.12. Synthesis of naproxen via a ruthenium/BINAP-catalyzed asymmetric 
hydrogenation.
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Since then, the number of significant results in the field of asymmetric synthesis has 
grown exponentially. The most important are: the Sharpless asymmetric 
dihydroxylation45, the Jacobsen asymmetric epoxidation46, the synthesis of the 
DUPHOS ligand family47, synthesis of oxazoline ligands48, the asymmetric allylic 
substitution49, etc. 
In 2001, K.B. Sharpless, W.S. Knowles and R. Noyori received the Noble Prize in 
Chemistry for their contributions to the development of catalytic asymmetric 
synthesis.50  
1.4 CHIRAL ORGANIC LIGANDS FOR ASYMMETRIC TRANSITION 
METAL CATALYSIS 
The choice of an appropriate ligand is crucial for the success of an asymmetric 
transition metal-catalyzed reaction. Given the complexity of most catalytic processes, 
a rational design of a chiral ligand is seldom straightforward. Therefore, the synthesis 
of new ligands is often the result of a knowledge-based intuition or serendipity. 
A chiral ligand has to fulfill a list of demands to be attractive to the organic chemist. 
Several important requirements can be distinguished51,52 (Table 1.1).  
Requirements for chiral ligands 
1. Wide scope (with well defined and known limitations); 
2. Air and/or moisture stable; 
3. Modular, straightforward and easily up-scalable synthesis; 
4. High chemoselectivity; 
5. Catalyst performance: high enantioselectivity, high TON, high TOF; 
6. Freedom to operate: patent protection and licensing; 
7. Marketing; 
8. Speed to implement the process and process robustness. 
Table 1.1. Ligand success factors. 
Certain classes of ligands are enantioselective over a wide range of different 
reactions. These ligands are called ‘privileged chiral ligands’.53,54 In figure 1.5, a few 
important privileged ligands and catalysts are shown, e.g. BINAP43, MeDUPHOS55, 
cinchona alkaloids56, Brintzinger’s ligand57, TADDOL58, MonoPhos59, bisoxazolines60, 
salen ligands61 and Josiphos62. Most privileged ligands are C2-symmetrical, possess 
a rigid structure and are bidentate ligands. However, these factors are not a 
prerequisite for a successful ligand structure.63
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N
M
N
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t-Bu
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MeDUPHOS
OH
OHO
O
Ph Ph
PhPh
TADDOL
N N
O O
t-Bu t-Bu
bisoxazoline
N
OH
N
OMe
cinchona alkaloid
derivatives
O
O
P N
MonoPhos
FePPh2
PCy2
Me
Josiphos
M
Figure 1.5. Examples of privileged chiral ligands and catalysts.
The presence of a C2-symmetrical axis in a catalyst can reduce the number of 
possible competing diastereomeric transition states.64 This can have a beneficial 
effect on the enantioselectivity because of the possible elimination of less-selective 
pathways. The C2-symmetry is especially useful in mechanistic studies. However, 
there is no fundamental reason why a C2-symmetrical ligand should be superior to a 
C1-symmetrical ligand.
65 In some cases, a C1-symmetrical ligand can give better 
enantioselectivities than the corresponding C2-symmetrical ligand.
66 An interesting 
example is the synthesis of mixed P,N-ligands where the phosphorous atom is soft 
and the nitrogen atom is hard. This understanding led to the synthesis of so-called 
PHOX ligands (Scheme 1.13).67 These ligands are highly successful in the 
asymmetric allylic alkylation reactions. Complexation of these ligands results in an 
electronic differentiation of the two allylic termini due to the higher trans-effect of 
phosphorous as compared to nitrogen. This results in an attack of the nucleophile 
trans to P. 
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OAc
CH2(COOMe)2/BSA/NaOAc
[Pd(C3H5)Cl]
CH(COOMe)2
PPh2
O
N
PHOX
98.5% ee
Scheme 1.13. Asymmetric allylic alkylation reactions with chiral PHOX ligands.
The use of a ligand can be severely hampered if it is extremely air- and moisture 
sensitive. Since most catalysts are rather substrate specific, a modular structure of 
the ligand is advisable. As a result, the ligand can be tailored to the specific needs of 
each substrate class. A straightforward synthesis of the ligand class is an important 
advantage for its commercialization. Ligands have often complex structures or 
require special precautions while synthesizing or handling them, e.g. oxygen free 
conditions. If special precautions are not required, the ligand will be more readily 
used.  
An easy synthesis is also a prerequisite for a ligand to be used on an industrial scale 
because it makes a fast implementation possible. The use of a ligand in an industrial 
process will also increase its availability on the market. 
A catalyst should meet the high requirements that are demanded by the organic 
chemists. A high chemoselectivity is needed. In other words, the necessity of 
functional group protection should be kept as low as possible. The induced 
enantioselectivity should be high and predictable. To be commercially viable, the 
most important factor is the catalyst productivity, quantified as TON-68 and TOF-
numbers69. 
Most of the new and interesting ligands are patented both by academics and 
companies. However, a patented ligand is much less likely used by chemists in the 
industry because of uncertainties regarding the freedom to operate and the royalty 
costs. 
Marketing is a very important factor in the development of a catalyst. Nowadays, the 
synthesis of new ligands grows exponentially, meaning that the choice is 
overwhelming. A good promotion strategy consists of writing publications and 
reviews, giving lectures, etc. This is necessary to persuade the chemical community 
of the utility of a new ligand design. 
A catalytic step must be easily implemented in the, sometimes, existing industrial 
process. The earlier in the process an asymmetric catalytic step can be implemented, 
the greater the chance it will be applied on a commercial scale. Moreover, scaling up 
of a catalytic step from laboratory scale to production scale must be predictable. The 
catalytic step should be able to work reliable even when there are small variations in 
the process, which are typical for production operations. 
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1.5 ASYMMETRIC SYNTHESIS ON AN INDUSTRIAL SCALE 
In recent years, there has been a movement away from racemic compounds towards 
the production of enantiomerically pure compounds (Table 1.2).70 This trend is 
caused by the stricter regulations of regulatory authorities worldwide. Since 1992, the 
FDA demands that for every newly designed chiral drug a systematic characterization 
of each enantiomer is performed. In addition, the possibility of an extension of a 
patent term, by means of a so-called ‘chiral switch’, resulted in an increasing interest 
in asymmetric synthesis.71 ‘Chiral switches’ are chiral drugs that have already been 
claimed, approved and marketed as racemates or as a mixture of diastereoisomers, 
but have been redeveloped and ‘repatented’ as single enantiomers. However, the 
prerequisite for patentability is that the two enantiomers of a chiral drug should 
display sufficiently different pharmacological effects from both each other and the 
racemate.  
Year Racematesa Single Enantiomers Achiral 
Worldwide
(%) 
FDAb
(%) 
Worldwide
(%) 
FDAb
(%) 
Worldwide
(%) 
FDAb
(%) 
1983 37 n.a. 26 n.a. 37 n.a. 
1984 28 n.a. 26 n.a. 46 n.a. 
1985 38 n.a. 22 n.a. 40 n.a. 
1986 26 n.a. 26 n.a. 48 n.a. 
1987 18 n.a. 49 n.a. 33 n.a. 
1988 26 n.a. 39 n.a. 35 n.a. 
1989 29 n.a. 26 n.a. 45 n.a. 
1990 33 n.a. 35 n.a. 32 n.a. 
1991 20 9 40 65 40 26 
1992 21 33 44 42 35 25 
1993 16 17 45 29 39 54 
1994 38 5 38 57 24 38 
1995 21 37 46 30 33 33 
1996 9 14 41 43 50 43 
1997 24 8 30 38 46 54 
1998 15 9 50 41 35 50 
1999 13 4 52 46 35 50 
2000 9 19 62 37 29 44 
2001 0 0 68 60 32 40 
2002 6 0 55 53 39 47 
a Including diastereomeric mixtures. 
b n.a.: not applicable. 
Table 1.2. Annual distribution of worldwide and FDA-approved drugs according to 
their enantiomeric purity.72
The same trend is also visible in the agrochemical industry. Use of only the active 
enantiomer, instead of the racemate, leads to reduced quantities and so to a reduced 
environmental impact. One of the best known examples of asymmetric catalysis on 
an industrial scale is the synthesis of (S)-metolachlor, a widely used herbicide 
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(Scheme 1.14).73 For industrial asymmetric catalytic processes, the activity of the 
catalyst is the most important parameter. Xyliphos gave a lower but acceptable 
enantioselectivity (79% ee), however, the turnover number (TON) and turnover 
frequency (TOF) were very high. 
N
MeO
HN
MeO
FePPh2
Me
Pxyl2
Xyliphos
[Ir(COD)Cl]2
H2 (80 bar)
79% ee
TON 2.000.000
TOF (h-1) > 400.000
N
MeO
O
ClH2C
(S)-metolachlor
Scheme 1.14. Industrial production of (S)-metolachlor.
Two questions are important for deciding whether an asymmetric industrial process is 
appropriate in a certain case. Firstly, are the overall cost-of-goods in favor of an 
asymmetric synthesis or is the synthesis of a racemate with a resolution afterwards 
economically more favorable? Secondly, what is the chance that the development of 
a reliable asymmetric step will be successful?74,75  
In industry, alternatives for asymmetric syntheses, e.g. resolutions and using chiral 
pool products as starting materials, are still more popular. There are two main 
reasons for this.  
Firstly, asymmetric syntheses are considered as complicated and sensitive to small 
changes in the reaction conditions. Conversely, resolutions of racemic mixtures are 
pretty straightforward. As soon as the ideal resolving agent has been identified, the 
rest of the process is relatively easy. In other words, the implementation in an 
existing process can be faster done for a resolution than for asymmetric 
methodologies.   
Secondly, given the fact that in the pharmaceutical industry 90% of the selected drug 
candidates are discontinued before they reach the market, designing a time-
consuming asymmetric synthesis can be too expensive. The use of a resolution step 
is far more attractive because it allows a rapid delivery of the target product at a large 
scale.  
An example where the classical diastereomer resolution with an in situ racemization 
step is preferred over the enantioselective syntheses, is the synthesis of (S)-
naproxen, a non-steroidal anti-inflammatory drug (NSAID) (Scheme 1.15).76 There 
are several reasons for this. Firstly, the resolution process with a racemization-
recycling loop is almost perfect (>98% yield). Secondly, the starting reagents are 
much cheaper for the resolution than for the asymmetric catalytic syntheses. And 
finally, the enantioselective catalytic transformation is not perfect (98% ee), as a 
result an additional recrystallization step is required to obtain the enantiomerically 
pure product.  
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MeO
Br 1. Mg
2. CO2MgCl
Br
MeO
CO2H
MeO
CO2H
MeO
CO2H
H2 (135 atm)
Ru-(S)-BINAP
> 98% ee
N-alkyl-D-glucamine
> 95% yield including
a recycling loop
(S)- naproxen
Scheme 1.15. Side-by-side comparison of two possible approaches towards the 
synthesis of (S)-naproxen.
But, syntheses that produce racemates suffer from several drawbacks. Half of the 
material will be lost or has to be recycled. In times of an increasing environmental 
awareness, an important disadvantage is the use of large amounts of solvents and 
the production of other chemical waste. On the basis of this reasoning, industrial-
scale synthesis of enantiomerically pure molecules can only be considered as ‘green 
chemistry’ when asymmetric catalytic methodologies are used. Tremendous 
advances over the recent decades have been made in asymmetric catalytic 
chemistry. Research in this field is still on the move. The popularity of the alternatives 
results from the generally perceived complexity of asymmetric catalysis. 
Nonetheless, convincing results will continue to accumulate and will drive this 
fascinating technology forward. 
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2 
AIMS AND OUTLINE OF 
THIS THESIS 
Since its first appearance, more than 40 years ago, the field of asymmetric catalysis 
has known a tremendous evolution. A wide variety of chiral catalysts for a huge 
number of enantioselective reactions has been developed. This gives the impression 
that for almost every reaction an enantioselective catalytic variant is available. 
However, the number of truly useful enantioselective catalysts is still limited. Many of 
the existing methods still need to be improved and the search for new and better 
ligands is still ongoing.  
The key to efficient asymmetric catalysis is the combination of a metal with a suitable 
chiral organic ligand. An ideal ligand is easily accessible and has a modular structure 
that allows rapid diversification. Current approaches in finding new catalysts are still 
rather empirical in which chance, intuition and a systematic screening play an 
important role. A purely rational approach is hampered by the lack of mechanistic 
understanding and the complexity of most catalytic processes.  
The development of novel ligand classes can result in the discovery of new 
reactivities and, as a consequence, give access to new enantiomerically enriched 
molecules and new enantioselective catalytic processes. Therefore, it remains 
important to continue the search for new and improved ligands.  
In this work, two main ligand classes have been studied: chiral diene ligands and 
chiral imidate ligands. Both have in common that their use was, until recently, 
precluded from asymmetric catalysis due to their presumed instability. The use of 
chiral dienes was neglected because of their easy dissociation from the metal. 
However, dienes with the proper geometry can form very stable complexes. In 
contrast, the use of imidates was delayed by their assumed intrinsic instability. 
Imidates are mostly used as synthetic building blocks and sometimes as 
pharmacophoric groups. 
In chapter 3, we discuss the synthesis of chiral bicyclo[2.2.1]heptadiene ligands 2.2
via a novel route starting from an enantiomerically pure vinylic bistriflate 2.1 (Figure 
2.1). This work was stimulated by the synthesis of DIPHONANE in our laboratory 
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where the same bistriflate 2.1 was used as a key intermediate.1 Use of this bistriflate 
2.1 resulted into a more versatile route towards these chiral norbornadiene ligands2
2.2 as compared to the original route described by Hayashi et al.3 These ligands 
were tested in several rhodium-catalyzed reactions.
OTf
TfO
R
R
2.1 2.2
Figure 2.1. Synthesis of chiral diene ligands via a vinylic bistriflate.
In chapter 4, we report on the synthesis and application of imidates as a new 
nitrogen-based ligand class. This type of ligands has not yet been described in 
literature and is therefore extremely interesting. Starting from a central building block 
2.3, a small ligand library could be synthesized. We synthesized C1 and C2 –
symmetrical imidate ligands (2.4 and 2.5), as well as hybrid imidate, phosphane 
ligands 2.6 (Figure 2.2).4,5 These ligands were evaluated in several asymmetric 
metal-catalyzed reactions. 
O
NH
.HCl
R3
R2
R1
R4
O
N R
ONO N
R3
R2
R1
R4
R4
R3 R2
R1 R1
R2 R3
R4
*
*
Fe
PPh2 N O
R1
R2
R3
R4
2.4
2.5
2.6
2.3
Figure 2.2. Synthesis of an imidate ligand family: C1-symmetrical (2.4), C2-
symmetrical (2.5) and hybrid imidate,phosphane ligands (2.6).
The imidate ligand precursor 2.3 is also an interesting synthetic building block for 
other N-based ligands. This compound was used in the synthesis of chiral oxazoline-
alcohol ligands 2.76 and chiral imidazolidines 2.8 (Figure 2.3). 
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O
NH
.HCl
R3
R2
R1
R4
OH
N
O
R'
R''
*
*
R1
R2
R3
R4
HN NH
O
R1
R2
R3
R4
2.3
2.7 2.8
Figure 2.3. Synthesis of chiral oxazoline-alcohol ligands (2.7) and chiral 
imidazolidines (2.8).
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3 
CHIRAL DIENE LIGANDS 
3.1 INTRODUCTION 
In 1827, Zeise synthesized one of the first organometallic compounds: the platinum 
complex 3.1, containing an ethylene molecule (Figure 3.1).1  
Cl Pt
Cl
Cl
3.1
Figure 3.1. Zeise’s salt. 
Ever since, the use of olefin ligands in transition metal chemistry has become very 
important. Olefin ligands are known as labile ligands. Most of the time, they serve as 
“placeholders” for vacant coordination sites for ligand exchange reactions with 
stronger binding ligands, such as phosphanes and nitrogen ligands. Sometimes, 
olefin ligands also fulfil more complex functions in transition metal catalysis.2 Olefin 
ligands facilitate reductive elimination over -hydride elimination. The coordination of 
olefins to the metal fills the vacant coordination sites which are necessary for the -
hydride elimination. Since olefin ligands are labile ligands, they easily dissociate from 
the metal and hence promote oxidative addition. Olefins can also influence the 
product selectivity. 
Noteworthy are Pd2(dba)3 (3.2) and Pt2(dvds)3 (3.3). The first catalyst is a well-known 
precursor for cross-coupling reactions.3 The latter is also known as Karstedt’s 
catalyst and is used in hydrosilylation reactions (Figure 3.2).4  
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Ph Ph
O
O
Ph Ph
Pd
Pd
O
Ph Ph
Pd2(dba)3
MeSi
O
Me2Si
SiMe2
O
SiMe2
Me2Si SiMe2
O
Pt Pt
Pt2(dvds)3
Karstedt catalyst3.2
3.3
Figure 3.2. Olefin-containing transition-metal complexes: Pd2(dba)3 and Karstedt’s 
catalyst. 
The first chiral olefin was synthesized by Cope et al.5 (E)-cyclooctene (3.4) shows 
planar chirality and was obtained in an enantiomerically pure form via a fractional 
crystallization of diastereomeric Pt complexes (Scheme 3.1).  
Pt
Cl
Cl
Cl
K Pt
Cl
Cl
NH2
Me
Ph
(R)-phenylethylamine 1. rac- (E)-cyclooctene
2. fractional crystallization
Pt
Cl
Cl
NH2
Me
Ph
H
H
(-) 3.4
aq KCN
Scheme 3.1. Synthesis of chiral (E)-cyclooctene. 
3.2 THE METAL-OLEFIN BONDING6,7
The chemical bonding between an olefin and a transition metal is usually described 
via the Dewar-Chatt-Duncanson model (Figure 3.3).8 According to this model, a -
bond is formed between the 2p orbital of the olefin and an empty d orbital of the 
metal. The  electrons of the olefin are donated to the metal (LM donation, d). This 
is accompanied by back donation of electrons from a filled d orbital of the metal to the 
empty 2p
* orbital of the alkene (ML back-donation, b). On binding, the C=C bond 
of the olefin lengthens. This is mainly caused by the back-donation (b) and results in 
a rehybridization of the coordinated olefin carbons from sp2 to sp3. This explains why 
strained alkenes bind very strongly to metals; as in these cases rehybridization leads 
to a relief of strain. 
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M
pi orbital
olefin
empty
d orbital
metal
donation (d)
M
back-donation (b)
filled
d orbital
metal
pi∗ orbital
olefin
Figure 3.3. Dewar-Chatt-Duncanson Model 
Frenking et al. developed a partitioning scheme for analyzing the donor-acceptor 
interactions in a complex, called charged decomposition analysis (CDA).9 The CDA 
can be used as a quantitative expression of the Dewar-Chatt-Duncanson model. It 
calculates the relative amount of electron donation (d) and back-donation (b) in 
transition metal complexes for different ligands and metals. The orbital contributions 
to the charge distribution are divided in 4 parts: 
1) mixing the occupied orbitals of the ligand and the unoccupied MO’s of the 
metal fragment (LM donation, d); 
2) mixing the unoccupied orbitals of the ligand and the occupied MO’s of the 
metal fragment (ML back-donation, b); 
3) mixing the occupied orbitals of the ligand and the occupied MO’s of the 
metal fragment (LM repulsive polarization, r); 
4) mixing the unoccupied orbitals of the ligand and the unoccupied MO’s of 
the metal fragment (residual term ). The residual term  should be ~0 for 
true donor-acceptor complexes. Thus the residual term  serves as a 
control term. 
In table 3.1 CDA results are given for some HAu-L complexes. Some interesting 
conclusions can be drawn. The data show that olefins are quite good donors 
comparable to N-heterocyclic carbenes (NHC). Phosphanes are the strongest, while 
acetylene and amines are weak donors. The acceptor properties of olefins are again 
comparable with NHCs. Phosphanes are very good acceptors. Amines are the 
weakest acceptors, as a result the d/b ratio becomes very large. 
H Au
b
d
H Au
b
d
H Au
b
d
C O
H Au
b
d
P
Me
Me
Me H Au
b
d
H
N
N
H
H Au
b
d
N
Me
Me
Me
Ligand (L) d b d/b 
C2H4 0.36 0.13 2.9 
C2H2 0.16 0.12 1.3 
CO 0.27 0.22 1.2 
PMe3 0.53 0.16 3.3 
imidazol-2-ylidene 0.36 0.12 3.0 
NMe3 0.20 0.01 32.7 
Table 3.1. CDA analyses for some HAu-L complexes. All energies are in kcal.mol-1. 
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A second important method is the extended transition state (ETS) promoted by 
Ziegler and Rauk.10 It is an energy partitioning method which calculates the energies 
associated with the ligandmetal donation and the metalligand back-donation. 
The bond dissociation energy –De between two fragments A and B is partitioned into 
several contributions. First, -De is separated into two major components Eprep and 
Eint: 
-De = Eprep + Eint  (1) 
Eprep is the energy needed to promote the fragments A and B from their equilibrium 
geometry and electronic ground state to the geometry and electronic state in the 
compound AB. Eint is the interaction energy between the two fragments in the 
molecule. This component can be divided on his part in three more components: 
Eint = Eelstat + EPauli + Eorb (2) 
Eelstat gives the electrostatic interaction energy between the two fragments. EPauli is 
a component giving the repulsive interactions between the fragments due to the fact 
that two electrons with the same spin cannot occupy the same region in space. Eorb 
is the stabilising orbital interaction term. The Eelstat term can be associated with the 
ionic bonding and Eorb with the covalent contributions to the bond.
11 In table 3.2 
these energies are shown for the HAu-L complexes. 
Ligand (L) Eint Eelstat EPauli Eorb
C2H4 -27.6 116.5 -90.9 -53.2 
C2H2 -26.6 118.5 -91.4 -53.8 
CO -34.2 154.2 -120.3 -68.1 
PMe3 -43.8 153.5 -144.3 -53.0 
imidazol-2-ylidene -52.7 174.1 -173.3 -53.5 
NMe3 -29.9 82.5 -81.7 -30.7 
Table 3.2. ETS analyses for some HAu-L complexes. All energies are in kcal.mol-1.
It is clear that the Eorb is similar for all ligands except the CO and amine ligand; this 
shows that this term should be carefully used in the context of complex stabilities. 
The repulsive term EPauli is not counterbalanced with Eelstat in the case of olefin, 
acetylene and CO ligands. In the case of NHC, the attractive term Eelstat is almost 
completely neutralized by the repulsive term EPauli. This makes that NHCs, together 
with phosphanes, are the strongest ligands in this series. 
Grützmacher et. al. investigated the influence of substituents  on the donation and 
back-donation in the bonding of both olefin and phosphine ligands with a platinum 
metal via CDA and ETS.12 In table 3.3 the most important data are represented. For 
the olefin ligands, it is clear that neither the donation (d) nor the back-donation (b) 
depends largely on the nature of the substituent R.  However, when we look at the 
d/b ratios some trends become clear. The acrylonitrile is the strongest acceptor while 
the enol is the strongest donor olefin. In phosphanes, again the d/b ratio is high. This 
means that electron donation makes a significant contribution to the binding. The 
most important conclusion we can draw from this table, is that variation of the 
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substituents R has a larger effect in the phosphane complexes. This indicates that 
the electronic properties of a transition-metal complex may be more easily controlled 
by changing the substituent of a coordinated phosphane than in an olefin complex. 
 R d b d/b  De Eint
H3P
Pt
PH3
H H
H R
H 0.51 0.38 1.33 -0.01 15.4 56.9 
CN 0.47 0.42 1.13 -0.01 17.6 62.8 
F 0.51 0.40 1.27 -0.02 11.9 58.9 
NH2 0.51 0.38 1.35 -0.02 6.6 54.7 
OH 0.50 0.37 1.37 -0.02 9.9 53.9 
        
H3P
Pt
P
PH3
H H
R
H 0.38 0.23 1.67 0.02 9.7 28.3 
CN 0.35 0.29 1.20 0.02 11.4 30.1 
F 0.46 0.34 1.35 -0.04 19.6 44.3 
NH2 0.49 0.27 1.78 0.01 14.2 35.8 
OH 0.47 0.30 1.53 0.00 16.3 38.7 
Table 3.3. CDA and ETS analysis of Pt-olefin and Pt-phosphane complexes. All 
energies are in kcal.mol-1. 
The dissociation energy De is the energy which is required to dissociate the complex 
Pt(PH3)2L into the fragments Pt(PH3)2 and L. Both fragments should be in their 
ground state structures, i.e. Pt(PH3)2 being linear and the ligand L in the 
uncomplexed structure (scheme 3.2).  
H3P
Pt
L
PH3
H3P Pt PH3 + L
H3P PH3
Pt + L*
*
De
Eint
E1prep E2prep
∆
∆ ∆
Scheme 3.2. Illustration of the dissociation energy (De), the interaction energy (Eint) 
and the preparation energies (E1prep and E
2
prep). 
The dissociation energy De is smaller than the interaction energy Eint by the sum of 
the preparation energies E1prep and E
2
prep: 
De = Eint – (E
1
prep + E
2
prep) (3) 
Most of the time, De and Eint do not differ too much from each other, e.g. when only 
small deviations are needed to prepare the “ready-to-bind” states MX2* and L*. 
However, it is clear from table 3.3 that E2prep are especially large for olefin ligands. 
This is due to the elongation of the double bond and rehybridization of the carbon 
atoms from sp2 to sp3 upon complexation. This is the reason why olefin ligands are 
relatively weakly bonded ligands. 
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3.3 CHIRAL OLEFIN LIGANDS IN ASYMMETRIC TRANSITION-
METAL CATALYIS7,13
Whereas olefins have been used as ligands since the emergence of Zeise’s salt, the 
use of chiral olefin ligands in asymmetric transition metal catalysis has long been 
neglected. This was mainly due to the observed lability of olefin ligands. Lemaire 
observed that the nature of an achiral diene had a great influence on the asymmetric 
reduction of ketones.14 He also stated that it is worthwhile to study complexes with a 
chiral diene. This idea was, however, not immediatly put into practice. 
In 2003, the first chiral diene ligand was disclosed by Hayashi et al.15 He synthesized 
a C2-symmetrical diene (3.10) based on a rigid bicyclo[2.2.1]heptadiene framework. 
The catalytic activity exerted by the chiral olefin-rhodium complex in asymmetric 1,4-
additions was one of the highest observed. In addition, very high selectivities were 
obtained (up to 97% ee) (Scheme 3.3).  
This work was rapidly followed by a publication from Carreira’s group.16 Independent 
from the work of Hayashi, Carreira et al. synthesized a chiral diene based on a 
bicyclo[2.2.2]octadiene backbone (3.12). They evaluated the catalytic properties of 
this diene in the iridium-catalyzed kinetic resolution of allyl carbonates. Again very 
high enantioselectivities were obtained (Scheme 3.4).  
It is entirely clear that the synthesis of Carreira’s ligand has some advantages over 
Hayashi’s synthesis. Firstly, the synthesis is much shorter and starts from cheap 
carvone. Secondly, introduction of side chains is not straightforward in the case of 
Hayashi, due to the sequential introduction of the two side chains.  
H
H
HO
OH
O
O O
O
O
O
O
Bn Ph
Ph
Hayashi Ligand (3.10)
a, b c d
e, f g, e, f
O
+   RB(OH)2
O
RKOH (50 mol%)
dioxane/H2O (10:1)
20 - 50 °C
[RhCl(C2H4)2]2 / 3.10
3 mol%
*
Rh/diene-catalyzed asymmetric 1,4-addition
3.5 3.6 3.7 3.8
3.9
73-96% yield
88-99% ee
Scheme 3.3. Synthesis of Hayashi’s ligand (3.10): a) HSiCl3, [PdCl(-allyl)]2/ (R)-
MeO-MOP (0.1 mol% Pd), 0°C. b) i)MeOH, Et 3N; ii) H2O2, KHF2, THF/MeOH. c) 
Swern conditions. d) HOCH2CH2OH, TsOH. e) i) LDA, THF; ii) Tf2Npy-2. f) 
BnMgBr/Et2O, PdCl2(dppf) (1 mol%). g) dil HCl/THF. 
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3.11
O
Me
Me
(-) carvone
OMe
OMeMe
Me
OMeMe
R
+ diastereomer
Carreira Ligand (3.12)
a, b c, d
R
OCO2Me OH
R
OCO2Me
+
R
OPh[IrCl(COE)2]2 / 3.12
CH2Cl2 , 25°C
+
28-40% yield
80-98% ee
38-50% yield
45-92% ee
R= alkyl, 
      aryl
Ir/diene-catalyzed kinetic resolution of allylic carbonates
Scheme 3.4. Synthesis of Carreira’s ligand (3.12): a) NBS, MeOH. b) t-BuOK,  
t-BuOH. c) LDA, PhNTf2. d) ArZnCl, cat Pd.
The pioneering work of Hayashi and Carreira demonstrates that dienes with the 
proper geometry can be used as stable ligands for asymmetric transition metal 
catalysis. Since then a large number of chiral olefin ligands has been synthesized by 
various groups (Figure 3.4). The most intriguing examples will be discussed in more 
detail.  
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3.21a: Ar= Ph
3.21b: Ar= Bn
3.21c: Ar= p-Me-O-Ph
3.21d: Ar= 1-naphthyl
H
H
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Ar
Xu & Lin26
Laschat27
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3.22a: R= OCH2OCH3
3.22b: R= OH
3.22c: R= Ph
3.22d: R= OSiPh3
3.22e: R= (-)-menthoxy
F
F
F
F
R
R 3.23a: R= CO2Me
3.23b: R= CH2OH
3.23c: R= CH2OMe
3.23d: R= CMe2OH
3.23e: R= CMe2OMe
Me
R
Hayashi28, 29 Hayashi30
Figure 3.4. Overview  of the chiral dienes synthesized by various groups. 
Shortly after their first paper, Carreira et al. synthesized a novel diene ligand (3.15a-
e).19 Via a slight modification of the original synthetic route, two substituents could be 
introduced (Scheme 3.5). The most successful member of this ligand class is 
commercially available in both enantiomeric forms from Sigma-Aldrich under the 
name DOLEFIN (3.26). These ligands were used for asymmetric 1,4-addition to , -
unsaturated carbonyl compounds and to , -unsaturated aldehydes. 
Chapter 3. Chiral diene ligands 
34
3.24 3.25
O
Me
Me
(-) carvone
a, b
Me
Me
O
c, d
Me
OMeMe
+ diastereomer
O
e, f, g
Me
OMeMe
DOLEFIN
3.26
Scheme 3.5. Synthesis of Carreira’s disubstituted DOLEFIN (3.26): a) i-BuMgBr, 
Et2O. b) PCC, CH2Cl2. c) NBS, CH2Cl2, MeOH. d) t-BuOK, THF. e) i) LDA, THF; ii) 
BnBr. f) LiNEt2, PhNTf2, THF. g) Pd(OAc)2, Ph3P, HCO2H, DMF. 
Hayashi et al. synthesized  a whole range of bicyclic dienes. The 
bicyclo[2.2.2]octadiene ligand (3.14a-b) was resolved through a fractional 
crystallization of a hydrazone in very low yield which is a major drawback of this 
ligand family.18 The bicyclo[3.3.1]nonadiene (3.16) and bicyclo[3.3.2]decadiene 
(3.17) ligands were resolved via preparative HPLC on a chiral stationary phase.22 The 
low yield for the recrystallization and the use of preparative HPLC techniques for the 
separation of ligands can seriously hamper their use in both university and industry. 
A very elegant method for the separation of chiral ligands was demonstrated by 
Grützmacher et al.24 and later by Hayashi et al (Scheme 3.6).23  The chirality of the 
prochiral diene (3.27) is generated and fixed on coordination to the metal (3.28). 
Ligand substitution with (R)-1,1’-binaphthyl-2,2’-diamine formed a mixture of 
diastereomeric complexes (3.28). Fractional crystallization yielded selectively one of 
the diastereomeric isomers (3.29). Removal of the chiral diamine with HCl in 
acetonitrile followed by abstraction of the chloride with AgBF4 afforded the 
enantiomerically pure complex (3.18). This complex 3.18 was used in the rhodium-
catalyzed asymmetric 1,4-addition. It appeared that the enantioselectivity was lower 
when higher conversions were obtained. This was due to the racemization of the 
catalyst under the reaction conditions. They realized that if one could find conditions 
making the addition step faster than the catalyst racemization, higher selectivities 
could be obtained. By using phenylzinc chloride in the presence of 
chlorotrimethylsilane - which is a very fast reaction31 - high enantioselectivities were 
obtained.  
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3.29
Ph
Ph
Rh
Cl
2
Ph
Ph
Rh
Cl
2
+
Ph
Ph
Rh
N
N
H
H BF4
-
Ph
Ph
Rh
NCMe
NCMe
BF4
-
a
b, c d, e
O
O
+ PhZnCl
3.18/ Rh (3 mol%)
Me3SiCl (1.5 equiv)
THF, 0°C, 20 min
O
O
Ph
99% yield
98% ee
3.18
Scheme 3.6. Resolution of a substituted cyclooctadiene (3.27) by complexation with 
a chiral diamine: a) [RhCl(C2H4)2]2, benzene . b) i) (R)-1,1’-binaphthyl-2,2’-diamine; ii) 
AgBF4, CH2Cl2. c) recrystallization in THF/benzene. d) conc HCl, MeCN. e) AgBF4, 
MeCN. 
Trauner et al. synthesized a bisenone (3.20) that formed an air- and moisture-
insensitive, stable Pd(0)-complex.25 Unfortunately, the complex did not show any 
asymmetric induction. 
Xu and Lin developed a new chiral diene ligand class based on a bicyclo[3.3.0]-2,6-
octadiene framework (3.21a-d).26 This C2-symmetrical  tetrahydropentalene-rhodium 
catalytic system showed remarkable yields and enantioselectivities (98-99% ee) in 
the addition of a wide range of arylboronic acids to imines (Scheme 3.7). This ligand 
is now commercially available from Sigma-Aldrich. 
Ar1 N
Ts
Ar1 Ar2
+  Ar2B(OH)2
NHTs
Ph
Ph H
H
[RhCl(C2H4)2]2
solvent, Et3N, 55°C
up to 99% yield
98-99% ee
3.21a
Scheme 3.7. Catalytic asymmetric 1,2-addition of arylboronic acids to N-
tosylarylimines. 
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In an efficient way, Hayashi et al. developed a new diene ligand (3.23a) in one step 
via a [4+2] cycloaddition of (R)--phellandrene with methyl propiolate in 73% yield.30
Several analogues (3.23b-e) could be synthesized from this diene (Scheme 3.8). 
High selectivities were obtained with this ligand in rhodium-catalyzed asymmetric 
conjugate addition reactions. 
CO2Me
H
(R)-α-phellandrene
+ CO2Me
Me
Me Me
OH OH
Me2AlCl
CH2Cl2, 0°C, 6h
MeLiHAlBui2
3.23a
3.23b 3.23d
Scheme 3.8. Easy one-step synthesis of chiral dienes.
As already mentioned, asymmetric conjugate additions are very suitable reactions for 
diene catalyst systems. Several substrates have been addressed by various groups, 
e.g. substituted maleimides32 (3.30), ,-unsaturated esters33 (3.31), ,-unsaturated 
Weinreb amides34 (3.32), -silyl-substituted- ,-unsaturated carbonyl compounds35
(3.33), quinone monoketals36 (3.34) and arylmethylene cyanoacetates37 (3.35) 
(Figure 3.5).  
  
3.30 3.31 3.32 3.33
3.34 3.35
NBn
O
O
R
Ar OtBu
O
9 examples
82-98% yield
80-98% ee
14 examples
62-95% yield
89-94% ee
R N
O
OMe
Me
R3Si R
O
8 examples
74-93% yield
80-92% ee
12 examples
86-96% yield
93-99% ee
O
OO
11 examples
86-98% yield
96-99% ee
Ar
CO2Me
CN
11 examples
90-99% yield
96-99% ee
Figure 3.5. Different acceptors in Rh/diene-catalyzed 1,4-additions.
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Chiral diene-metal complexes can even catalyze efficiently domino reactions. Domino 
reactions, or cascade reactions, are processes involving two or more bond-forming 
transformations which take place under the same reaction conditions without adding 
additional reagents and catalysts, and in which the subsequent reactions result as a 
consequence of the functionality formed in the previous step.38,39 These domino 
reactions are very powerful methods for the preparation of structurally complex 
molecules in a convergent manner from relatively simple precursors. Hayashi et al.
evaluated the effectiveness of chiral diene ligands in several cascade reactions 
(Scheme 3.9).  
For example, the organorhodium species can undergo a syn addition across the triple 
bond of alkynals.40 The formed intermediate readily cyclizes by an intramolecular 
attack on the aldehyde. The resulting cyclic allylic alcohols were obtained in high 
yield and selectivity (Scheme 3.9a). In the presence of (S)-BINAP, low yields are 
obtained and only moderate selectivities (24% yield, 76% ee).  
Remarkable chemoselectivity was observed when alkyne-tethered electron-deficient 
olefins were used as substrates.41 Using bisphosphanes, such as (S)-BINAP and 
dppf, the 1,4 addition was more effectively catalyzed than the arylation of alkynes. A 
low chemoselectivity was observed with (S)-BINAP resulting in various products. In 
contrast, Rh/diene (3.14b) catalysts favor effectively the arylation of alkynes and high 
selectivities were obtained (Scheme 3.9b).  
A rhodium-chiral diene complex (3.14a) served as a high-performance catalyst for the 
intramolecular asymmetric [4+2] cycloaddition of alkyne-1,3-dienes.42 A rhodium-
COD complex was 20 times more active than a rhodium-bisphosphane complex: (R, 
R)-Me-DUPHOS gave only 9% yield and 44% ee (Scheme 3.9c).  
Also indenols could be synthesized in high yield and good selectivity.43 The same 
reaction with phosphane ligands failed to produce the desired product (Scheme 
3.9d). 
Attempts to synthesize indanols with diene ligand (3.14b) all failed. In contrast, higher 
activities of the rhodium-complex were obtained with the tetrafluorobenzobarrelene 
(tfb) ligands (Scheme 3.9e).44 In equilibrium experiments between both diene ligands 
and their iridium complexes, a higher coordination ability was observed for the tfb 
ligand. 
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Scheme 3.9. Overview of diene/metal-catalyzed cascade reactions. 
Recently, several groups designed phosphane-olefin hybrid ligands (Figure 3.7). 
These ligands combine the high coordination ability of phosphane ligands and the 
good chiral environment created around the metal by olefin ligands (Figure 3.6). The 
two groups on phosphorus shield both the top-left and bottom-left sections of the 
space around the metal, while the group on the olefin blocks only the top-right 
section.  
P
M
high coordination
ability
efficient creation
of a chiral 
environment
Figure 3.6. Design of chiral phosphane-olefin ligands. 
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Figure 3.7. Literature examples of hybrid phosphane-olefin ligands. 
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3.4 DEFINITION OF THE PROBLEM
As we already stated, the synthesis of Hayashi’s ligand (3.10) had some serious 
drawbacks.15 Because they were unable to synthesize the vinylic bistriflate (3.45), an 
elaborate synthesis was carried out (9 steps) (Scheme 3.3). As a result of this 
tedious synthesis, variation of the side chains was labour-intensive and therefore not 
straightforward.17  
A solution for this problem was found in our laboratory. Vandyck found that 
enolization of the racemic diketone (±)-3.7 with KHMDS at -78°C and subsequent 
trapping with triflating agent PhNTf2 resulted in racemic bistriflate (±)-3.45 in good 
yield (Scheme 3.10).52, 53 
O
O
TfO
OTf
Ph2P
PPh2
O
O
PPh2
Ph2P
H
H
PPh2
Ph2P
H
H
a b
c f
DIPHONANE
R R
R: =O
R: =O
R: = BH3
(±)-3.7 (±)-3.45 (±)-3.46
d
e
3.47
3.48
3.49
3.47
(±)-
Scheme 3.10. Synthesis of DIPHONANE (3.49): a) i) KHMDS, -78°C; ii) PhNTf 2, 
-78°C. b) i) HPPh 2, Pd(OAc)2, BINAP, DIPEA, 45°C; ii) H 2O2. c) Pd/C (10 w/w %), 4 
atm H2, MeOH. d) i) (R,R)-(2,3-di[O-(phenylamino)carbonyl]tartaric acid, 
EtOAc/CHCl3; ii) 1M NaHCO3. e) i) HSi(OEt)3, Ti(O
iPr)4, toluene, 100°C, 2h; ii) 
BH3.Me2S. f) EtOH, reflux. 
Our aim was to synthesize enantiomerically pure bistriflate 3.45 and synthesize 
Hayashi’s ligand 3.10 along with some side chain-analogues. 
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3.5 SYNTHESIS OF BISTRIFLATE 3.45
3.5.1 Synthesis of (1S, 4S)- bicyclo[2.2.1]heptane-2,5-dione (3.7) 
3.51
Cl3Si
SiCl3
(MeO)3Si
Si(OMe)3
HO
OH
O
O
a b
c d
OMe
Ph2P
(S)-MeO-MOP (3.52)
3.503.5
3.6 3.7
64% over 
three steps
82%
Scheme 3.11. Synthesis of dione (1S,4S)-(3.7): a) HSiCl3, [PdCl(C3H5)]2/(S)-MeO-
MOP (0.1 mol % Pd), -3°C. b) MeOH, Et 3N, Et2O. c) H2O2.urea, KHF2, THF/MeOH. 
d) i) (COCl)2, THF, -78°C, 1h; ii) Et 3N, -78°C. 
The synthesis starts with a palladium-catalyzed asymmetric hydrosilylation of 
bicyclo[2.2.1]heptadiene (3.5) with (S)-MeO-MOP (3.52) as chiral monodentate 
phosphane ligand.54 If norbornadiene reacts with 1 equivalent of trichlorosilane, the 
monosilylated product is formed with a selectivity of 95% ee. However, when the 
reaction is performed with 2.5 equivalents of trichlorosilane the disilylated product 
(3.50) is formed with a higher selectivity (99% ee). This due to the double 
stereoselection and the fact that the minor isomer is converted to the meso product. 
The opposite enantiomer can be synthesized in the same way by using (R)- MeO-
MOP. 
Although high and reproducible selectivities are usually obtained, the reaction has 
some tedious drawbacks. The only silane that can be used is HSiCl3, which is volatile 
(bp 33°C) and hydrolyses readily. Moreover, the chi ral ligand (S)-MeO-MOP (3.52) is 
very expensive. And finally, the reaction itself is very exothermic. Hence, a slow  and 
controlled addition of norbornadiene (3.5) to the reaction mixture is recommended.  
The most commonly accepted mechanism for the hydrosilylation was described by 
Chalk and Harrod (Scheme 3.12).55,56,57 First, oxidative addition of a hydrosilane 
gives a hydrido-silyl complex B. This intermediate coordinates with the olefin (C). 
Insertion into the M-hydride bond (D) and finally reductive elimination gives the 
hydrosilylated product (3.53) and regenerates the catalyst (A).  
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3.53
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[M]
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SiR3
H SiR3
[M]
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SiR3
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H
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Scheme 3.12. Chalk-Harrod mechanism for hydrosilylation 
Next, the chlorosilane 3.50 can be oxidized in one step with 30% aqueous H2O2 in 
the presence of KF/KHCO3.
54c Berkessel et al. mentioned that this method gave 
rather poor yields and suggested a two-step method.58,59 Firstly, the chlorosilane was 
converted into a methyl silicate 3.51 by treatment with methanol and triethylamine. 
Oxidation with H2O2.urea in the presence of KHF2 gave the desired alcohol 3.6. The 
product was always accompanied by a small amount of meso alcohol. Via flash 
chromatography pure alcohol 3.6 could be obtained in 64% overall yield. 
Swern oxidation of bisalcohol 3.6 nicely afforded the diketone 3.7 in 82% yield.60 
3.5.2 Synthesis of (S, S)-bistriflate 3.45 
It is known that triflating of bicyclo[2.2.1]heptanone-derivatives with triflic anhydride 
and a base does not result in vinyltriflates but in geminal bistriflates (scheme 3.13a)61
or rearrangement products (scheme 3.13b)62. 
O OTf
OTf
50-60%
Na2CO3/Tf2O
O Na2CO3/Tf2O
TfO
+
OTf
(a)
(b)
Scheme 3.13. Triflate formation with triflic anhydride and Na2CO3.
In our laboratory, Vandyck et al. was able to synthesize racemic bistriflate (±)-3.45 in 
one step from dione (±)-3.7 in good yield (Table 3.4).53 Crucial for a good yield were 
the low temperature and the use of KHMDS as a base. Hayashi et al. used LDA as a 
base for enolization and was not able to synthesize the bistriflate. Therefore, 
monoacetalization of the dione was necessary (scheme 3.3).15,17 KHMDS has a pKa
of 26 in THF and is a considerably weaker base than LDA (pKa = 36).
63,64 The use of 
LiHMDS afforded a comparable yield, indicating that the potassium counterion is not 
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really essential. Lowering the reaction temperature resulted in good yields of the 
bistriflate (±)-3.45. 
3.54O
O
a
TfO
OTf OTf
O
+
3.7 3.45(±)- (±)- (±)-
 enolization equiv triflate formationc equiv (±)-3.45
(%) 
(±)-3.54
(%) 
1 KHMDS, 0°C, 30 min 2.2 PhNTf2, 0°C, 3h 2.3 20 24 
2 LiHMDS, 0°C, 15 min 2.6 PhNTf2
b 2.6 23 0 
3 KHMDS, -78°C, 1h 2.6 3.55, -78°C, 3h 2.6 69 0 
4 KHMDS, -78°C, 1h 2.6 PhNTf 2, -78°C, 3h 2.6 71 0 
5 KHMDS, -78°C, 1h 2.1 PhNTf 2, -78°C, 3h 2.1 68 14 
a
Reagents and conditions: i) enolization with KHMDS at indicated temperature and time; ii) trapping 
with triflating agent at indicated temperature and time. 
b LiHMDS was added to a solution of diketone (±)-3.7 and PhNTf2.
65 
c Triflating agents: 
N
Tf
Tf
N N
Tf
Tf
Cl
PhNTf2 3.55
Table 3.4. Bis-enol triflate-formation from dione 3.7a 53
Using  the procedure as described in table 3.4 (entry 4) we could synthesize 
enantiomerically pure bistriflate 3.45 on a large scale (7g) in good yield (55-60% 
yield).
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3.6 SYNTHESIS OF NORBORNADIENE LIGANDS VIA A 
GRIGNARD COUPLING
Introduction of the side chains succeeded via a palladium-catalyzed cross-coupling of 
3.45 with Grignard reagents in the presence of PdCl2(dppf).CH2Cl2 as a catalyst.
66,67
In general, good yields were obtained via this method (Table 3.5).  
OTf
TfO
R
R
+   RMgX
Fe
Ph2
P
PPh2
Pd
Cl
Cl
.CH2Cl2
(2.3 mol %)
Et2O3.45
3.10: R= Bn
3.56: R= i-Bu
3.57: R= c-Hex
3.58: R= allyl
Entry RMgX Product Yield (%)
1 BnMgCl (20 w/w % in THF) (S, S)-Bn-nbd* (3.10) 72 
2 i-BuMgBr (2 M in Et2O) (S, S)-i-Bu-nbd* (3.56) 33 
3 c-HexMgCl (2 M in Et2O) (S, S)-c-Hex -nbd* (3.57) 77 
4 AllylMgBr (1 M in Et2O) (S, S)-Allyl-nbd* (3.58) 41 
a 
Reagents and conditions: bistriflate 3.45 (1 equiv), RMgX (7 equiv), PdCl2(dppf).CH2Cl2 (2.3 
mol%), Et2O. 
Table 3.5. Palladium(0)-catalyzed Grignard cross-coupling.
We were able to synthesize Hayashi’s ligand with the benzyl side chain (3.10) (Table 
3.5, entry 1). Cross-coupling with BnMgCl produced a significant amount of 1,2-
diphenylethane via homocoupling. The latter was readily sublimed from the diene 
ligand under reduced pressure at room temperature. 
Furthermore, we wanted to prepare more sterically demanding analogues (3.56: R= i-
Bu and 3.57: R= c-Hex) and one with exocyclic double bonds (3.58) (Table 3.5, 
entries 2-4). The low yields, obtained for the i-Bu- (3.56) and allyl-analogue (3.57), 
are due to the volatility of the ligands because of their low molar mass and branched 
structure in the absence of any functionality. The allyl analogue (3.58) was inspired 
by the work of Carreira.19 Carreira et al. found that the presence of an allyl 
substituent resulted in an enhancement of the selectivity in the rhodium-catalyzed 
asymmetric 1,4-addition. A study of 3.59 by 1H NMR indicated that all three double 
bonds were involved in the complexation with rhodium. They synthesized two new 
ligands to investigate this remarkable effect: 3.60 failed to give a significant amount 
of product while 3.61 gave the product in high yield but with a decreased selectivity 
(Scheme 3.14).  
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3.59 3.60 3.61
OMe OMe OMe
O O
+ PhB(OH)2
Ph
ligand
[Rh(C2H4)2Cl]2
KOH
dioxane/H2O
87% yield, 95% ee 93% yield, 58% ee< 10 % conversion
Scheme 3.14. Effect of the introduction of exocyclic olefin moieties.
We synthesized a rhodium complex of (S,S)-allyl-nbd* (3.62). Unfortunately, the 
complex 3.62 was an oil so no X-ray structures could be obtained. Therefore, we 
performed a study by 1H NMR and APT towards the structure of this complex 3.62. 
Surprisingly, we could only detect one type of complex. It was immediatly clear that 
the coordination with the rhodium metal occured via the norbornadiene double 
bounds (Table 3.6 and 3.7) (Figure 3.8 and 3.9). Very large high field shifts are 
observed for the 1H and 13C nuclei of the endocyclic double bonds. In the APT 
spectrum, we observed Rh-13C coupling constants for all nuclei of the norbornadiene 
backbone. In sharp contrast, no coupling constants and almost no coordination shifts 
are noticed for the allyl substituents, indicating that these are not involved in the 
bonding with the metal. 
Norbornadienes are highly strained bicyclic compounds. Rehybridization of the 
coordinated olefinic carbon center from sp2 to sp3 leads to a certain relief of strain. 
This explains why the complexation occurs exclusively with the norbornadiene double 
bonds.  
Unfortunately, Carreira did not include the spectra of his complex, so we could not 
compare our spectra with his. The low conversion in the case of 3.60 suggests that 
the high selectivity of 3.59 is probably due to its pseudo C2-symmetry. 
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3.62
Rh
1
2
3
456
7
Cl
2
Figure 3.7. [RhCl(S,S)-allyl-nbd*]2 
Chemical shift (ppm)  = (complex- free ligand) assignment
1.18 - 0.77 1 
2.45 - 0.49 5 
2.94 0 5 
3.57 + 0.35 2 
3.60 - 2.59 3 
5.17 + 0.1 7trans
5.27 + 0.1 7cis
6.37 + 0.59 6 
Table 3.6. 1H NMR of Rh/(S,S)-allyl-nbd* (3.62), coordination shift () and  
assignment.
  
Chemical shift 
(ppm) 
multiplicity  = (complex- free ligand) assignment
38.47  + 2.47 5 
47.40 d, JC-Rh= 10.6 Hz - 86.11 3 
53.12 d, JC-Rh= 3.0 Hz - 0.19 2 
59.51 d, JC-Rh= 7.5 Hz - 12.28 1 
69.41 d, JC-Rh=11.3 Hz - 87.62 4 
116.62  + 0.81 7 
135.39  - 0.35 6 
Table 3.7. 13C NMR of Rh/(S,S)-allyl-nbd* (3.62), multiplicity,  coordination shift () 
and assignment.
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Figure 3.8. Comparison of the 1H NMR-spectra of (S,S)-allyl-nbd* (3.58) and 
[RhCl(S,S)-allyl-nbd*]2 (3.62). 
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Figure 3.9. Comparison of the 13C NMR-spectra of (S,S)-allyl-nbd* (3.58) and 
[RhCl(S,S)-allyl-nbd*]2 (3.62). 
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3.7 SYNTHESIS OF NORBORNADIENE LIGANDS VIA A SHAPIRO 
REACTION
An interesting method for preparing various norbornadiene ligands may be via a 
modified Shapiro reaction (Scheme 3.15).68,69 When bis-trisylhydrazone 3.63 reacts 
with 2 equivalents of n-BuLi, a vinylic bis-carbanion is formed after decomposition at 
0°C. This can then be trapped with a wide range of electrophiles to give the product 
alkene.70 Via this method, it would be possible to synthesize norbornadiene ligands 
with silyl-substituents.71
N
N NHTris
TrisHN
R
R
R Cl
Cl R
3.63
Scheme 3.15. Synthesis of dieneligands via a Shapiroreaction
Treatment of enantiomerically pure diketone 3.7 with trisylhydrazide resulted in bis-
trisylhydrazone 3.63. We selected the trisylhydrazone instead of a tosylhydrazone 
because it is known that, in this way, benzylic metalation is avoided and the 
decomposition of the N,-dianion to the vinyl anion is accelerated.70 
Next, the trisylhydrazone 3.63 was subjected to a Shapiro reaction. At low 
temperature (-78°C), to a solution of 3.63 in THF was added 4 equivalents of sec-
BuLi. After an hour, the orange-red solution was warmed to room temperature. 
Immediately, evolution of N2 started. When N2 evolution ceased, TMSCl was added 
and the resulting reaction mixture was stirred for another hour. TLC indicated a very 
complex mixture of products, however no sign of the desired bis-vinylsilane was 
observed. The use of TMEDA as a co-solvent had no beneficial effect. 
The reason why we did not observe any product formation is not totally clear. 
Probably the dianion on a strained norbornadiene skeleton is not stable enough.  
O
O
N
N NHTris
TrisHN
SiMe3
Me3Si
a
3.7 3.63 3.64
70%
Scheme 3.16. Synthesis of (S,S)-TMS-diene: a) trisylhydrazide (2 equiv), THF.
However, the Shapiro reaction starting from camphor is possible.72 Recently, (S,S)-
bicyclo[3.3.1]nona-2,6-diene was synthesized via a Shapiro reaction in high yield.73
Introduction of side chains via this method were not included. 
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3.8 APPLICATION OF THE SYNTHESIZED CHIRAL 
NORBORNADIENE LIGANDS
3.8.1 Rhodium-catalyzed 1,4-additions74
1,4-Addition of organometallic reagents to ,-unsaturated compounds is a very 
useful method for the formation of carbon-carbon bonds in organic synthesis.75 The 
use of copper- and rhodium-catalyzed asymmetric 1,4-addition reactions has been 
most extensively studied. Copper catalysis has typically been used for the 1,4-
addition of alkyl groups76, whereas the introduction of aryl- and alkenylgroups is 
effected with rhodium catalysts. 
Miyaura was the first to use a rhodium catalyst for the addition of aryl- and 
alkenylboronic acids to several ,-unsaturated ketones in water-containing 
solvents.77 A year later, in 1998, Miyaura and Hayashi developed an efficient 
asymmetric variant using Rh(acac)(C2H4)2/(S)-BINAP as a catalyst.
78
Following the pioneering work of Miyaura and Hayashi, several other chiral ligands 
were developed for the rhodium-catalyzed asymmetric 1,4-addition of arylboronic 
acids to ,-enones (Figure 3.10).  
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Figure 3.10. Chiral ligands exhibiting high enantioselectivity in the rhodium-catalyzed 
1,4-addition of arylboronic acids to ,-enones.
As described in section 3.3, chiral dienes are excellent ligands for asymmetric 
conjugate additions. The high catalytic activity of diene-rhodium complexes was 
proven in kinetic studies by Hayashi et al.84  The  catalytic cycle is shown in scheme 
3.17. An equilibrium (Kdimer) exists between a monomeric species and an inactive 
dimeric hydroxorhodium complex. Next, a transmetallation results in the formation of 
a phenylrhodium species. The transmetallation was identified as the rate-determining 
step. Insertion of the enone and liberation of the phenyl-adduct by addition of water 
regenerates the catalytically active monomeric hydroxorhodium complex. The 
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creation of a hydroxorhodium complex explains why the addition of bases has an 
accelerating effect on the 1,4-addition.85
O
+   PhB(OH)2
O
PhB(OH)3
dioxane/H2O (10:1)
30 or 50 °C
[RhOH(COD)]2
 [RhOH(BINAP)]2
*
[Rh]
O
H
[Rh]
H
O
[Rh]
Sol
OH
[Rh]
Sol
PhKdimer
k1
k2
PhB(OH)2 B(OH)3
OO Ph
* + H2O
Scheme 3.17. Mechanism of the Rhodium-catalyzed 1,4-addition of phenylboronic 
acid to enones. 
[ ][ ]
[ ]
totaler
total
RhK
RhOHPhBk
v
.811
.)(.2
dim
21
++
= (1) 
Reaction rate expression (1) was in good agreement with the reaction results. The 
assumption was made that k2.[enone] was much larger than k1.[PhB(OH)2]. Next, the 
rate and equilibrium constants could be determined by fitting the experimental data 
and equation 1 (Table 3.8).  
 Rh/COD 
30°C 
Rh/COD 
50°C 
Rh/BINAP86
50°C 
k1 [M
-1. s-1] 1.3 6.7 0.5 
Kdimer [M
-1] 3.8 x 102 3.8 x 102 8 x 102 
Table 3.8. Rate and equilibrium constants.
The dimerization constants do not differ much from one another. However, the rate 
constant k1 for the COD complex is 13.4 times higher than for the BINAP-complex. 
Such a large value for the rate-determining transmetallation step (k1) explains the 
high catalytic activity of diene ligands in rhodium-catalyzed 1,4-additions of PhB(OH)2
to enones. Miyaura et al. reported a TOF of 1.0 x 104 h-1 in the 1,4-addition of an 
arylboronic acid with [Rh(OH)(cod)]2 as a catalyst.
85 An asymmetric variant with a 
chiral bicyclo[2.2.2]octadiene ligand gave a TOF of 1.4 x 104 h-1 and a selectivity of 
96% ee.87 This TOF number is the highest reported for a catalytic asymmetric 
carbon-carbon bond-forming reaction. 
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The newly synthesized norbornadiene ligands (Figure 3.11) were evaluated and 
compared with Hayashi’s ligand 3.10 in the rhodium(I)-catalyzed 1,4-addition of 
phenylboronic acid to cyclohexenone and cyclopentenone (Table 3.9). 
3.10 3.56 3.57 3.58
Figure 3.11. Chiral diene ligands evaluated in the asymmetric 1,4-addition. 
The first test reaction was a verification experiment: the yield and selectivity were 
identical to those obtained in the original experiment of Hayashi.15 Next, we used our 
new analogues (3.56-3.58). It is immediatly clear from table 3.9 that similar 
selectivities were obtained. An increasing sterical demand of the ligand substituents 
did not lead to a difference in selectivity, whereas the reaction rate was greatly 
influenced (Table 3.9, entries 2-3). Remarkably, the selectivity did not drop with 
(S,S)-allyl-nbd* (3.58). This again suggests that the complexation with rhodium 
should happen with the norbornadiene double bonds. As a result, a C2-symmetrical 
complex is formed and high selectivities were obtained. 
The addition to 2-cyclopentenone, a more difficult substrate, led to some surprising 
results. The highest selectivity was obtained with (S,S)-allyl-nbd* (3.58) (Table 3.9, 
entry 8), which is slightly better than the selectivity reported for (R,R)-Bn-nbd* (3.10) 
(Table 3.9, entry 5). The more sterically demanding (S,S)-c-Hex-nbd* (3.57) showed 
a considerably lower reactivity than (S,S)-i-Bu-nbd* (3.56), but, surprisingly, also a 
somewhat lower selectivity (Table 3.9, entries 6-7).  
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O
+   PhB(OH)2
dioxane/1.5 M aq KOH 
(10:1)
[RhOH(C2H4)2]2 / ligand
(3 mol % Rh)
n
(2 equiv)
O
n
Ph
(S)-3.71a-b3.70a-b
n=1 (a), 0 (b)
Entry substrate Ligand Temp 
(°C) 
Time (h) Yield (%) ee (%)b
1 3.70a 3.10 30 1.5 95 96 
2 3.70a 3.56 30 5 80 95 
3 3.70a 3.57 30 16 94 95 
4 3.70a 3.58 30 4.5 72 95 
5c 3.70b 3.10 50 1 88 88 
6 3.70b 3.56 25 16d 73 85 
7 3.70b 3.57 25 16d 54 82 
8 3.70b 3.58 25 16d 44 90 
a 
Reagents and conditions: 3.70 (0.3 mmol), PhB(OH)2 (0.6 mmol), [RhCl(C2H4)2]2 (3 mol % Rh), 
ligand (ligand/Rh = 1.1/1.0), dioxane/1.5 M aq KOH(10:1). 
b Determined by HPLC analysis with a chiral stationary phase column (Chiralpak AS-H) 
c Result adopted from the literature.15 
d The reaction was not complete after the indicated time. 
Table 3.9. Rhodium(I)-catalyzed asymmetric 1,4-addition of PhB(OH)2 to cyclic 
enones. 
The absolute configuration of all the products obtained with our chiral diene ligands is 
exclusively (S). With regard to the origin of stereoselectivity, the stereo-determining 
step is the insertion of the enone to the carbon-rhodium species coordinated with a 
chiral diene ligand. As shown in scheme 3.18, 2-cyclohexen-1-one (3.70a) should 
approach from the Si-face to avoid the steric hindrance of the side chain of the diene 
ligand. This leads to the 1,4-adduct with (S)-configuration, which is consistent with 
the observed stereochemical outcome. 
Rh
R
OPh
Rh
R
O
Ph
O
Ph
si- face (S)-3.71a
Rh
R
Ph
re- face
O
Scheme 3.18. The stereoselectivity in the Rh(I)-catalyzed 1,4-addition with (S,S)-
disubstituted-diene ligands.
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It should be noted that the mode of enantioface discrimination of diene ligands is 
substantially different from that of bisphosphane ligands. The creation of a chiral 
environment around the metal by C2-symmetrical diene ligands is very efficient. This 
is due to the sterical difference between the hydrogen and the bulky substituents 
(Figure 3.12a). In contrast, the chiral environment of a metal/bisphosphane complex 
is usually controlled by the face/edge orientations of the phenyl groups on the 
phosphorus atoms (Figure 3.12b). The space discrimination is rigidly controlled by 
the size of the substituents in the case of chiral dienes. This rigid feature makes it 
easy to predict the stereochemical outcome of the reactions. In the case of BINAP, it 
is rather a conformational differentiation. 
Rh
H
H
PP
Rh
(a) (b)
Figure 3.12. Comparison of the creation of the chiral environment by (a) chiral (S,S)-
c-Hex-nbd* (3.57) and (b) (S)-BINAP. 
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An interesting reaction is the 1,4-addition of PhB(OH)2 to -acetamido acrylic ester 
3.72 giving phenylalanine derivatives 3.73 (Scheme 3.19). The stereochemistry is in 
this case not determined at the insertion step but at the hydrolysis step. The use of 
bisphosphonite 3.74 resulted in quantitative yield and a selectivity of 77% ee.80 A 
bisphosphite ligand 3.75 formed the product in 91% yield and a selectivity of 72% 
ee.88 The use of a BINAP/rhodium catalyst and PhBF3K resulted in 100% conversion. 
However, the product was racemic when water was used as a proton source. The 
use of guaiacol, a more-hindered proton source, proved to be crucial and a selectivity 
of 89.5% ee was achieved.89 With PhB(OH)2, a lower yield and selectivity was 
obtained (42% yield, 42% ee). This was explained by the fact that boronic acids can 
act as competitive proton sources. 
CO2Me
NHAc
+   PhB(OH)2 /
     PhBF3K
[Rh] / Chiral Ligand
CO2Me
NHAcPh
*
3.72 3.73
Fe
P
P
O
O
O
O
Br
Br
Br
Br
3.74
3.75
O
O
P
P
OH
OH
X
X
X
X
X
X =
Bisphosphonite (100% yield, 77% ee) Bisphosphite (91% yield, 72% ee) 
    
PPh2
PPh2 OMe
OH
guaiacol
3.76
BINAP (89% yield, 89.5% ee)  
Scheme 3.19. Rhodium(I)-catalyzed asymmetric 1,4-addition to -acetamido acrylic 
ester. 
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We wanted to investigate if diene ligands were effective in this type of 1,4-addition. 
First, we tried to optimize the reaction conditions with achiral ligands (Table 3.10).  
CO2Me
NHAc +   PhB(OH)2
      (4 equiv)
[Rh] / Ligand
CO2Me
NHAcPh
*
NaF (3 equiv)
dioxane/H2O (10:1)
+
CO2Me
NHAcPh
3.72 3.73 3.77
 Rhodium catalyst Additive Temp 
(°C) 
Time 
(h) 
Total 
Yieldb
(%) 
% 
Conjugate 
adductc
3.73 
% Heck 
productc
3.77 
1 [Rh(COD)Cl]2 / 100 24 77 82 18 
2 [Rh(COD)Cl]2 / 50 24 21 67 33 
3 [Rh(COD)Cl]2 1.5M aq KOH 50 24 23 64 36 
4 Rh(COD)(CH3CN)2.BF4 / 100 48 54 83 17 
5 [Rh(COD)OH]2 / 100 24 56 74 26 
6 [Rh(nbd)Cl]2 / 100 24 36 22 78 
7 [Rh(ethene)Cl]2 / 100 48 39 25 75 
8 Rh(acac)(ethene)2 / 100 48 34 21 79 
a
Reagents and conditions: 3.72 (0.5 mmol), PhB(OH)2 (2.0 mmol), NaF (1.5 mmol), [Rh] (3 mol % 
Rh), dioxane/H2O (10:1). 
b Isolated as a mixture of 1,4-adduct and Heck product. 
c The ratio conjugate adduct / Heck product was determined via GC on a Chiralsil-Val column. 
Table 3.10. Rhodium(I)-catalyzed 1,4-addition versus Heck reaction.  
The reaction proceeded well but, to our surprise, we found that besides the conjugate 
addition product also a Heck-type product was formed. This was not yet reported in 
the literature for this substrate. Normally Heck reactions are typically catalyzed with 
Pd(0)-complexes.90 Also, iridium91- and ruthenium92-catalyzed Heck reactions are 
described in the literature.  
Lautens et al. were the first to describe a rhodium-catalyzed Heck-type coupling with 
styrenes.93 It was attributed to the fact that styrenes are incapable of enolization. 
Almost at the same time, Mori et al. reported that it was possible to produce the Heck 
product with a rhodium catalyst in anhydrous THF.94 However by a simple solvent-
switch to THF/H2O, the major product became the 1,4-adduct. The reason for this is 
that the intermediate oxa--allylrhodium is readily protonated to form the conjugate 
adduct and at the same time the hydroxorhodium complex is regenerated. The 
preference for the conjugate addition appears to improve when the substrate has a 
more electron-deficient carbonyl group. Methyl vinyl ketone gives exclusively the 1,4-
adduct, unsaturated amides give a mixture and unsaturated esters give preferentially 
the Heck product. Lautens et al. observed that the reaction of t-butyl acrylate with 
phenylboronic acids gave preferentially the Heck product.95 Remarkable was the fact 
that the solvent was toluene/H2O. With bulky boronic acids, the conjugate product 
was selectively formed. The boronic acid was probably bulky enough to interfere in 
the Rh-H elimination. In the presence of - or -substituents on the acrylate, the 
formation of the 1,4-adduct was selective. The substituents on the acrylate may 
render the oxa--allylrhodium intermediate more basic through -bond inductive 
electron-donation and hence the protonation becomes faster. 
Several reaction parameters were adjusted in order to manipulate the reaction 
outcome (Table 3.10, entries 2-8). A lower temperature resulted in a lower yield and 
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also a lower selectivity for the conjugate addition product (Table 3.10, entry 2). 
Addition of KOH gave a similar result (Table 3.10, entry 3). Rh(COD)(CH3CN)2.BF4 
as a catalyst resulted in a similar selectivity as the first experiment but a somewhat 
lower yield (Table 3.10, entry 4). With OH- as counterion, a lower yield and a lower 
selectivity for 1,4-adduct was obtained (Table 3.10, entry 5). A remarkable result was 
obtained with norbornadiene and ethene as ligands: the selectivity was clearly in 
favour of the Heck product (Table 3.10, entry 6-8). So, by a proper choice of the 
ligand the selectivity could clearly be altered. Zou et al. have already demonstrated 
that Heck-coupling was selectively obtained in the presence of triphenylphosphane 
while conjugate addition was favoured in the presence of bisphosphanes.96
Although the selectivity for the conjugate addition was low in the presence of 
norbornadiene (22 % 1,4-adduct), we wanted to perform the reaction in the presence 
of the chiral Hayashi ligand 3.10 (Table 3.11). First, we carried out the reaction 
analogous to the experiment with the achiral norbornadiene. The results were similar; 
a slightly higher total yield was obtained (Table 3.11, entry 1). A higher selectivity for 
the conjugate adduct was observed but no chiral induction. The use of aq. KOH as 
cosolvent resulted in both a lower total and 1,4-adduct yield. A noticeable 
enantioselectivity was observed, albeit very low (Table 3.11, entry 2). Again, lowering 
the reaction temperature resulted in a lower total yield and a lower selectivity for the 
1,4-adduct (Table 3.11, entry 3). Using toluene/H2O (10:1) as a solvent-system gave 
a higher selectivity in favour of the 1,4-adduct. The enantioselectivity was higher 
although still unsatisfactory (Table 3.11, entry 4). The use of EtOH/H2O resulted in an 
almost 50/50 mixture of Heck product and 1,4-adduct and a similar enantioselectivity 
(Table 3.11, entry 5).  
3.72 3.73 3.77
CO2Me
NHAc
+  PhB(OH)2
    (4 equiv)
[Rh(ethene)Cl]2
NaF (3 equiv)
solvent CO2Me
NHAcPh
CO2Me
NHAcPh
* +
3.10
Entry Solvent Temp 
(°C) 
Time 
(h) 
Total Yieldb
(%) 
% Conjugate 
adduct 
(ee [%])c 
% Heck 
productc 
1 dioxane/H2O (10:1) 100 24 40 30 (rac) 70 
2 dioxane/ 1.5M aq KOH (10:1) 100 24 27 24 (9) 76 
3 dioxane/H2O (10:1) 50 48 8 27 (6) 73 
4 toluene/H2O (10:1) 50 48 12 60 (20) 40 
5 EtOH/H2O (10:1) 50 48 10 46 (21) 54 
a 
Reagents and conditions: 3.72 (0.25 mmol), PhB(OH)2 (1.0 mmol), NaF (0.75 mmol), 
[RhCl(C2H4)2]2 (3 mol % Rh), 3.10 (3.10/Rh = 1.1/1.0), solvent.
b Isolated as a mixture of 1,4-adduct and Heck product. 
c The ratio conjugate adduct / Heck product and enantiomeric excess was determined via GC on a 
Chiralsil-Val column. 
Table 3.11. Chiral diene/rhodium(I)-catalyzed 1,4-addition versus Heck reaction. 
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A mechanism for the observed transformations is proposed in scheme 3.20.95 The 
catalytically active hydroxorhodium (I) transmetallates with phenylboronic acid to form 
the phenylrhodium species (II). Next, insertion of the alkene (3.72) results in 
formation in a Rh-C bond (III). Addition of H2O results in the formation of the 1,4-
adduct (3.73) and regenerates the hydroxorhodium (I) catalyst. A second possibility is 
the -hydride elimination to generate the Heck product (3.77) and a rhodium hydride 
(IV). Subsequently the rhodium hydride (IV) should be converted into the 
hydroxorhodium (I). This can be done if we consider that the alkene (3.72) is used as 
a hydride acceptor (path A). Although we did not immediately discover traces of this 
product, it would explain the low yields obtained when the Heck product was the 
major product. It can also explain the lower ee’s in the asymmetric reactions when 
the Heck product (3.77) is used as as hydride acceptor. A second possibility is 
reaction of Rh-H (IV) with H2O to Rh-OH (path B).
97 The excess of boronic acid is 
partly consumed by reaction of the phenylrhodium species (II) with H2O.  
LnRh(OH)
Ph
B
OH
OH
B(OH)3
transmetalation
Ph
Rh Ln
CO2Me
NHAc
Ph
NHAc
LnRh
CO2Me
H2O
CO2Me
NHAcPh
1,4-adduct
-H-Eliminationβ
CO2Me
NHAcPh
LnRh(H)
CO2Me
NHAc
CO2Me
NHAc
H2
H2O
Insertion
Heck product
I
II
III
IV
A
B
H2O PhH
LnRh(OH)
I(3.73)
3.72
(3.77)
3.72
Scheme 3.20. Proposed catalytic cycle for rhodium-catalyzed 1,4-addition versus 
Heck coupling.
3.8.2 The asymmetric synthesis of diarylmethanols via a rhodium-catalyzed 
1,2-addition98,99,100
Enantiomerically pure diarylmethanols are important precursors for the synthesis of 
biologically active compounds, e.g. (R)-orphenadrine (3.78, an anticholinergic drug), 
(R)-neobenodine (3.79, an antihistamine drug), (R,R)-clemastine (3.80, an 
antihistamine drug) and (S)-carbinoxamine (3.81, an antihistamine drug) (Figure 
3.13).101
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O
Me
Cl
MeN
H
O
Cl
NMe2
N
O
NMe2
R R'
R= Me, R'= H      3.78
R= H, R'= Me      3.79
3.80 3.81
Figure 3.13. Chiral physiologically active compounds with a diarylmethane moiety.
The asymmetric synthesis of diarylmethanols can be achieved via two strategies: 
either an asymmetric reduction of the prochiral ketones or the asymmetric addition of 
aryl organometallic reagents to arylaldehydes (Scheme 3.21). The reduction strategy 
is often very efficient and cost-effective. However, high enantioselectivities are almost 
exclusively obtained with ortho-substituted benzophenones.102 In contrast, the 
asymmetric addition of aryl organometallic reagents to benzaldehydes looks more 
appropriate for obtaining high selectivities due to the larger difference between the 
phenyl and the hydrogen atom. 
OH
R1
R2
O
R1
R2
O
R1
R2
XnM'
+
H2
MLn MLn
Scheme 3.21. General synthetic strategies towards diarylmethanols.
A very convenient method was developed by Bolm et al. using a mixture of 
Ph2Zn/Et2Zn (1:2). Several benzaldehydes were arylated with high 
enantioselectivies.103 This method was further extended by mixing Et2Zn with 
triphenylborane104 or with phenylboronic acids105. 
The use of arylboronic acids as arylating agents has some important advantages 
over zinc reagents. They are shelf stable, readily available and compatible with a 
large variety of functional groups. Several groups have tried to synthesize chiral 
diarylmethanols via a rhodium-catalyzed 1,2-addition of phenylboronic acids to 
benzaldehydes (scheme 3.22). In 1998, Miyaura et al. reported an enantioselectivity 
of 41% ee with (S)-MeO-MOP (3.52) as a ligand.106 Bidentate phosphanes such as 
BINAP (3.84) and DIOP (3.85) resulted in the formation of racemic alcohols. Also, 
chiral nitrogen-based ligands (-)-sparteine (3.86), bisoxazoline (3.87) resulted in very 
low selectivities.107 Bolm et al. synthesized a chiral [2.2] paracyclophane-based NHC
(3.88). However, again low selectivities were obtained.108
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H
O
+
B(OH)2
OH
*[Rh]
OMe
Ph2P
3.52
Monodentate phosphane
78% yield,
41% ee
PPh2
Ph2P
bisphosphane
0% ee
O
O
PPh2
PPh2
N
OO
N
t-Bu t-Bu
nitrogen-based ligands
< 10% ee
N
N
H
H
H
H
PPh2
N
N
R
Br
3.88
imidazolium salt
85% yield, 
38% ee
3.82 3.83
3.84 3.85
3.86 3.87
Scheme 3.22. Literature examples for the rhodium-catalyzed 1,2-addition of 
phenylboronic acids to benzaldehydes.
Given the excellent performance of chiral diene/rhodium catalysts in the asymmetric 
1,2-addition of arylboronic acids to imines7, we wanted to investigate their ability to 
catalyze the challenging 1,2-addition to aldehydes. In a first attempt, we tried to find 
optimal reaction conditions using achiral norbornadiene as a ligand. We chose this 
ligand because of the similarity of this catalyst with our own chiral diene ligands 
(Table 3.12).  
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F3C
O
H
B
OHHO
+
[Rh(nbd)Cl]2
(3 mol % Rh)
F3C
OH
(2 equiv)3.89 3.90
Entry Solvent Temp (°C) Time (h) Yield (%)
1 dioxane/H2O (10:1) 60 48 0 
2 dioxane/1.5 M aq KOH (10:1) 60 48 32 
3b dioxane/1.5 M aq KOH (10:3) 50 6 78 
4c dioxane/1.5 M aq KOH (10:3) 50 16 50 
a 
Reagents and conditions:  3.89 (0.5 mmol), PhB(OH)2 (1 mmol), [Rh(nbd)Cl]2 (3 mol % Rh).
b PhB(OH)2 (6 equiv) was added in portions of 2 equiv with an interval of 2h to obtain complete 
conversion. 
c The rhodium/norbornadiene complex was formed in situ by mixing [Rh(C2H4)2Cl]2 and norbornadiene 
(norbornadiene/Rh, 1.1/1.0). 
Table 3.12. [Rh(nbd)Cl]2-catalyzed 1,2-addition of PhB(OH)2 to  
p-trifluoromethylbenzaldehyde.a 
In the absence of KOH, no conversion was observed (Table 3.12, entry 1) whereas in 
dioxane/1.5 M aq KOH (10/1) 3.90 was obtained in low yield (Table 3.12, entry 2). 
However, we noticed that all the PhB(OH)2 was consumed due to hydrolysis. 
Therefore, 6 equiv of PhB(OH)2 was added in portions of 2 equiv with an interval of 
2h to give complete conversion in dioxane/1.5 M aq KOH (10/3) (Table 3.12, entry 3). 
When the catalyst was formed in situ a slower reaction was observed (Table 3.12, 
entry 4). These results indicated that the diene ligands can indeed efficiently catalyze 
the 1,2-addition to aldehydes. 
Quite remarkably, with (S,S)-Bn-nbd* (3.10) as a chiral ligand (Table 3.13), the 
reaction was finished within 1 h, using only 2 equiv of PhB(OH)2 (Table 3.13, entry 1). 
The reaction was highly accelerated by this catalyst, although the selectivity was only 
25% ee. Changing the solvent did not improve the ee (Table 3.13, entries 2 and 3). 
Adding 2 equiv of KF instead of KOH did not lead to any improvement (Table 3.13, 
entry 4). Lowering the reaction temperature resulted in a higher selectivity up to 33% 
ee, while -remarkably- no loss of catalytic activity was observed (Table 3.13, entries 5 
and 6). Changing the ligand showed higher selectivity and equal reactivity for (S,S)-i-
Bu-nbd* (3.56) (37% ee) (Table 3.13, entry 7), while the selectivity and reactivity 
were considerably lower for the more bulky (S,S)-c-Hex-nbd* (3.57) (12% ee) (Table 
3.13, entry 8). The selectivity of (S,S)-allyl-nbd* (3.58) was slightly lower than for 
(S,S)-Bn-nbd* (3.10) (Table 3.13, entries 9 and 6). Changing the rhodium source 
appeared to have a pronounced influence on the reactivity. Use of [Rh(acac)(C2H4)2]2
as a catalyst precursor led to a comparable enantioselectivity but a much slower 
reaction at room temperature in combination with 3.58 (Table 3.13, entry 10). Using 
[Rh(COD)2]BF4.xH2O as a catalyst precursor in combination with 3.58 resulted in a 
high yield, albeit after a considerably longer reaction time, but poor enantioselectivity 
(Table 3.13, entry 11). 
  
In an attempt to further improve enantioselectivity by lowering reaction temperature to 
-25 °C, a combination of dioxane and ethanol (1/1) was used (Table 3.13, entry 12), 
resulting in a significantly higher enantioselectivity but a slow and incomplete 
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reaction. Because of the apparent beneficial influence of a protic solvent on the ee, 
dioxane was omitted and replaced by methanol, ethanol or isopropanol at 0–25 °C 
(Table 3.13, entries 13–15). In all cases, high yields and an improved selectivity were 
obtained as compared to dioxane (Table 3.13, entry 7). In methanol, the reaction rate 
at room temperature had decreased as compared to dioxane at 0 °C (Table 3.13, 
entries 13 and 7), while for ethanol and isopropanol at 0 °C it was comparable (Table 
3.13, entries 14 and 15). Performing the reaction in ethanol at -25 °C (Table 3.13, 
entry 16) led to the highest selectivity observed (48% ee), but a slow and incomplete 
reaction resulting in low yields. 
3.89
F3C
O
H
B
OHHO
+
[Rh(C2H4)2Cl]2 / ligand
(3 mol % Rh)
F3C
OH
(2 equiv)
solvent, additive
(R)- 3.90
Entry Ligand Solvent/additive Temp 
(°C) 
Time 
(h) 
Yield 
(%) 
Eeb
(%) 
1 3.10 dioxane/1.5 M aq KOH (10:3) 50 1 96 25 
2 3.10 DME/1.5 M aq KOH (10:3) 50 1 95 21 
3 3.10 toluene/1.5 M aq KOH (10:3) 50 6 72 22 
4 3.10 dioxane/H2O (10:3) / KF (2 equiv) 50 3 96 25 
5 3.10 dioxane/1.5 M aq KOH (10:3) 25 1 97 28 
6 3.10 dioxane/1.5 M aq KOH (10:3) 0 1 95 33 
7 3.56 dioxane/1.5 M aq KOH (10:3) 0 1 99 37 
8 3.57 dioxane/1.5 M aq KOH (10:3) 0 16 89 12 
9 3.58 dioxane/1.5 M aq KOH (10:3) 0 1 81 31 
10c 3.58 dioxane/1.5 M aq KOH (10:3) 25 16 60 28 
11d 3.58 dioxane/1.5 M aq KOH (10:3) 25 16 91 11 
12 3.56 dioxane/EtOH/1.5 M aq KOH (5:5:3) -25 72 23 44 
13 3.56 MeOH/1.5 M aq KOH (10:3) 25 16 93 40 
14 3.56 EtOH/1.5 M aq KOH (10:3) 0 3 98 41 
15 3.56 i-PrOH/1.5 M aq KOH (10:3) 0 5 92 42 
16 3.56 EtOH/1.5 M aq KOH (10:3) -25 72 26 48 
a 
Reagents and conditions: 3.89 (0.5 mmol), PhB(OH)2 (1 mmol), [RhCl(C2H4)2]2 (3 mol% Rh), ligand
(ligand/Rh = 1.1/1.0).
b Determined by HPLC analysis with a chiral stationary phase column (Chiralcel OJ-H). 
c [Rh(acac)(C2H4)2] was used as a rhodium source. 
d [Rh(COD)2]BF4.xH2O was used as a rhodium source. 
Table 3.13. Rhodium-catalyzed asymmetric 1,2-addition of PhB(OH)2 to p-
trifluoromethylbenzaldehyde. 
The absolute configuration of the major enantiomer obtained with our chiral diene 
ligands was (R). The origin of stereoselectivity is analogous to the model for the 1,4-
addition. In order to avoid repulsion of the aromatic ring from the substrate with the 
side chains of diene ligand, the substrate should approach from the si-face. This 
results in the formation of the (R)-enantiomer and is consistent with our observations. 
Chapter 3. Chiral diene ligands 
64
(R)- 3.90
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Scheme 3.23. The stereoselectivity in the Rh(I)-catalyzed 1,2-addition with (S,S)-
disubstituted-diene ligands.
3.9 FURTHER DEVELOPMENTS
During our work, Hayashi et al. published a paper where he also uses the bistriflate 
3.45 to synthesize analogues of 3.10.109 In addition, they were able to synthesize the 
rhodium-complexed phenyl analogue. The free ligand was previously reported to be 
unstable.18 The origin of the instability is due to the presence of a styrene moiety in a 
strained bicyclo[2.2.1]heptadiene. This causes the lowering of the * orbital making 
the compound susceptible to radical- and acid-catalyzed decomposition. This feature 
makes that the ligand itself is inherently unstable but it is also key for the increasing 
stability of the rhodium complex. 
One of the main reasons why we chose to test our diene ligands in the rhodium-
catalyzed asymmetric 1,2-addition of phenylboronic acids to benzaldehydes was the 
lack of good ligands for this transformation. While we were performing the tests, two 
new publications appeared on this subject. Feringa et al. reported that via a 
combinatorial approach a bidentate phosphoramidite 3.91 was selected which 
induced good selectivities (47-75% ee) (Scheme 3.24).100,110  
O
HAr1
+   Ar2B(OH)2
Rh(acac)(C2H4)2 (3 mol%)
2-propanol, reflux, 4h
OH
Ar2Ar1
P
O
O
N N P
O
O
3.91
(7.5 mol%)
(3 equiv)
61-94% yield
47-75% ee
Scheme 3.24. Feringa’s bidentate phosphoramidite. 
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Almost simultaneously with the publication of Feringa, Zhou et al. reported that spiro 
monophosphite 3.92 gave good yields and selectivities in this type of reaction 
(Scheme 3.25).111  
O
HAr1
+   Ar2B(OH)2
[RhCl(C2H4)2]2 (0.5 mol%)
toluene/H2O (1:1), 
2 equiv KF, 0 °C, 7h
OH
Ar2Ar1(2 equiv)
88-97% yield
62-87% ee
O
P
O
O
3.92
(2.1 mol%)
Scheme 3.25. Zhou’s monodentate phosphate. 
3.10 CONCLUSIONS
In summary, a novel route to synthesize chiral disubstituted bicyclo[2.2.1]heptadiene 
ligands was described. Advantages are a higher overall yield and the possibility of a 
simultaneous introduction of both substituents (Scheme 3.26).  
O
O
TfO
OTf
1. KHMDS, THF, -78°C, 1u.
2. PhNTf2, -78°C, 3u.
55-60 %
R
R
O
O
O
O
O
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O
O
R R
O
TfO
R
HOCH2CH2OH,
TsOH
97 %
1. LDA, THF
2. Tf2N py-2
70 %
RMgX, 
PdCl2(dppf)
97 %
2.0N HCl, THF
94 %
1. LDA, THF
2. Tf2N py-2
81 %
RMgX, 
PdCl2(dppf)
       45 %
RMgX, PdCl2(dppf)
33 - 77 %
Yield determined for R = Bn:
Hayashi:                  23 %
Our Method:            44 %
3.7 3.45 3.10
3.8
3.9
Scheme 3.26. Comparison of our new method and the original method of Hayashi.
Next, the ligands were tested in several rhodium-catalyzed asymmetric test reactions. 
The ligands performed best in the rhodium-catalyzed asymmetric 1,4-addition to 
cyclic enones. Enantioselectivities up to 96% ee were obtained.   
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In the 1,4-addition to -acetamido acrylic ester, the formation of a Heck-type product 
was observed as a side product. Moreover, the ratio of the conjugate adduct / Heck 
product could be adjusted by the proper choice of the ligand in the achiral version. 
When we turned to the asymmetric reaction with ligand 3.10 low yields and 
selectivities were detected. 
Given the nice results of chiral diene/rhodium complexes in 1,4-additions to cyclic 
enones, we investigated the rhodium-catalyzed 1,2-addition of phenylboronic acids to 
benzaldehydes. This reaction can be considered as a challenging reaction. The 
presence of the alkyl side chains on the ligand appeared to be crucial for the catalytic 
effect, resulting in a dramatically higher reactivity as compared to unsubstituted 
norbornadiene as a ligand. On the other hand, enantioselectivities could be improved 
from poor to fair with ligand 3.56 (up to 48% ee). 
In conclusion, chiral dienes can be used as highly selective ligands for asymmetric 
transition metal catalysis. However, till now they have been used almost exclusively 
in rhodium- and iridium-catalyzed reactions. Future work should be directed to the 
search of new metals compatible with these diene ligands. As a result, new reactions 
can be addressed.  
Part of this chapter has been published: Noël, T.; Vandyck, K.; Van der Eycken, J., 
“Some new C2-symmetric bicyclo[2.2.1]heptadiene ligands: synthesis and catalytic 
activity in rhodium(I)-catalyzed asymmetric 1,4- and 1,2-additions” , Tetrahedron
2007, 63, 12961-12967. 
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4 
CHIRAL IMIDATE 
LIGANDS 
4.1 INTRODUCTION 
In asymmetric catalysis, the most widely-used ligands are phosphane ligands. 
However, nitrogen-containing ligands have several distinct advantages.1,2 First, they 
are largely available in enantiomerically pure form from the chiral pool. In addition, 
the production of chiral amines from the resolution of racemates is probably one of 
the easiest methods of enantiomer separation. In contrast to chiral phosphanes, 
chiral nitrogen atoms are difficult to obtain because of instantaneous epimerization at 
room temperature. The formation of a stable chiral center on a nitrogen is however, 
possible by using bicyclic structures, e.g. quinine (4.1), cinchonine (4.2) and 
sparteine (4.3) (Figure 4.1).  
N
N
HO
H
N
N
HO
H
MeO
N
N
H
H
H
H
4.1 4.2
4.3
Figure 4.1. Ligands containing chiral nitrogen atoms. 
Nitrogen-containing ligands may be used in asymmetric catalysis with other transition 
metals, less expensive than noble metals, e.g. cobalt complexes.3 And they turn out 
to be suitable for heterogeneous catalysis which is one of their main advantages over 
phosphane ligands.4
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4.2 THE METAL-NITROGEN BONDING5,6  
Like phosphanes, nitrogen-donors have a lone pair on the central atom which can be 
donated to a metal. In contrast to nitrogen-donors, phosphanes are also  acceptors. 
The -bond is formed between the * orbital of the P-R bond and a filled d orbital of 
the metal (Figure 4.2). Nevertheless,  interactions are possible with ligands 
containing sp2-hybridized nitrogen donors. 
M N
R
R
R
M P
R
R
R
Nitrogen ligands Phosphane ligands
donation donation + back-donation
Figure 4.2. Coordination model with a metal for nitrogen and phosphane ligands. 
In table 4.1, M-L bond energies are listed. The results indicate that M-C bonds are 
weaker than the M-N bonds, which in turn are weaker than the M-O bonds. 
ML4 X-M
+ 
L Ti Zr Hf M H CH3 NH2 
CH2t-Bu 188 227 224 Sc 57(2) 59(3) 85(2) 
NEt2 309 340 367 Ti 54(3) 54(2) 85(3) 
Oi-Pr 444 518 534 V 48(2) 50(2) 73(2) 
F 586 648 665 Fe 50(2) 58(2) 67(12) 
    Co 47(2) 49(4) 62(2) 
    Ni 40(2) 45(2) 56(5) 
Table 4.1. Mean M-L bond dissociation enthalpies [kJ.mol-1] for homoleptic 
complexes ML4 and M-X bond dissociation enthalpies for X= H, C, N [kcal.mol
-1].
Particularly relevant for the transfer of stereospecific information from a complex to a 
substrate is the stability of the ligand metal complex. In table 4.2, the dissociation rate 
constants for mono- and bidentate nitrogen heterocycles from NiII and CoII complexes 
are listed.7 It is immediately clear that the monodentate ligand pyridine is much more 
labile than bidentate ligands, such as 2,2’-bipyridine and phenanthroline. 
Phenanthroline, which is a rigid ligand, is less labile than the more flexible 2,2’-
bipyridine. 
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complex M = Ni M = Co 
[M(H2O)5(pyridine)]
2+ 40 8 x 10-2
[M(H2O)4(2,2’-bipyridine)]
2+ 5 x 10-5 6 x 10-2
[M(H2O)(phenanthroline)]
2+ 1 x 10-5 1 x 10-2
Table 4.2. Rate constants [s-1] for the dissociation of mono- and bidentate nitrogen 
heterocycles from NiII and CoII complexes: T= 25°C, pH  6.0.
The stability of metal-ligand bonds must take into account sterical interactions. These 
have been successfully parametrized for P-donors with Tolman’s cone angle concept 
(Table 4.3).8 The cone angles (P) are obtained by taking a space-filling model of the 
M(PR3) group, folding back the R substituents away from the metal, and measuring 
the angle of a cone that will just contain all of the ligand while the apex of the cone is 
at the metal (Figure 4.3). The corresponding values for nitrogen donors (N) have 
also been reported (Table 4.3).9 The cone angle for N-donors is in general larger 
than for the corresponding P-donors. Moreover, the difference between the two 
becomes greater for the larger ligands. This indicates that the strength of M-N bonds 
will be affected much more by sterical effects than that of the corresponding M-P 
bonds. 
Figure 4.3. Tolman’s cone angle concept. 
Ligand P [°] N [°] 
XH3 87 94 
XMe3 118 132 
XEt3 132 150 
XPh3 145 166 
Table 4.3. Tolman’s cone angle values for P-donors (P) and the corresponding N-
donors (N). 
An important difference between phosphane and nitrogen ligands is their trans-effect. 
The trans-effect can be defined as the effect of a ligand upon the rate of ligand 
replacement of the group trans to itself.10 As can be seen from table 4.4, phosphane 
ligands exert a very large labilizing effect of a trans positioned ligand. In sharp 
contrast, nitrogen donors are very weak. 
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trans-effect Donor ligand krel. 
very large CO, CH-, C2H4, PR3 ca. 10
5
large SC(NH2)2, NO2
-, I-, SCN-, 
CH3
-, C6H5
-
ca. 102
moderate Br-, Cl- ca. 1 
weak pyridine, NH3, OH
- ca. 10-1
Table 4.4. Common donors arranged in order of decreasing trans-effect and 
approximate values of the exchange rates of the trans ligands in a PtIIcomplex. 
4.3 IMIDATES11,12,13
Imidates (4.4) are esters of the hypothetical imidic acids or iso-amides (4.5).14 Cyclic 
imidates can be divided in three groups: (1) the imidate function lies completely within 
the ring, e.g. oxazolines (4.6) and dihydro-oxazines (4.7); (2) the oxygen function has 
an exocyclic position (4.8); (3) the imino-nitrogen has an exocyclic position (4.9). 
R OR"
NR'
R OH
NR'
R
N
O
N
O
R
N OMe O
NH
4.4 4.5
4.6 4.7 4.8 4.9
The nitrogen analogue of imidates is the amidine group. In comparison to amidines, 
imidates have a smaller dipole moment. This shows that conjugation in the imidate 
group is less pronounced than in the case of amidines. However, the conjugation 
favours a planar arrangement of the imidate group (Figure 4.4).  
R OR"
NR'
R OR"
NR'
Figure 4.4.
The C=N double bond vibrations of amidines fall in the range from 1658 cm-1 to 1582 
cm-1. In contrast, the C=N double bond vibrations of imidates lies in the range from 
1670 cm-1 to 1646 cm-1 which is close to the values obtained for unconjugated 
imines. Again these data suggest that the resonance for imidates is not so important. 
Imidates are weaker bases than aliphatic amines, while unsubstituted amidines are 
stronger bases. In table 4.5 some characteristic pKa values are collected.15
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Compound Formula pKa Solvent 
ammonia NH3 9.245 water 
methylamine CH3NH2 10.624 water 
aniline C6H5NH2 4.65 water 
acetamidine 
H3C NH2
NH
12.40 water 
N,N-di-n-butylbenzamidine 
C6H5 N
N
H
n-Bu
n-Bu
11.27 50% aq methanol 
phenyl N-acetimidate 
H3C OC6H5
N
CH3
6.2 water 
methyl benzimidate 
C6H5 OCH3
N
H
5.6 water 
Table 4.5. pKa-values of some nitrogen bases. 
The conformation of imidates is presented in figure 4.5.16  For ring imidates with an 
exocyclic oxygen function where n= 28, the conformation is syn because of steric 
requirements. However, when the ring size increases (n= 913), the imidates tend 
to exist in the anti form. Open-chain analogues exist also in the anti configuration. It 
is suggested that this is due to interorbital electron repulsion between the non-
bonding electrons on oxygen and the lone pair localised in an sp2 orbital on nitrogen. 
High barriers for interconversion of the syn and anti forms of O-imidates were 
observed.16
N
OMe
(CH2)n
H2C
N
OMe
(CH2)n
CH2
N
Me
MeO R
syn anti anti
Figure 4.5. Imidate conformation.
Imidates are known to be very useful synthetic building blocks and pharmacophores, 
hence the interest in their preparation.17 The classical method to synthesize imidates 
is the Pinner reaction.18,19 Hereby, a nitrile is condensed with an alcohol under 
anhydrous conditions in the presence of hydrogen chloride or hydrogen bromide at 
0°C (Figure 4.6).  
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R1 C N R2 OH+
R1
C
O
R2
N
H H Cl
nitrile alcohol imidate ester
hydrochloride salt
HCl (dry)
Solvent
Figure 4.6. Pinner Reaction.
Since the pioneering work of Pinner, several new methods to synthesize imidate 
esters have been developed14, e.g. a base-catalyzed reaction of nitriles with 
alcohols20; reaction of amines with orthoesters21; a modified Staudinger ligation22; a 
three-component coupling of terminal alkynes, sulfonyl azides and an alcohol in the 
presence of a copper catalyst23; a palladium-catalyzed insertion of isonitriles into 
ortho bromo arylalcohol24; three-component coupling using arynes, isonitriles and 
aldehydes.25
  
4.4 DEFINITION OF THE PROBLEM 
Nitrogen-containing ligands are known as cheap, easily accessible and stable 
alternatives for phosphane ligands. As a result, the design, synthesis and application 
of a wide variety of nitrogen ligands has received a lot of attention, e.g. oxazolines 
(4.10)26, semicorrins (4.11)27, diimines (4.12)28, salen (4.13)29, 2,2’-bipyridines 
(4.14)30, amidines (4.15)31 and sulfoximines (4.16)32 (Figure 4.7). 
N N
O O
R R
4.10
N N
R R
4.11
H
CN
N N
Ar Ar
4.12
N N
4.13
OH HO
N N
OR RO4.14
N N
Me2N NMe24.15
N NS S
Me Ar
O O
Ar Me
4.16
Figure 4.7. Chiral nitrogen-containing ligands.
Surprisingly, imidates have never been used as ligands in catalysis. Their usage was 
probably precluded due to their generally assumed instability.  
In an attempt to find a stable alternative for diimine ligands, Vandyck synthesized 
bisimidate 4.19 via a condensation of cyclic imidate ester 4.18 with chiral as-
indaceen bisamine 4.17.33 Ligand 4.19 was tested in Cu(I)-catalyzed asymmetric 
cyclopropanations, however, no reaction occurred. 
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N
N
O
O
NH3Cl
NH3Cl
a
93 %
O
NH2Cl
+
4.17 4.18 4.19
Scheme 4.1. Synthesis of bisimidate ester (4.19): a) 2.9 eq 4.18, 5.5 eq Et3N, 
CH2Cl2, RT, 24u.  
Although the first results were disappointing, a further and more thorough 
investigation of this imidate ligand family was necessary. In this chapter, we will 
present the synthesis of several bisimidates with various backbones and their 
application in several asymmetric test reactions. In addition, we have developed a 
synthesis for substituted imidates. And to conclude, mixed phosphorous-imidate 
ligands are synthesized. 
4.5 SYNTHESIS OF IMIDATE LIGANDS 
4.5.1 Synthesis of 1,3-dihydro-iminoisobenzofuran hydrochloride (4.18) 
The synthesis of cyclic imidate esters is described in the literature. 2-
Bromomethylbenzanilide 4.20 forms the corresponding imidate ester 4.21 upon 
heating, however low yields are usually obtained.34 A second possibility is starting 
from 1-thionophthalide 4.23 in the presence of Hg(OTf)2.
35 High yields are obtained 
but a major drawback is the necessity to use 3 equivalents of amine which is not 
interesting for the synthesis of bidentate imidate ligands. Phthalides 4.22 can be 
directly converted into imidate ester 4.24 in low yield.36 A palladium-catalyzed 
insertion of isonitriles 4.26 into 2-bromobenzyl alcohol 4.25 affords cyclic imidates 
4.24 in good yield.24a The drawbacks of this method is the disagreeable odour of 
isonitriles37 and the fact that chiral isonitriles are not commercially available (Scheme 
4.2).  
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N
H
O
Br
O
N
T
4.20 4.21
O
O
O
S
O
N R
Lawesson's Reagent
toluene, 110°C
4.22 4.23 4.24
3 equiv RNH2
Hg(OTf)2
RNH2
Et3N / AlCl3
(CH2Cl)2
Br
OH
+ R NC
PdCl2 / dppf
NaOtBu, toluene, reflux
O
N R
4.244.25
4.26
Scheme 4.2. Literature results for the synthesis of cyclic imidates.
A better approach would be the condensation of an imidate ligand precursor 4.18
with an appropriate amine, in analogy with the reaction of imidate esters 4.27 and 
amino alcohols 4.28 to oxazolines 4.29 (Scheme 4.3).38  
EtO OEt
NH NH
. 2HCl
NH2
OH
+
Et3N, (CH2Cl)2, reflux
72 %
N N
O O
4.27 4.28 4.29
Scheme 4.3. Synthesis of oxazoline ligands by reaction of an aminoalcohol 4.28 with 
an imidate ester hydrochloride 4.27 
The synthesis of the imidate ligand precursor 4.18 is known in the literature via a 
Pinner reaction starting from ortho-cyanobenzylalcohol 4.31.39 Surprisingly, we found 
that the cyclic imidate ester was immediately formed after treatment of 2-
cyanobenzaldehyde 4.30 with NaBH4 in EtOH (Scheme 4.4). This was confirmed by 
IR spectroscopy where no characteristic IR absorption of a nitrile functionality could 
be detected. The free imidate base 4.32 was a -slightly impure- brownish oil. When 
the free imidate base was treated with HCl in dry Et2O a very pure crystalline HCl salt 
4.18 was formed. This one-step procedure was easily scaled up (8.3 g 4.18, 92 % 
yield) and the product can be stored for years at -18°C without any sign of 
decomposition. 
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H
O
CN
OH
CN
O
NH
a
4.31
O
NH
. HCl
4.18
4.30 4.32
b
Scheme 4.4. Synthesis of imidate hydrochloride 4.18: a) NaBH4, EtOH, -78°C0°C, 
35 min. b) HCl in dry Et2O. 92% yield over both steps. 
4.5.2 Synthesis of a small imidate ligand library by condensation of imidate 
ligand precursor 4.18 with various chiral amines 
In order to investigate the properties of this new ligand family, we decided to 
synthesize a small ligand library. In figure 4.8, various chiral amines are presented. 
These chiral amines were commercially available or synthesized in our laboratory.  
NH2
NH2
NH2
NH2
OO
NH2 NH2
NH2H2N
NH2NH2
OH
NH2 NH2
4.33 4.34 4.35 4.36
4.37 4.384.17
Figure 4.8. Chiral amines. 
The C2-symmetrical amines 4.33
40, 4.3441, 4.3542, 4.3643 were chosen because their 
backbones are known to create very effective asymmetric environments.44 Bisamine 
4.17 was synthesized in our laboratory.45 Monoamines 4.37 and 4.38 were selected 
to synthesize, respectively, a mixed imidate-hydroxyl ligand and a monodentate 
imidate ligand. 
Condensation of these amines with the imidate precursor 4.18 in the presence of 
Et3N resulted in the corresponding imidate ligands in excellent yields (Table 4.6).  
Chapter 4. Chiral imidate ligands 
81 
NN
N
OO
N N
NN
OH
N
N
O O
4.39
N
O
O
4.40
O
O
4.41
O O
4.42
NN
O
O
4.19
O O
4.43 4.44
O
NH
.HClO
N R*
R*-NH2
ONO N
NH2H2N
4.18
*
*
entry Amine Product 
Yield 
(%)
1 (1R,2R)-(-)-diaminocyclohexane (4.33) 4.39 85 
2b (R)-(+)-1,1’-binaphtyl-2,2’-diamine (4.34) 4.40 71 
3 (1S,4S)-DIANANE (4.35) 4.41 56 
4 (4S,5S)-4,5-di(aminomethyl)-2,2-dimethyldioxolane (4.36) 4.42 92 
5 
(1R,8R)-1,2,3,6,7,8-hexahydro-as-indacene-1,8-diamine 
(4.17) 
4.19 93 
6c (1R,2R)-(-)-trans-1-amino-2-indanol (4.37) 4.43 91 
7c R-(-)-aminoindane (4.38) 4.44 74 
a 
Reagents and conditions: amine (1 equiv), 4.18 (2.6 equiv), Et3N (13 equiv), CH2Cl2.  
b Reflux in MeOH.  
c 1.3 equiv of 4.18.  
Table 4.6. Synthesis of imidate ligands. 
All reactions were performed in dry CH2Cl2 at room temperature. When the reaction 
was performed at reflux temperature, the reaction was finished faster. The 
condensation reaction with 4.34 as chiral amine was an exception. With CH2Cl2 as a 
solvent at refluxtemperature, no conversion was observed even after 24h. Therefore, 
we chose ClCH2CH2Cl as a solvent with a higher boiling point. A marginal amount of 
product 4.40 was formed after one night, however, prolonged reaction times resulted 
in decomposition of the target molecule. Use of other bases, such as DBU and 
DIPEA, gave no improvement. Also the use of DMF as a solvent or microwaves did 
not result in the desired product. A breakthrough was achieved when the reaction 
was performed in protic solvents. The best result was obtained with MeOH as a 
solvent. After 5 days, the bidentate ligand 4.40 was almost exclusively formed (72% 
yield). No trace of decomposition products was noticed.   
Chapter 4. Chiral imidate ligands 
82 
4.5.3 Synthesis of a copper complex of bisimidate 4.39 
A study by molecular modelling towards the structure of bisimidate 4.39 revealed that 
the imidate groups were axially orientated (Figure 4.9). This was confirmed by 1H 
NMR, bisimidate 4.39 showed for the alfa-protons on the cyclohexane ring two small 
vicinal coupling constants (dd, J= 3.9, 4.7 Hz) suggesting an axial position of the 
imidate groups. The flipped chair, where the imidate groups are equatorally 
orientated, differs 8.002 kJ/mol from the global minimum. 
Global minimum of 4.39 (ax-ax 4.39) All conformers that differ up to 5 kJ/mol 
from the global minimum. 
Flipped Chair (eq-eq 4.39): differs 8.002 kJ/mol from the global minimum. 
Figure 4.9. Molecular modelling of bisimidate 4.39.
The potential for bisimidate 4.39 to act as a ligand was investigated by treating 4.39 
with Cu(CH3CN)4PF6 in CH3CN. Suitable crystals for X-ray diffraction were grown 
from a solution of the complex in MTBE/CH3CN. An X-ray structure was obtained, 
shown in figure 4.10. This revealed that in the complex the opposite chair 
conformation was adopted, with the imidate groups in equatorial position and 
therefore suitable for complexation with Cu(I). The Cu(I)-complex shows a tetrahedral 
arrangement with two bidentate ligands around the metal. The Cu-N bond lengths 
are 2.07 Å and 2.05 Å for both ligands. The angles between N(2)-Cu(1)-N(9) and 
N(28)-Cu(1)-N(35) are respectively 84.0° and 84.4°.  The imidate groups clearly 
possess the (Z)-geometry dissecting the space around the metal effectively in a C2-
fashion. 
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Figure 4.10. X-ray structure of Cu(4.39)2.PF6. Hydrogens and PF6 are omitted for 
clarity. Selected distances, bond angles and torsion angles: Cu(1)-N(2) 2.065 Å, 
Cu(1)-N(9) 2.054 Å, Cu(1)-N(28) 2.078 Å, Cu(1)-N(35) 2.046 Å; N(2)-Cu(1)-N(9) 
84.02°, N(2)-Cu(1)-N(28) 127.49°, N(2)-Cu(1)-N(35) 120.08°, N(9)-Cu(1)-N(28) 
117.70°, N(9)-Cu(1)-N(35) 128.75°, N(28)-Cu(1)-N(35 ) 84.41°; N(2)-C(3)-C(8)-N(9) -
49.6°; N(28)-C(29)-C(34)-N(35) -46.7°. 
4.5.4 Synthesis of substituted imidate precursors 
In an attempt to broaden the scope of the imidate ligand family, we wanted to put 
substituents on the aromatic ring of the imidate ligand precursor (Scheme 4.5). These 
substituents are important to modulate the electron density of the imidate. Complex 
Cu(4.39)2.PF6 contained two imidate ligands for each copper atom. Substituents on 
the R1 position of the imidate would increase the steric bulk around the metal and, 
hence, it would be possible to synthesize copper species with only one ligand on the 
metal. 
O
NH
.HClO
N R*
R*-NH2
ONO N
NH2H2N
R1
R2
R3
R4
R3
R2
R1
R4
R4
R3 R2
R1 R1
R2 R3
R4
*
*
Scheme 4.5. Synthesis of substituted imidate ligands  
Unfortunately, there were no substituted ortho-formylbenzonitriles commercially 
available. Therefore, we needed to find a simple and easily upscalable synthetic 
route towards these compounds. There are two fundamentally different approaches: 
an introduction of a cyano group or an introduction of a formyl group on the aromatic 
ring (Scheme 4.6). 
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CN
O
H
X
O
H
CN
X
Scheme 4.6. Two different approaches to the design of ortho-formylbenzonitriles.
A classical procedure to introduce a nitrile on an aromatic ring is via a Rosenmund-
von Braun reaction.46 Hereby, aryl halides are cyanated with an excess of 
copper(I)cyanide in a polar high-boiling solvent such as DMF at reflux temperature. 
Drawbacks of this type of reaction is the requirement of stoichiometric amounts of 
CuCN, the necessity to protect the aldehyde under the severe reaction conditions 
and the low reactivity of aryl chlorides and bromides (in general the use of expensive 
aryl iodides is required).47  
More recently, palladium-48 and nickel-catalyzed49 aryl cyanation methods have been 
developed as milder alternatives to the classic Rosenmund-von Braun reaction. 
Although many successful applications of the palladium-catalyzed aryl cyanation 
reaction have been documented, the method suffers from poor reliability.50
Also interesting is the Sandmeyer reaction where aryl nitriles are synthesized from 
aryldiazonium salts.51
X
O
H
CN
O
H
CuCN, DMF, ∆
or
MCN, [Pd] or [Ni]
N2
+X-
O
H
CN
O
H
CuCN
Scheme 4.7. Introduction of cyano group on the aromatic ring. 
Introduction of a formyl group on the aromatic ring can easily happen via a two-step 
procedure starting from commercially available substituted 2-methylbenzonitriles 
(Scheme 4.8).52 Given the mild conditions of this procedure, we preferred this 
method for the synthesis of the ortho-formylbenzonitriles. 
CN CN
O
H
CCl4, NBS, BPO Me3NO, DMSO, CH2Cl2
CN
Br
Scheme 4.8. Introduction of a formyl group on the aromatic ring. 
A Wohl-Ziegler reaction with 1.1 equiv NBS resulted in certain cases in a mixture of 
monobrominated 4.46 and dibrominated product 4.47. This resulted in lower yields 
and a difficult separation of both compounds. Oxidation of 4.46 with Me3NO resulted 
in the corresponding formylbenzonitrile 4.48 in low yield (48-67%). When a mixture of 
4.46 and 4.47 was used in the oxidation reaction, only the monobrominated product 
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formed the corresponding formylbenzonitrile 4.48 while the dibrominated product 
remained unchanged. Because of the loss of a significant amount of product, we tried 
to find another procedure.53 When a Wohl-Ziegler reaction was performed with 3 
equiv NBS, we obtained selectively the dibrominated product 4.47a-b in excellent 
yields (94-96%). Hydrolysis of 4.47a-b with AgNO3 in CH3CN/H2O delivered the 
target product (4.48a-b) in high yields (83-90%). 
On the other hand, for 4.45c, a mixture of 4.46c and 4.47c was obtained with method 
B even after prolonged reaction times. For 4.45d, only the formation of 
monobrominated product was observed. However, it was impossible to form the 
corresponding aldehyde 4.48d. This was probably due to the high sterical hindrance. 
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CN
R
CN
R
CN
R
Br Br
Br
+Wohl-Ziegler
CN
R
H
O
4.45 4.46 4.47
4.48
Method A
a
Method B
b
Mono-
brominated
Di-
brominated
Aldehyde
Mono-
brominated
Di-
brominated
Aldehyde
CN
Cl
4.45a 
82% 
(4.46a) 
n.d.c 
67% 
(4.48a) 
n.d.c 
94% 
(4.47a) 
90% 
(4.48a) 
CN
Cl
4.45b 
57% 
(4.46b) 
24% 
(4.47b) 
48-53% 
(4.48b) 
n.d.c 
96% 
(4.47b) 
83% 
(4.48b) 
CN
Br
4.45c 
- - - 
44% 
(4.46c) 
46% 
(4.47c) 
76% 
(4.48c) 
Br
Br
CN
4.45d 
- - - 
35% 
(4.46d) 
n.d. n.r.d,e
a
Reagents and conditions: Method A: (i) methylbenzonitrile (1 equiv), NBS (1.1 equiv), 
benzoylperoxide (3 mol%), CCl4. (ii) bromomethylbenzonitrile (1 equiv), Me3NO (4 equiv), DMSO, 
CH2Cl2.  
b
Reagents and conditions: Method B: (i) methylbenzonitrile (1 equiv), NBS (3.0 equiv), 
benzoylperoxide (3 mol%), CCl4. (ii) dibromomethylbenzonitrile (1 equiv), AgNO3 (4.0 equiv), CH3CN, 
H2O. 
c n.d.: not detected. 
d n.r.: no reaction occurred. 
e
Reagents and conditions: bromomethylbenzonitrile (1 equiv), Me3NO (4 equiv), DMSO, CH2Cl2. 
Table 4.7. Synthesis of ortho-formylbenzonitriles.  
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As with the unsubstituted ortho-formylbenzonitrile, formation of the substituted cyclic 
imidate ester (4.49) occurred smoothly with NaBH4 in EtOH (Table 4.8).  
H
O
CN a
O
NH
. HClR R
4.48 4.49
Entry ortho-formylbenzonitrile Cyclic imidate ester
1 4.48a 94% (4.49a) 
2 4.48b 96% (4.49b) 
3 4.48c 69% (4.49c) 
a
Reagents and conditions: (i) NaBH4, EtOH, -78°C0°C, 35 min. (ii) HCl in dry Et 2O. 
Table 4.8. Synthesis of substituted cyclic imidate esters.
2-Bromo-6-methylbenzonitrile (4.45c) is not commercially available, however, it could 
be easily synthesized starting from the corresponding 2-amino-6-methylbenzonitrile 
via a Sandmeyer reaction. Arylbromides can also be prepared from primary aromatic 
amines in one step by treatment of the amine with tert-butyl nitrite and anhydrous 
CuBr2 in anhydrous acetonitrile at 65°C.
54 This procedure is in fact a combination of a 
diazotization and a Sandmeyer reaction. An additional advantage is that cooling to 
0°C is not needed. It was reported that a substitut ion of a bromide at the aromatic 
ring positions ortho and para to the original amine position can take place.54 With 
arylamines that do not possess para substituents, orientation of the bromine to the 
para position is highly favored. 
This is what we also observed when the reaction was performed on 4.50: 4.45c and 
4.45d were formed in almost equimolar amounts (Scheme 4.9).  
Br
Br
CN
Br
CN
NH2
CN
+
a
46% for 4.45c
41% for 4.45d
4.45c
4.45d
4.50
2 ArNH2 + 2 t-BuONO + CuBr2  2 ArBr + CuO + H2O + 2 N2 + 2 t-BuOH 
Scheme 4.9. Synthesis of 4.45c and 4.45d: a) arylamine (1 equiv), CuBr2 (1.2 equiv), 
tert-butyl nitrite (1.5 equiv), CH3CN. 
4.5.5 Synthesis of chlorine-substituted bisimidate ligands and their 
corresponding copper(I) complexes 
In analogy with Jacobsen’s imine 4.51 where ortho chlorine substituents on the 
phenyl ring resulted in a highly effective ligand in aziridination reactions (cf. Chapter 
4.7.1), we synthesized bisimidate ligands 4.52 and 4.53 (Figure 4.11). 
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N N
Cl Cl
4.51
Cl Cl N N
O O
N N
O O
Cl Cl
Cl Cl
4.52 4.53
Figure 4.11. Chlorine-substituted bisimine and bisimidate ligands.
The synthesis was carried out according to our typical procedure (Table 4.9). The 
lower yield with imidate ester 4.49a was attributed to the increasing bulk ortho to the 
imidate nitrogen. (Table 4.9, entry 1) 
H2N NH2
N N
O O
R R
O
NH
. HCl+
a
R
4.33
Entry Imidate ester Yield bisimidate 
1 4.49a 50% (4.52) 
2 4.49b 75% (4.53) 
a
Reagents and conditions: 4.33 (1 equiv), imidate ester (2.6 equiv),  
Et3N (13 equiv), CH2Cl2. 
Table 4.9. Synthesis of chlorine-substituted imidate ligands. 
Next, the corresponding copper(I) complexes were synthesized from bisimidates 4.52
and 4.53 by treating them with Cu(CH3CN)4PF6 in CH3CN. Unfortunately, several 
attempts to obtain suitable crystals for X-ray diffraction have all failed. The Cu(I)-
complex of 4.52 resulted in a white powder while the corresponding complex of 4.53
resulted in a yellow powder like Cu(4.39)2.PF6. Next, ES-MS of the different 
complexes were recorded. The largest mass peak for the copper(I) complexes of 
4.39 and 4.53 was attributed to respectively [Cu(4.39)2]
+ and [Cu(4.53)2]
+. In sharp 
contrast, the largest mass peak for the copper(I) complex of 4.52 was attributed to 
[Cu(4.52)]+ (Figure 4.12). These results, together with the different colour, indicates 
that an increasing sterical bulk around the metal indeed results in the formation of a 
copper species with only one ligand around the metal.  
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Figure 4.12. Electro Spray Mass Spectra of copper(I) complexes of  
(a) ligand 4.39, (b) ligand 4.52 and (c) ligand 4.53. 
4.5.6 Synthesis of mixed imidate-phosphane ligands 
A literature survey of the different ligand structures reveals that a large number of 
them are C2-symmetrical.
55 The presence of C2-symmetry in a ligand can be 
advantageous because it reduces the number of possible catalyst-substrate 
arrangements and, consequently, the number of reaction pathways and transition 
states. This feature can have a beneficial effect on the enantioselectivity because 
competing less-selective pathways are possibly eliminated. In addition, C2-symmetry 
is of particular advantage in mechanistic and structural studies because it facilitates 
the analysis of the ligand-substrate interactions that may be responsible for 
enantioselection. However, there is no fundamental reason why a non- C2-
symmetrical ligand should be inferior to a C2-symmetrical ligand. For certain 
reactions, nonsymmetrical ligands could allow more effective enantiocontrol than C2-
symmetrical ligands, e.g. transition metal-catalyzed asymmetric allylic alkylations. 
From this point of view, we wanted to synthesize mixed phosphane-imidate ligands 
because of the distinctly different characteristics of the P-atom and the N-atom. Very 
recently, several aminophosphane ligands became commercially available from 
Sigma-Aldrich.56 We chose ferrocenylaminophosphanes 4.54 as the most interesting 
compound because they are known to be air-stable57 and they represent a 
convenient source of chirality for ligand construction.58
Synthesis of the mixed imidate-phosphane ligands (4.55a-d) occurred smoothly in 
one step via our typical condensation procedure (Table 4.10). For non sterically 
hindered imidate esters, high yields were obtained (Table 4.10, entries 1 and 3). 
However, when the reaction was performed with more sterically demanding imidate 
esters lower conversions were obtained (Table 4.10, entries 2 and 4).  
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Fe
PPh2 N O
R
Fe
PPh2 NH2
a
4.54 4.55a-d
+ O. HCl
NHR
Entry Imidate Ester Imidate-phosphane 
Yield 
(%)
1 4.18 
Fe
PPh2 N O
4.55a
97 
2 4.49a 
Fe
PPh2 N O
4.55b
Cl
61 
3 4.49b 
Fe
PPh2 N O
4.55c
Cl
99 
4 4.49c 
Fe
PPh2 N O
4.55d
Br
51 
a
Reagent and conditions: (Rp)-1-[(1S)-(1-aminoethyl)]-2-(diphenylphosphino)-ferrocene (1 equiv), 
imidate ester (1.3 equiv), Et3N (3 equiv), CH2Cl2, reflux. 
Table 4.10. Synthesis of mixed imidate-phosphane ligands. 
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4.6 SYNTHETIC APPLICATIONS OF IMIDATES 
4.6.1 One-step synthesis of chiral oxazoline-alcohol ligands 
Chiral oxazolines bearing a hydroxyl substituent show excellent catalytic activity in 
the asymmetric addition of diethylzinc to aldehydes.59  Bolm et al. studied the role of 
planar chirality versus central chirality in ferrocene ligands (Figure 4.13).60,61 The 
combination of the proper planar chirality and central chirality resulted in a highly 
active ligand 4.56. Remarkably, ligand 4.57 containing only the central chirality gave 
also high enantioselectivity and catalytic activity.61 
Fe
4.56
N
O
t-Bu
OH
Ph
Ph
OH
Ph Ph
N
O
t-Bu
4.57
Figure 4.13. Oxazoline ligands developed by Bolm and coworkers.
It is known that the synthesis of oxazolines can happen efficiently via reaction of an 
aminoalcohol and an imidate ester. As a result, substituents at the two position of the 
oxazoline moiety can be incorporated.62 From this point of view, we wondered if it 
would be possible to use cyclic imidate esters in the synthesis of oxazolines (Scheme 
4.10). Because of the use of a cyclic imidate ester, the required hydroxyl-functionality 
would immediately be incorporated in the ligand structure. 
OHH2N
R1 R2
* *
O
NH
+
R
OHN
R1 R2
* *
O
R
OH
N
O
R
R1
R2
*
*
4.58 4.59
4.60
?
Scheme 4.10. Synthetic scheme towards oxazoline-alcohol ligands.
Condensation of imidate esters (4.18, 4.49a-b) with several aminoalcohols resulted in 
the corresponding oxazoline ligands or imidate ligands (Table 4.11) (Figure 4.14). No 
formation of the imidate alcohols was observed for (1S,2R)-cis-1-amino-2-indanol, 
(S)-tert-leucinol  and (S)-valinol; the oxazoline alcohol was obtained in quantitative 
yield (Table 4.11, entries 1,3 and 4). However, with (S)-phenylglycinol and (S)-
phenylalaninol a mixture of imidate alcohol and oxazoline alcohol was formed (Table 
4.11, entries 5-6). Separation of the two components via preparative HPLC was 
impossible, suggesting that the energy difference between oxazoline and imidate is 
too small to form one exclusively. With (1R,2R)-trans-1-amino-2-indanol, it was 
possible to selectively form the imidate alcohol (Table 4.11, entry 2). The 
condensation of the substituted imidate esters (4.49a-b) with (1S,2R)-cis-1-amino-2-
indanol resulted again in the corresponding oxazolineligands (4.60d-e) in good yield 
(Table 4.11, entries 7-8). 
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NH2
OH
4.58a
H2N
R
OH
R= t-Bu (4.58b), i-Pr (4.58c)
     Ph (4.58d), PhCH2 (4.58e)
NH2
OH
4.37
H2N
R2R1
OH
* * :
OHH2N
R1 R2
* *
O
NH
+
R
OHN
R1 R2
* *
O
R
OH
N
O
R
R1
R2
*
*
4.58 4.59 4.604.18, 4.49a-b
a
  
Entry Imidate 
ester 
aminoalcohol Yield imidate 
(%)b 
Yield oxazoline
(%)b 
1 4.18 (1S,2R)-cis-1-amino-2-indanol 
(4.58a) 
n.d. Quant. (4.60a) 
2 4.18 (1R,2R)-trans-1-amino-2-indanol 
(4.37) 
91 (4.43) n.d. 
3 4.18 (S)-tert-leucinol (4.58b) n.d. Quant. (4.60b) 
4 4.18 (S)-valinol (4.58c) n.d. Quant. (4.60c) 
5c 4.18 (S)-2-phenylglycinol (4.58d) 48.3 51.7 
6c 4.18 (S)-phenylalaninol (4.58e) 30.9 69.1 
7 4.49a (1S,2R)-cis-1-amino-2-indanol 
(4.58a) 
n.d. 83 (4.60d) 
8 4.49b (1S,2R)-cis-1-amino-2-indanol 
(4.58a) 
n.d. 66(4.60e) 
a
Reagents and conditions: aminoalcohol 4.58 (1 equiv), imidate ester (1.1 equiv), Et3N (3 equiv), 
CH2Cl2, room temperature, 24h. 
b n.d.: not detected. 
c Unseparable mixture of imidate and oxazoline is formed. 
Table 4.11. Synthesis of imidate-alcohol ligands (4.59) and oxazoline-alcohol ligands 
(4.60). 
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HO
O
N
HO
O
N
HO
O
N
HO
O
N
Cl
HO
O
N
Cl
N
OH
O
4.60a 4.60b 4.60c
4.60d 4.60e
4.43
Figure 4.14. Synthesized oxazoline- and imidate-alcohol ligands.
Suitable crystals for X-ray diffraction were grown from a solution of 4.60a in 
isooctane/Et2O. An X-ray structure was obtained, shown in figure 4.15. The hydroxyl 
proton forms a hydrogen bond with the nitrogen of the oxazoline moiety. As a result, 
a stable seven-membered ring chelate is formed. 
Figure 4.15. X-ray structure of 4.60a.
Interestingly, Bolm et al. found that a rearrangement from the oxazoline alcohol 4.57
to the imidate alcohol 4.57b can occur in the solid state (Scheme 4.11).63 It was 
assumed that this is due to the increasing rigidity of the imidate alcohol 4.57b which 
results in a better packing of the molecules in the solid state. However, when the 
product was dissolved, the equilibrium was again shifted to the oxazoline alcohol 
product (4.57). 
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OH
Ph Ph
N
O
t-Bu
4.57
solid state
solution
O
N
t-Bu
HO
4.57b
Scheme 4.11. Rearrangement of oxazoline alcohol 4.57 to imidate alcohol 4.57b.
4.6.2 Synthesis of chiral imidazolidines 
In an attempt to synthesize a small ligand library, we also selected (1R,2R)-(+)-
diphenylethylenediamine (4.61) (cf. Chapter 4.5.2). However, when we tried to make 
the bidentate imidate ligand 4.62, imidazolidine 4.64 was formed instead. We 
observed no characteristic infrared absorption originating from the imidates, however, 
a signal arising from the NH-bond was clearly visible (Scheme 4.12). 
NH2H2N
O
NH
+
4.61 4.18
a
NNO O NH2NO HN NH
O
4.62 4.63 4.64
98%
Expected IR signals : 1689 cm-1 1689 cm-1 3265 cm-1
Expected Mass [M+H]+ : 445.1 329.1 329.1 
Observed IR signals : no imidate vibration no imidate vibration 3253.5 cm-1
Observed Mass [M+H]+ :   329.1 
Scheme 4.12. Synthesis of chiral imidazolidines: a) amine 4.61 (1 equiv), 4.18 (2.6 
equiv), Et3N (13 equiv), CH2Cl2, RT, 24h.  
Imidazolidines can be made by reacting 4.61 with one equivalent of an aldehyde or 
ketone. However, when a second equivalent is added a bidentate bisimine is 
formed.64 In contrast, imidazolidine 4.64 is a very stable compound and no formation 
of a bidentate bisimidate ligand was observed with 2.6 equiv of 4.18 or after heating 
for several days. This is due to a reversible opening and closing of the furan moiety, 
the equilibrium being in favour of the spiro compound 4.64 (scheme 4.13). 
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HN NH
O
N NH
OH
Scheme 4.13. Ring opening of the furan moiety of imidazolidine 4.64.
Chiral imidazolidines are typically used as organocatalysts in asymmetric Michael 
reactions65 and asymmetric -halogenations66.67 Jørgensen et al. used chiral 
imidazolidine 4.65 in the asymmetric synthesis of warfarin 4.66 (Scheme 4.14).68 It 
could be interesting to test the potential of imidazolidine 4.64 as an organocatalyst in 
this type of test reactions. 
O
OH
O
Ph Me
O
+
O
OH
O
Me
Ph ON
H
H
N
Ph
Ph
CO2H
96% yield
82% ee (R)
4.65
4.66
Scheme 4.14. Organocatalytic asymmetric formation of warfarin (4.66) using a chiral 
imidazolidine catalyst (4.65).
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4.7 APPLICATION OF THE SYNTHESIZED CHIRAL LIGANDS 
4.7.1 Copper(I)-catalyzed asymmetric aziridination69,70
A number of molecules in nature possess an aziridine ring. These compounds exhibit 
a potent biological activity, which is associated with the reactivity of the strained 
heterocycle. The best-known class are the Mitosanes (Figure 4.16). 
N
O
O
NZ
OY
O
NH2
O
X
N
O
O
NMe
OYX
Mitomycin A  X= OMe, Y= Me, Z= H
Mitomycin B  X= OMe, Y= H, Z= Me
Mitomycin C  X= NH2, Y= Me, Z= H
Porfiromycin X= NH2, Y= Me, Z= Me
Mitomycin G  X= NH2, Y= Me
Mitomycin H  X= OMe, Y= H
Mitomycin K  X= OMe, Y= Me
Figure 4.16. The Mitosanes 
Moreover aziridines are known as very interesting building blocks in organic 
chemistry comparable to epoxides.71 In sharp contrast with these epoxides, the 
methods for asymmetric aziridine formation are scarce. This is due to the fact that the 
discovery of useful methods for asymmetric aziridination catalysis has proven to be 
extremely difficult. The transfer of a nitrene group to an olefin, the reaction between 
diazo esters and imines mediated by either carbene transfer catalysts or Lewis acid 
catalysts are three fundamentally different approaches to the design of asymmetric 
catalysts for aziridination (Scheme 4.15). The nitrene transfer to olefins has received 
the greatest share of attention. Therefore we discuss only this type of catalysis in the 
following.  
R"
N R'
R
LnM  +  R"NX LnM NR"
RCH CHR'
R'CHN2  +  LnM
NR"RCH
LnM CHR'
N2
NR"RCH +  R'CHN2
Lewis acid (LA)
R
R'
N
N2
R" LA
N2
Scheme 4.15. Three different approaches to the design of asymmetric aziridination 
catalysts. 
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A breakthrough in aziridination catalysis was made by Evans. He used Cu(I)- and 
Cu(II)-catalysts and (N-(p-toluenesulfonyl)imino)phenyliodinane (PhINTs), as a 
nitrene precursor, for the aziridination of both electron-rich and electron-deficient 
olefins.72
The research of asymmetric aziridination was stimulated by the knowledge about 
catalytic cyclopropanations and the discovery that metal ions useful for 
cyclopropanations were also effective in aziridinations. Only a limited number of 
ligands are effective in the asymmetric Cu-catalyzed aziridination. The two main 
groups are chiral bisoxazolines and chiral diimine-based ligands (Table 4.12). 
Evans et al. used a chiral bisoxazoline 4.10a and 4.10b with Cu(I)triflate in the 
aziridination of cinnamate ester derivatives with high enantioselectivities (Table 4.12, 
entries 1-3).73 No other substrate classes have been demonstrated to undergo 
aziridination with synthetically-useful selectivity. The group of Jacobsen optimized 
chiral 1,2-diimine derivatives, e.g. 4.51 and 4.67 (Table 4.12, entries 4-6).74 The 
ligand prepared from 2,6-dichlorobenzaldehyde was the most enantioselective. Again 
the substrate scope was limited and the highest selectivities were obtained for cis-
alkenes. Scott et al. developed biaryl Schiff base ligand 4.68. Remarkably, ligand 
4.68 gave high enantioselecties in the aziridination of both 6-acyl-2,2-
dimethylchromene 4.74 and cinnamate esters (Table 4.12, entries 7-9).75 Ligand 4.69
showed very low selectivities for styrene but moderate too high for cinnamate esters 
(Table 4.12, entries 10-12).76  
A mechanism for the copper-catalyzed asymmetric aziridination was suggested by 
Jacobsen (Scheme 4.16).74a  Mechanistical studies provided support for this redox 
mechanism.   
L*Cu+ PF6
-
L*Cu NTs
PF6
-
PhI=NTs
PhI
R1
R2
R3
R1
R2
R3
N
Ts
Scheme 4.16. Redox mechanism for Cu(I)-catalyzed aziridinations of olefines with 
PhI=NTs.
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The newly synthesized imidate ligands (Figure 4.17) were evaluated in the Cu(I) 
catalyzed aziridination to methylcinnamate 4.70, t-butylcinnamate 4.71 and 2,2-
dimethylchromene 4.73.  
NN
N
OO
N N
NN
OH
N
N
O O
4.39
N
O
O
4.40
O
O
4.41
O O
4.42
NN
O
O
4.19
O O
4.43 4.44
NN
O O
4.52
NN
O O
4.53
Cl Cl
Cl Cl
Figure 4.17. Chiral imidate ligands evaluated in Cu(I)-catalyzed asymmetric 
aziridination
We observed excellent yields for all bisimidates (Table 4.13, entries 1 and 3-5) 
except for imidate 4.40 derived from binaphtyldiamine 4.34 (Table 4.13, entry 2). With 
imidate alcohol 4.43 and monodentate imidate 4.44 as a chiral ligand, low yields 
were obtained (Table 4.13, entries 6 and 7). The enantioselectivities were low (Table 
4.13, entries 4-7) to moderate (Table 4.13, entries 1-3). Nevertheless, the result 
obtained with ligand 4.39 was promising (Table 4.13, entry 1. 
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CO2Me Cu(MeCN)4PF6 / ligand
PhINTs
CO2Me
N
Ts
4.70 4.75
Entry ligand Time (h) Yield (%)b % eec Configurationd
1 4.39 22 90 45 2S,3R 
2 4.40 21 22 26 2S,3R
3 4.41 22 90 37 2S,3R
4 4.42 23 97 3 n.d. 
5 4.19 21 87 <1 n.d. 
6 4.43 24 24 6 2S,3R
7e 4.44 21 18 11 2S,3R
a
Reagents and conditions: 4.70 (1 mmol), PhINTs (0.2 mmol), Cu(MeCN)4PF6 (10 mol%), ligand 
(11 mol%), 100 mg 4Å molecular sieves, 2.5 mL CH2Cl2, T= -40°C. 
b Yield calculated on PhINTs as limiting reagent. 
c Determined by HPLC analysis with a chiral stationary phase column (Chiralcel OD-H). 
d Assigned by the sign of the optical rotation. 
e Because 3g is a monodentate ligand 22 mol% was used. 
Table 4.13. Cu(I)-catalyzed asymmetric aziridination of methylcinnamate (4.70).
Given the good results obtained with ligand 4.39, we wanted to investigate the 
influence of a chlorine on the aromatic ring of the imidate ligand (ligands 4.52 and 
4.53). Ligand 4.52 was synthesized in analogy with the Jacobsen imine ligand 4.51. 
While the latter gives an excellent enantioselectivity when chlorine atoms are present 
in the ortho position, our ligand 4.52 gave the target product 4.75 with only a 
marginal selectivity (4% ee). Ligand 4.53 gave a selectivity of 29% ee. 
With ligand 4.39, we tried to optimize the reaction conditions by varying different 
reaction parameters (Table 4.14). Changing the copper source resulted in a lower 
yield and comparable selectivities (Table 4.14, entries 1-3). With a copper (II) 
species, the reaction was sluggish and almost no conversion was observed (Table 
4.14, entry 4). Changing the solvent led to very slow reactions (Table 4.14, entries 5-
8). Dichloroethane as a solvent afforded a good yield but lower enantioselectivity 
than dichloromethane (Table 4.14, entry 9). The highest enantioselectivity was 
observed at a temperature of -78°C (51% ee) (Table 4.14, entry 11). 
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CO2Me
PhINTs
CO2Me
N
Ts
4.70 4.75
NN
O O
4.39
[Cu]
Entry [Cu] Solvent 
Temp  
(°C) 
Time 
(h) 
Yield 
(%)b 
% eec 
1 CuOTf CH2Cl2 - 40 24 18 42 
2 Cu(MeCN)4BF4 CH2Cl2 - 40 24 24 42 
3 Cu(MeCN)4OTf CH2Cl2 - 40 24 44 46 
4 Cu(OTf)2 CH2Cl2 - 40 24 - - 
5 Cu(MeCN)4PF6 toluene - 40 48 < 5 < 1 
6 Cu(MeCN)4PF6 CH3CN - 40 24 31 28 
7 CuOTf toluene - 40 24 - - 
8 CuOTf benzene 25 24 56 14 
9 Cu(MeCN)4PF6 (CH2Cl)2 - 30 24 87 33 
10 Cu(MeCN)4PF6 CH2Cl2 25 24 64 27 
11 Cu(MeCN)4PF6 CH2Cl2 - 78 24 58 51 
a
Reagents and conditions: 4.70 (1 mmol), PhINTs (0.2 mmol), [Cu] (10 mol%), ligand 4.39 (11 
mol%), 100 mg 4Å molecular sieves, 2.5 mL solvent. 
b Yield calculated on PhINTs as limiting reagent. 
c Determined by HPLC analysis with a chiral stationary phase column (Chiralcel OD-H). 
Table 4.14. Cu(I)-catalyzed asymmetric aziridination of methylcinnamate (4.70): 
Optimization of the reaction parameters with ligand 4.39.
To conclude, we tested ligand 4.39 in the Cu(I)-catalyzed asymmetric aziridination of 
t-butylcinnamate 4.71 and 2,2-dimethylchromene 4.73 (scheme 4.17). Aziridination of 
4.71 gives a disappointing yield and selectivity. Aziridination of a cis-alkene 4.72 
resulted in high yields, however, the induced selectivity was very low.  
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CO2tBu
PhINTs
CO2tBu
N
Ts
4.71 4.76
NN
O O
4.39
Cu(MeCN)4PF6
T= -40°C: 56% yield, 27% ee
T= -78°C: 26% yield, 25% ee
O
NC PhINTs
Cu(MeCN)4PF6
O
NC
NTs4.72 4.77
T= -40°C: 94% yield, 6% ee
T= -78°C: 76% yield, 8% ee
Scheme 4.17. Cu(I)-catalyzed asymmetric aziridination of t-butylcinnamate (4.71) 
and 2,2-dimethylchromene (4.72) with ligand 4.39. 
The aziridination of a prochiral alkene 4.70 with a nitrene-copper complex can be 
explained as shown in scheme 4.18.77 The tosyl group is orientated in such a way 
that the phenyl can interact via -stacking with one of the phenyls of the bisimidate 
ligand. The alignment of the cinnamate ester is now controlled by the chiral ligand via 
the orientation of the tosyl group. The cinnamate ester is precisely orientated via a 
two-centre binding with the nitrene-copper complex. The carbonyl oxygen of the 
CO2Me group coordinates with the copper and hence a four-coordinate copper 
species is formed. This results in the formation of the (2S,3R)-enantiomer and is 
consistent with our observations. 
N
N
Cu
N
O
S
O
O
H
O
Me
H
O
O
CO2Me
N
Ts
(2S,3R)-4.75
Scheme 4.18. The stereoselectivity in the Cu(I)-catalyzed aziridination with 4.39 as a 
ligand.
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4.7.2 Catalytic asymmetric organozinc additions to carbonyl compounds78,79
In 1984, Oguni and Omi reported that (S)-leucinol catalyzed the reaction of 
diethylzinc with benzaldehyde with moderate enantioselectivity (49% ee).80 Since 
then a large number of chiral catalysts have been developed and high selectivities 
have been achieved. In addition, the reaction of diethylzinc has become a classical 
test in the design of new ligands. 
Enantioselective alkylation of aldehydes has distinct advantages over 
enantioselective reduction of ketones: (1) A chiral center is created in combination 
with an elongation of the carbon chain; (2) In general, higher enatioselectivities are 
obtained for aliphatic aldehydes via an enantioselective alkylation. 
The most successful ligands for this type of transformation are aminoalcohols.81 Also 
oxazoline ligands catalyze the reaction with high selectivities. However, bisoxazoline 
ligands without a hydroxyl functionality induce very low selectivities.82 Diols, such as 
TADDOL (4.81) and BINOL (4.82), in combination with Ti(iOPr)4 are very efficient 
catalyst systems for the Et2Zn addition (Figure 4.18).
83,84   
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N N
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N
OH HO
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4.80
93% ee
Fe OH
Ph
Ph
N
O
4.56 
93% ee
OH
Ph Ph
N
O
4.57
92% ee
OH
OHO
O
ArAr
Ar Ar
TADDOL (4.81)
up to 99% ee
OH
OH
BINOL (4.82)
89% ee
Figure 4.18. Literature results for the asymmetric diethylzinc addition to 
benzaldehyde. 
Dialkylzinc reagents do not easily react with aldehydes in the absence of a catalyst 
because their alkyl metal bond is rather non polar. Addition of a Lewis base activates 
the dialkylzinc reagent. It increases the polarity of the alkyl-Zn bond which is now 
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able to react with aldehydes (Figure 4.19). The catalyst not only accelerates the 
reaction, but, because it is chiral, it also directs the stereochemical outcome. 
R Zn R
unreactive
Zn
B*R
reactive
:B*= N, O, S
Fig 4.19. Activation of dialkylzinc reagents. 
Noyori has suggested a mechanism for the enantioselective addition of dialkylzinc 
reagents to aldehydes.85 The aminoalcohol and R2Zn generate the alkylzinc alkoxide 
4.83 which is in equilibrium with the dimer 4.84. Next, 4.83 reacts with R2Zn to give 
4.85, which subsequently complexes with benzaldehyde. An intramolecular alkyl-
transfer reaction leads to 4.88 and reaction with R2Zn forms a stable cage tetramer 
4.89. Work-up in water delivers the free alcohol (Scheme 4.19). 
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Scheme 4.19. Catalytic Cycle for -Amino Alcohol Promoted Addition of Dialkylzinc 
to Aldehydes. 
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The synthesized chiral imidate and oxazoline-alcohol ligands were tested in the 
asymmetric addition of Et2Zn to aldehydes. 
4.7.2.1 Asymmetric 1,2-addition of diethylzinc to benzaldehyde in the 
presence of chiral imidate ligands. 
The bisimidate ligands (4.19 and 4.39-4.44) were tested in 1,2-additions of 
diethylzinc to benzaldehyde. We also compared our bisimidate ligands with 
bisamidine ligands 4.15 and 4.90 (Figure 4.20).31  
N N
Me2N NMe24.15
N N
Me2N NMe24.90
Figure 4.20. Chiral bisamidine ligands.
We observed excellent yields with all bisimidate ligands, except for ligand 4.42 and
4.19 (Table 4.15, entries 1-5). The monodentate imidate ligands gave slower 
reactions (Table 4.15, entries 6-7). Also the bisamidines gave very good yields (Table 
4.15, entries 8-9). However the enantioselectivities were in general low for both 
bisimidates and bisamidines, with one exception: ligand 4.40 afforded the product in 
good yield and enantioselectivity (83%, 75% ee) (Table 4.15, entry 2). With ligand 
4.40, we tried to optimize the reaction conditions (Table 4.15, entries 10-15). Addition 
of Ti(iOPr)4 resulted in lower selectivities (Table 4.15, entries 10-12). Decreasing the 
temperature resulted in a much slower reaction (Table 4.15, entry 13). Increasing the 
amount of ligand resulted in a  selectivity comparable to our first experiment with 
ligand 4.40 and a slight decrease in yield (Table 4.15, entries 14-15). 
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H
O
+ Et2Zn
OH
*
ligand
toluene, RT
4.91 4.92
Entry Ligand Time (h) Yield (%) % eeb Configuration
1 4.39 48 80 11 S-(-) 
2c 4.40 24 83 75 R-(+) 
3 4.41 24 87 14 R-(+) 
4 4.42 24 38 <1 n.d. 
5 4.19 24 42 5 R-(+) 
6 4.43 24 14 36 S-(-) 
7 4.44 24 23 4 R-(+) 
8 4.15 24 87 4 S-(-) 
9 4.90 3 95 24 S-(-) 
10c,d 4.40 24 87 64 R-(+) 
11c,e 4.40 24 73 54 R-(+) 
12c,f 4.40 24 77 46 R-(+) 
13c,g 4.40 72 18 59 R-(+) 
14h 4.40 48 70 75 R-(+) 
15g,h 4.40 48 71 76 R-(+) 
a
Reagents and conditions: 4.91 (1 mmol), Et2Zn (1.5 mmol), ligand (5 mol %), 4 mL toluene, the 
reaction was performed at room temperature. 
b Determined by HPLC analysis with a chiral stationary phase column (Chiralcel OD-H). 
c 2.5 mol % ligand was added. 
d 2.5 mol % Ti(iOPr)4 was added. 
e 20 mol % Ti(iOPr)4 was added. 
f 30 mol % Ti(iOPr)4 was added. 
g Reaction temperature = 0°C. 
h 10 mol % of ligand 4.40.
Table 4.15. Asymmetric addition of Et2Zn to benzaldehyde in the presence of chiral 
imidate and amidine ligands.  
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4.7.2.2 Asymmetric 1,2-addition of diethylzinc to benzaldehyde in the 
presence of chiral imidate- and oxazoline-alcohol ligands. 
The synthesized imidate- and oxazoline-alcohol ligands were tested and compared in 
the asymmetric diethylzinc addition to aldehydes (Figure 4.21).  
HO
O
N
HO
O
N
HO
O
N
HO
O
N
Cl
HO
O
N
Cl
N
OH
O
4.60a 4.60b 4.60c
4.60d 4.60e
4.43
Figure 4.21. Chiral imidate- and oxazoline- alcohol ligands evaluated in the 
asymmetric diethylzinc 1,2-addition to aldehydes.
The best result was obtained with 4.60a as a chiral ligand (69% yield, 85% ee) (Table 
4.16, entry 1). Less bulky groups on the oxazoline ring result in a lower selectivity 
(Table 4.16, entries 2-3). When performed with the imidate alcohol 4.43 as a chiral 
ligand, the reaction was sluggish and a low enantioselectivity was observed (Table 
4.16, entry 4). Surprisingly, when the reaction was performed with ligand 4.60d, 
containing a chlorine substituent in the ortho-position, 4.91 was obtained in a low 
yield and enantioselectivity (Table 4.16, entry 5). In contrast, ligand 4.60e, bearing a 
chlorine in the para-position of the oxazoline substituent, afforded a yield and 
selectivity which were only slightly lower than with 4.60a (Table 4.16, entry 6). 
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H
O
+ Et2Zn
OH
ligand
toluene, 0°C
4.91 4.92
Entry Ligand Time (h) Yield (%) % eeb Configurationc
1 4.60a 48 69 85 S-(-) 
2 4.60b 48 31 55 S-(-) 
3 4.60c 48 60 44 S-(-) 
4d 4.43 24 14 36 S-(-) 
5 4.60d 48 25 15 S-(-) 
6 4.60e 48 66 79 S-(-) 
a
Reagents and conditions: 4.91 (0.5 mmol), Et2Zn (0.75 mmol), ligand (10 mol %), 2 mL toluene,  
T = 0°C. 
b Determined by HPLC analysis with a chiral stationary phase column (Chiralcel OD-H). 
c Assigned by the sign of the optical rotation. 
d Reaction performed at room temperature 
Table 4.16. Asymmetric additions of Et2Zn to benzaldehyde in the presence of chiral 
imidate- and oxazoline-alcohol ligands.  
With 4.60a as our best ligand, we tried to optimize the reaction parameters (Table 
4.17). Addition of Ti(iOPr)4 resulted in a higher yield but a lower selectivity (Table 
4.17, entry 2). In the presence of Ti(iOPr)4 and n-BuLi, the reaction was rather 
unselective (Table 4.17, entry 3). When the reaction was performed with only n-BuLi 
to deprotonate the ligand, the yield and selectivity did not improve (Table 4.17, entry 
4). Varying the solvent had no beneficial effect compared to our initial experiment 
(Table 4.17, entries 1 and 5-8). 
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H
O
+ Et2Zn
OH
solvent, 0°C
4.91 4.92
HO
O
N
4.60a
Entry Solvent Additiveb Yield (%) %eec
1 toluene / 69 85 
2 toluene Ti(iOPr)4 82 55 
3 toluene Ti(iOPr)4 / n-BuLi 57 9 
4 toluene n-BuLi 46 63 
5 n-hexane / 13 29 
6 CH2Cl2 / 36 73 
7 THF / 9 81 
8 Et2O / 58 84 
a
Reagents and conditions: 4.91 (0.5 mmol), Et2Zn (0.75 mmol), ligand (10 mol %), 2 mL toluene,  
T= 0°C. 
b The additives were added in an equimolar amount in comparison to the ligand. 
c Determined by HPLC analysis with a chiral stationary phase column (Chiralcel OD-H).
Table 4.17. Asymmetric additions of Et2Zn to benzaldehyde in the presence of 4.60a 
as a chiral ligand: Optimization of the reaction parameters.
Next, a variety of substituted arylaldehydes was applied (Table 4.18). In general, 
lower yields and selectivities were obtained in comparison with the unsubstituted 
benzaldehyde. The best result was obtained with 2-naphtaldehyde (Table 4.18, entry 
4). 
Entry Benzaldehyde  Yield (%) % eea configurationb
1 2-Cl-benzaldehyde 57 55 S-(-)
2 3-Cl-benzaldehyde 46 74 S-(-)
3 4-Cl-benzaldehyde 24 62 S-(-)
4 2-naphtaldehyde 52 87 S-(-)
5 trans-cinnamaldehyde 32 61 S-(-)
a Determined by HPLC analysis with a chiral stationary phase column (Chiralcel OD-H, AD-H, OB-H). 
b Assigned by the sign of the optical rotation. 
Table 4.18. Asymmetric addition of Et2Zn to several substituted aldehydes in the 
presence of 4.60a as a chiral ligand.
Remarkably, while with (S)-4.60b as the ligand we obtained (S)-4.92 with an ee of 
55% (Table 4.16, entry 2), with the related (S)-4.57 as a ligand Bolm et al. reported 
formation of the opposite enantiomer (R)-4.92 in 92% ee.61 In order to verify if this 
chirality switch also holds for other ligands, we synthesized (1S,2R)-4.94 as an 
analogue of (1S,2R)-4.60a with a CPh2-tether (Scheme 4.20). When the diethylzinc 
addition was performed in the presence of 4.94, indeed the opposite enantiomer (R)-
(4.92) was obtained in 86% yield, but in only 22% ee.  
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NH2
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HO
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30%
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65%
4.93
4.94
Scheme 4.20. Synthesis of the analogue of 4.60a with a CPh2-connection: (a) 2-
bromobenzonitrile (1 equiv), anhydrous ZnCl2 (5 mol %), anhydrous chlorobenzene, 
Treflux. (b) (i) n-BuLi (1.1 equiv), Et2O, -78°C. (ii) benzophenone (1.15 equiv), -40°C to 
RT overnight. 
Clearly, this chirality switch is caused by the presence of the two phenyl substituents, 
as the absolute configuration of the ligand remained unchanged. Similar effects have 
been reported in other papers and are known as “dual stereocontrol”.86,87 
Furthermore, in the case of the indane-fused oxazolines 4.60a and 4.94, increasing 
the steric bulk of the tether resulted in a lower enantioselectivity. In contrast, when 
the chiral substituent on the oxazoline moiety was a t-butyl-substituent, higher 
enantioselectivities were obtained with a bulky phenyl-substituted tether.61 This 
effect, together with the dual stereocontrol, suggests that the introduction of the 
phenyl substituents modifies the catalytic mechanism or the structure of the catalytic 
site.86,87  
4.7.3 Asymmetric palladium-catalyzed allylic substitutions88
Transition metal-catalyzed allylic substitutions are highly versatile reactions. A wide 
variety of transition metal complexes derived from palladium88, iridium89, nickel90, 
ruthenium91, rhodium92, molybdenum93, copper94, platinum95 and other elements are 
known to catalyze allylic substitutions. However, the most widely used transition 
metal for this purpose is palladium. In 1977, Trost et al. were the first to report an 
example of an enantioselective metal-catalyzed allylic substitution.96 Since their 
pioneering work, a lot of effort has been devoted to develop practically useful 
enantioselective catalysts for this type or reaction. 
The mechanism of the palladium-catalyzed allylic substitution is generally believed to 
involve four fundamental steps (Scheme 4.21). The key intermediate of the catalytic 
cycle is a (-allyl)metal complex. Depending on the structure of the substrate, every 
step provides an opportunity for enantioselection, except for the decomplexation. The 
addition of a nucleophile involves two pathways in which the nature of the 
nucleophile leads to different stereochemical consequences. Soft nucleophiles 
(derived from conjugate acids with pKa < 25) usually add to the allyl moiety from the 
opposite side of the metal. Hard nucleophiles first coordinate to the metal centre and 
are then transferred intramolecularly to the allyl ligand. The most commonly used 
nucleophiles are the soft nucleophiles, such as stabilized carbanions or amines. As a 
consequence, both bond-breaking and bond-forming occurs on the -allyl face 
opposite the metal and its chiral ligand. Thus, efficient chirality transfer over the allyl 
barrier is key to a successful strategy for asymmetric allylic substitutions.  
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Scheme 4.21. Catalytic cycle of transition metal catalyzed allylic alkylation. 
The (-allyl)metal complexes exist in a dynamic equilibrium under typical substitution 
reaction conditions during which their conformation and geometry may change by 
intramolecular processes as well as by reversible ligand-dissociation an reassociation 
processes. There are three important cases: (1) -- (3-1-3) isomerization; (2) 
apparent allyl rotation; (3) palladium(0)-catalyzed allyl exchange.  
(1) -- (3-1-3) isomerization involves the rotation around the carbon-carbon 
bond in the allyl unit. This leads to the syn/anti interconversion as illustrated in 
scheme 4.22. (syn and anti refers to the positions syn and anti to the 
substituent at C2) In general, the thermodynamic equilibrium lies far on the 
side of the syn-isomer and only if a substituent is sufficiently small is the anti-
isomer present in notable amounts. 
LA LB
R1 R2
H
H H
R1 R2
H
H H
LA LB
R1
H
LA LB
H
R2H
H R2
H
R1 H
LA LB
anti
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1 2 3
Scheme 4.22. Syn/anti isomerization by a 3-1-3 mechanism.
(2) In the apparent allyl rotation process both termini of the allyl system switch 
position with respect to the other two coordination sites (Scheme 4.23). If the 
two ligands (LA and LB) are different and chiral, this isomerization leads to a 
diastereoisomeric complex even if the allyl system has structurally identical 
termini. However, when the two ligands (LA and LB) are identical, allyl rotation 
has no consequences. 
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There are three possible mechanisms for apparent allyl rotation. The first one 
involves a -- (3-1-3) isomerization with concomitant rotation around the 
Pd-C bond in the 1-intermediate. A second pathway involves a dissociation of 
one of the ligands (LA or LB). A third possibility is the addition of an external 
ligand, e.g. halides or polar solvents (DMSO, CH3CN), to give a pseudo-
square-planar allyl-Pd complex which leads to a ‘pentacoordinated’ complex 
that undergoes geometrical changes in which the two ligands (LA and LB) can 
switch positions. 
LA LB
R1 R2
H
H H
R1 R2
H
H H
LA LB
R1 R2
H
H H
LB LA
LB LA
R1 R2
H
H H
LA
R1 R2
H
H H
- LB + LB
LA LB
R1 R2
H
H H
X
+ X - X
pi−σ σ−pi
Scheme 4.23. Mechanisms for apparent allyl rotation.
(3) Isomerization of a -allyl species can also arise from a bimolecular reaction as 
shown in scheme 4.24. The Pd(0) complex adds to the free -face of the allyl 
ligand and displaces the Pd(II) complex on the backside. This process results 
in an inversion of the configuration of the -allyl complex. However, because 
the concentration of palladium is much lower than the concentration of the 
substrate and the nucleophile, this type of isomerization is very rare. 
LA LB
R1 R2
H
H H [Pd(0)LALB]
LA LB
R1 R2
H
H H
Scheme 4.24. Palladium(0)-catalyzed allyl exchange. 
A unique feature of these transition metal-catalyzed allylic substitutions is the wide 
variety of substrates that can be addressed. These substrates can be divided in 
several classes according to their substitution pattern and the nature of the 
corresponding allyl-metal complexes (scheme 4.25). In type A substrates there is a 
discrimination between two enantiotopic leaving groups. In type B, the two 
enantiomers of a racemic substrate form a meso--allyl complex wherein a 
preferential attack of the nucleophile at one of the two allylic termini leads to 
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asymmetric induction. This process is a dynamic kinetic enantioselective 
transformation. The third requires the differentiation between two enantiotopic 
transition states (type C). Next, the transition metal can complex with one of the two 
enantiotopic faces of the alkene (type D). Finally, there can be an 
enantiodiscrimination between the two enantiotopic sides of a prochiral nucleophile 
(type E). 
In the following, we will focus our research on the asymmetric allylic substitution of 
type B substrates. 
X X
X X
TypeA
Enantiotopic Leaving Group
X X
Enantiotopic Termini of the Allyl
TypeB
Enantiotopic Faces Exchange
TypeC
X X
Type D
Enantiotopic Faces of Olefin
Z
Y
X
Z
Y
X
Type E
Enantiotopic Faces of Nucleophile
Scheme 4.25. Various sources of enantiodiscrimination in asymmetric allylic 
substitution. 
Since the pioneering work of Trost et al.96,97, a lot of effort has been devoted by 
several groups into the design of chiral catalysts. However, the great majority of the 
catalytic systems developed to date have a rather limited substrate scope (Table 
4.19, entries 1, 3-7). Catalysts which have a wider scope are very scarce (Table 4.19, 
entries 2, 8-11).  Typically, high enantioselectivities are obtained for linear hindered 
substrates and low enantioselectivities for linear unhindered and cyclic substrates, or 
vice versa. Therefore, the development of enantioselective catalysts which show high 
enantioselectivities in both substrate classes remains a major challenge. 
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R R
OAc
R R
CH(COOMe)2CH2(COOMe)2/BSA
[Pd(C3H5)Cl]2/ligand
R=Ph (4.95)
R=Me (4.97)
R=Ph (4.98)
R=Me (4.100)
OAc
4.96
CH2(COOMe)2/BSA
[Pd(C3H5)Cl]2/ligand
CH(COOMe)2
4.99
Entry Ligand 4.98 4.99 4.100 References
1 NH HN
O O
P P
Ph PhPh Ph
9% yield 
52% ee 
86% yield 
96% ee 
98% yield 
92% ee 
97a-b 
2 O
S
P P
- 
97% ee 
- 
93% ee 
- 
82% ee 
98 
3 
PPh2N
O
R
100% yield 
99% ee 
- 
0% ee 
96% yield 
71% ee 
99 
4 
PPh2N
O
Ph
OMe
>99% 
conversion 
96% ee 
40% 
conversion 
56% ee 
87% 
conversion 
43% ee 
100 
5 
N PPh2
Me2N
98% yield 
95% ee 
trace 
62% ee 
36% yield 
59% ee 
31 
Table 4.19. Summary of the literature results for the most representative ligands 
developed for the Pd-(0)-catalyzed allylic substitution reactions. 
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6 Fe PPh2
N
O2N
99% yield 
94% ee 
81% yield 
83% ee 
- 101 
7 Fe
PPh2
N
N
95% yield 
98% ee 
69% yield 
73% ee 
- 102 
8 
S
OPAr2
CMe3
28% yield 
91% ee 
94% yield 
91% ee 
- 103 
9a 
Ph
H
N
OPh
P
P
O
O
O
O
100% 
conversion 
96% ee 
- 
81% ee 
- 
82% ee 
104 
10a 
OOO
N O
R
O
PO
O
Ph
100% 
conversion 
92% ee 
100% 
conversion 
75% ee 
- 
81% ee 
105 
11a O N
O
R
PO
O
100% 
conversion 
>99% ee 
100 
91% ee 
100 
73% ee 
106 
a  
      
O
O
t-Bu
t-Bu
t-Bu
t-Bu
O
O =
Table 4.19-sequel. Summary of the literature results for the most representative 
ligands developed for the Pd-(0)-catalyzed allylic substitution reactions. 
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We tested our ligands in the palladium-catalyzed asymmetric allylic substitution 
(Figure 4.22). Our investigation was started with the allylic substitution of 1,3-
diphenyl-2-propenyl acetate 4.101 with dimethylmalonate which is regarded as a 
standard test reaction for evaluating enantioselective catalysts (Table 4.20).  
NN
N
O O
4.39
N
O
O
4.40
Fe
PPh2 N O
4.55a
Fe
PPh2 N O
4.55b
Fe
PPh2 N O
4.55c
Fe
PPh2 N O
4.55d
Cl
Cl Br
Figure 4.22. Chiral bisimidate and chiral hybrid imidate-phosphane ligands evaluated 
in the asymmetric allylic alkylation.
  
Bisimidate ligand 4.39 gave no conversion while ligand 4.40 resulted in a moderate 
yield but an excellent enantioselectivity (Table 4.20, entries 1-2). High yields and 
excellent enantioselectivities were obtained with all imidate-phosphane ligands 
(Table 4.20, entries 3-6). The best result was obtained with ligand 4.55b (Table 4.20, 
entry 4). We observed also a pronounced BSA-activator effect (Table 4.20, entries 7-
9). The enantioselectivity could be further improved when NaOAc was used (Table 
4.20, entry 7). With KOAc and CsOAc as a BSA-activator, almost perfect 
enantioselectivities and reactivities were obtained (Table 4.20, entries 8-9). 
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Ph Ph
OAc
Ph Ph
CH(COOMe)2
CH2(COOMe)2/BSA
BSA activator
CH2Cl2, RT, 16h
[Pd(pi−C3H5)Cl]2 /
Ligand
4.101 4.102
*
Entry Ligand 
BSA-
activator 
Yield (%) % eeb Configurationc 
1 4.39 LiOAc n.c.d - - 
2 4.40 LiOAc 53 95  R 
3 4.55a LiOAc 82 94  S 
4 4.55b LiOAc 85 96  S 
5 4.55c LiOAc 84 96  S 
6 4.55d LiOAc 85 96 S 
7 4.55b NaOAc 93 99  S 
8 4.55b KOAc 99 99  S 
9 4.55b CsOAc 99 99  S 
a
Reagents and conditions: 4.101 (0.22 mmol), dimethylmalonate (0.66 mmol), BSA (0.66 mmol), 
BSA activator (10.6 mol), [Pd(3-C3H5)Cl]2 (5.5 mol), ligand (21.8 mol), CH2Cl2 (2 mL), room 
temperature, 16h. 
b Determined by HPLC analysis with a chiral stationary phase column (Chiralcel AD-H). 
c Assigned by the sign of the optical rotation. 
d n.c.: no conversion was observed. 
Table 4.20. Pd-catalyzed allylic alkylation of 4.101 with dimethylmalonate using 
bisimidate ligands 4.39-4.40 and imidate-phosphane ligands 4.55a-d.
To further study the potential of these readily available ligands, other nucleophiles 
were tested (Scheme 4.26). When the reaction was performed with bulky malonates, 
excellent yields and selectivities were obtained for the corresponding adducts 4.103 
and 4.104. Use of dimethylmethylmalonate as a nucleophile and LiOAc as a BSA 
activator led to 4.105 in excellent yield and good enantioselectivity. By variation of 
the BSA activator, the enantioselectivity could be further improved to >99% ee with 
NaOAc. Also acetylacetone was an effective nucleophile for the palladium-catalyzed 
allylic alkylation reaction: adduct 4.106 was formed in 96% yield and with an 
enantioselectivity of 94% ee. 
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Ph Ph
OAc
EtO OEt
O O
+
[Pd(pi−C3H5)Cl]2 /
Ligand 4.55b
4.101
BSA / LiOAc
CH2Cl2, RT, 16h
Ph Ph
CH(COOEt)2
4.103
Ph Ph
OAc
Ot-Bu
O O
+
4.101
Ph Ph
CH(COOt-Bu)2
4.104
Ph Ph
OAc
MeO OMe
O O
+
4.101
Ph Ph
CMe(COOMe)2
4.105
t-BuO
Ph Ph
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Scheme 4.26. Allylic substitution reactions with various carbon nucleophiles 
using 4.55b as an imidate-phosphane ligand.
Encouraged by the excellent performance of our new imidate-phosphane ligand 
4.55b, we studied its potential in the allylic alkylation of cyclic substrate 4.107 and 
unhindered linear substrate 4.109. Although highly selective catalyst systems have 
been developed for these substrates, they generally exhibit low enantiocontrol in 
more hindered substrates, such as substrate 4.101. Remarkably, also for the 
unhindered substrate 4.107 good enantioselectivities were observed with our catalyst 
system (Table 4.21, entries 1-5). The best result was obtained when NaOAc was 
used as a BSA activator (Table 4.21, entry 4). For the cyclic substrate 4.109, good 
enantioselectivities were obtained with all BSA activators in varying yields (Table 
4.21, entries 6-9). The best results were obtained with KOAc: a high yield was 
combined with a good enantioselectivity (Table 4.21, entry 7). 
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OAc CH(COOMe)2
CH2(COOMe)2/BSA
BSA activator
CH2Cl2, RT, 16h
[Pd(pi−C3H5)Cl]2 /
Ligand 4.55b4.107 4.108
OAc CH(COOMe)2
4.109 4.110
Fe
PPh2 N O
4.55b
Cl
Entry Substrate BSA-
activator 
Yield (%) % eeb Configurationc 
1 4.107 LiOAc 79 78 S 
2d 4.107 LiOAc 23 80 S
3 4.107 KOAc 86 59 S
4 4.107 NaOAc 91 83 S
5 4.107 CsOAc 80 65 S
6 4.109 LiOAc 49 74 R 
7 4.109 KOAc 76 74 R
8 4.109 NaOAc 31 73 R
9 4.109 CsOAc 61 73 R
a
Reagents and conditions: 4.107 or 4.109 (0.22 mmol), dimethylmalonate (0.66 mmol), BSA (0.66 
mmol), BSA activator (10.6 mol), [Pd(3-C3H5)Cl]2 (5.5 mol), ligand (21.8 mol), CH2Cl2 (2 mL), 
room temperature, 16h. 
b Determined by 1H NMR analysis by using (+) Eu(hfc)3. 
c Assigned by the sign of the optical rotation. 
d The reaction was performed at 0°C. 
Table 4.21. Pd-catalyzed allylic alkylation of 4.107 or 4.109 with dimethylmalonate 
using imidate-phosphane ligand 4.55b.
A mechanistic rationalization of the enantioselectivity observed with non-symmetrical 
ligands, such as imidate-phosphane ligand 4.55b, is often difficult and is mostly 
based on X-ray analyses107 or extensive NMR studies108,109. Unfortunately, attempts 
to grow a suitable crystal for X-ray analysis of the palladium-complexed ligand 4.55b 
all failed.110 However, a plausible explanation can be rationalized as depicted in 
scheme 4.27. The allylic moiety can adopt two possible conformations, i.e. an M-
shaped conformation or a W-shaped conformation. Computational studies111 and 
NMR investigations112 provide strong evidence that a nucleophile preferentially 
attacks the allylic carbon terminus trans to the phosphorus atom. Based on these 
data and the observed S-configuration of the product, we believe that the major 
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enantiomer is derived from the nucleophilic attack trans to the phosphorus centre of 
the W-shaped -allyl complex. 
Ph Ph
N
Pd
P
Me
O
Fe
PhPh
Nu- Nu-
Ph Ph
Nu
Ph Ph
Nu
(S)-4.102
(major)
(R)-4.102
(minor)
M-type W-type
N
Pd
P
Me
O
Fe
Scheme 4.27. The stereoselectivity observed in the palladium-catalyzed asymmetric 
allylic alkylation with imidate-phosphane ligand 4.55b.
4.8 CONCLUSIONS 
In summary, we introduced chiral imidates as a new class of chiral ligands. These 
ligands could be readily obtained via an efficient one-step synthesis starting from 
imidates and chiral amines (scheme 4.28). 
O
NH
.HClO
N R*
R*-NH2
ONO N
NH2H2N
R1
R2
R3
R4
R3
R2
R1
R4
R4
R3 R2
R1 R1
R2 R3
R4
*
*
Scheme 4.28. Synthesis of substituted imidate ligands.
These monodentate and bidentate ligands were tested in copper(I)-catalyzed 
asymmetric aziridinations (up to 97% yield and 51% ee) and asymmetric additions of 
Et2Zn to benzaldehyde (up to 87% yield and 76% ee). The best result was obtained 
in the palladium-catalyzed asymmetric allylic alkylation. Although the yield was only 
53%, an excellent enantioselectivity was observed (95% ee).  
In addition, we synthesized hybrid imidate-phosphane ligands. These ligands were 
demonstrated to be highly valuable in palladium-catalyzed allylic substitution 
reactions (Scheme 4.29). Excellent performance of this catalyst system was 
observed in the allylic alkylation of 1,3-diphenyl-2-propenyl acetate with various 
nucleophiles (up to 99% yield and >99% ee). Moreover, the allylic alkylation of linear 
unhindered and cyclic substrates resulted in good conversions and 
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enantioselectivities. Rarely are enantioselective catalysts successful in both substrate 
classes. Therefore, this imidate-phosphane ligand family can compete with a few 
other ligands which also provide high selectivities for both hindered and unhindered 
substrates.  
R R
OAc
+
[Pd(pi−C3H5)Cl]2 /
Ligand 4.55b
BSA / BSA activator
CH2Cl2, RT, 16h
R R
Nu
Fe
PPh2 N O
4.55b
Cl
Nu-HOAc Nu
up to 99% yield
up to 99% ee
Scheme 4.29. Pd-catalyzed asymmetric allylic alkylation with hybrid imidate-
phosphane ligand 4.55b. 
The cyclic imidate ligand precursor 4.18 could also be used efficiently as a synthetic 
intermediate for the synthesis of chiral oxazoline alcohol ligands 4.60 and the 
synthesis of  chiral imidazolidines 4.64. The chiral oxazoline alcohol ligands 4.60
were tested in asymmetric diethylzinc additions to benzaldehydes. 
Enantioselectivities up to 87% ee were obtained (Scheme 4.30).  
OHH2N
R1 R2
* *
O
NH
OH
N
O
R1
R2
*
*NH2H2N
HN NH
O
4.18
4.60
4.584.61
4.64
.HCl
Scheme 4.30. Synthetic applications of cyclic imidate esters. 
In conclusion, we can state that these chiral imidate ligands can evolve into an 
interesting new type of chiral nitrogen-containing ligands. We have demonstrated that 
these ligands are easy accessible in one step starting from imidate building blocks 
(4.18 and 4.49a-c). Their accessibility is an important advantage in the design of 
these new ligands. Some interesting results in catalytic asymmetric test reactions 
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have been presented in this chapter. However, in the future more research is 
required to develop more applications for these ligands. Especially the hybrid 
imidate-phosphane ligand family showed already very impressive results in the 
asymmetric allylic alkylation and we expect that this will also be the case for other 
test reactions. 
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5 
SUMMARY AND FUTURE 
PERSPECTIVES 
In this work, two main ligandclasses have been studied: chiral diene ligands and 
chiral imidate ligands. Both have in common that their use was, until recently, 
precluded from asymmetric catalysis due to their presumed instability.  
In 2003, Hayashi et al. published the first paper about chiral diene ligands. Although 
the catalytic properties of these ligands were excellent, its synthesis was rather 
elaborate.1 In chapter 3, we developed a novel route to synthesize chiral 
disubstituted bicyclo[2.2.1]heptadienes starting from enantiomerically pure bistriflate 
3.45 (Scheme 5.1). Advantages of this approach are the higher overall yield and the 
possibility to introduce simultaneously both sidechains.2  
O
O
TfO
OTf
1. KHMDS, THF, -78°C, 1u.
2. PhNTf2, -78°C, 3u.
55-60 %
R
R
O
O
O
O
O
OTf
O
O
R R
O
TfO
R
HOCH2CH2OH,
TsOH
97 %
1. LDA, THF
2. Tf2N py-2
70 %
RMgX, 
PdCl2(dppf)
97 %
2.0N HCl, THF
94 %
1. LDA, THF
2. Tf2N py-2
81 %
RMgX, 
PdCl2(dppf)
       45 %
RMgX, PdCl2(dppf)
33 - 77 %
Yielddetermined for R=Bn:
Hayashi:                  23 %
Our Method:            44 %
3.7 3.45 3.10
3.8
3.9
Scheme 5.1. Comparison of our new method and the original method of Hayashi.
With this method, we synthesized Hayashi’s ligand with benzyl-sidechain and three 
new ligands (with R= i-Bu, c-Hex and Allyl). An NMR-study of the rhodium complex of 
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(S,S)-allyl-nbd* revealed that the coordination of the metal happened exclusively via 
the norbornadiene double bounds. This contrasts with the observations of Carreira.3
The synthesized diene ligands were tested in several rhodium-catalyzed asymmetric 
test reactions. Excellent enantioselectivities (up to 96% ee) were observed in the 
rhodium(I)-catalyzed 1,4-addition of phenylboronic acids to cyclic enones (scheme 
5.2). An increasing sterical demand of the ligand substituents did not lead to a 
significant difference in selectivity, whereas the reaction rate was greatly influenced. 
O
+   PhB(OH)2
dioxane/1.5 M aq H2O 
(10:1)
[RhOH(C2H4)2]2
(3mol % Rh)
n
(2 equiv)
O
n
Ph
(S)-3.71a-b3.70a-b
n=1 (a), 0 (b) 82-96% ee
44-95% yield
R
R
Scheme 5.2. Rhodium(I)-catalyzed asymmetric 1,4-addition of PhB(OH)2 to cyclic 
enones.
In the 1,4-addition to -acetamido acrylic ester 3.72, the formation of a Heck-type 
product 3.77 was observed as a side product. Moreover, the ratio of the conjugate 
adduct (3.73) and Heck product (3.77) could be adjusted by the proper choice of the 
ligand in the achiral version (Scheme 5.3). When we turned to the asymmetric 
reaction with ligand 3.10, low yields and selectivities were observed. 
CO2Me
NHAc +   PhB(OH)2
      (4 equiv) CO2Me
NHAcPh
*
NaF (3 equiv)
dioxane/H2O (10:1)
+
CO2Me
NHAcPh
3.72 3.73 3.77
[Rh]
[Rh(COD)Cl]2: 82% 18%
Rh(acac)(ethene)2: 21% 79%
Scheme 5.3. Rhodium(I)-catalyzed 1,4-addition versus Heck reaction.
Finally, we investigated the rhodium-catalyzed 1,2-addition of phenylboronic acids to 
benzaldehydes. This reaction can be considered as a challenging reaction. The 
presence of the alkyl side chains on the ligand appeared to be crucial for the catalytic 
effect, resulting in a dramatically higher reactivity as compared to unsubstituted 
norbornadiene as a ligand. Enantioselectivities could be improved from poor to fair 
with ligand 3.56 (up to 48% ee) (Scheme 5.4). 
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3.89
F3C
O
H
B
OHHO
+
[Rh(C2H4)2Cl]2
(3 mol % Rh)
F3C
OH
(2 equiv)
solvent, additive
(R)- 3.90
3.56
up to 99% yield
up to 48% ee
Scheme 5.4. Rhodium(I)-catalyzed asymmetric 1,2-addition of PhB(OH)2 to p-
trifluoromethylbenzaldehyde.
In chapter 4, we introduced chiral imidates as a novel nitrogen-based ligand family. 
Imidates have never before been reported in the literature. This is probably due to 
their general assumed instability. 
The key factor which determines the utility of any ligand for asymmetric catalysis is 
the ease by which it can be accessed. We showed that these imidate ligands could 
be obtained readily via a one-step synthesis starting from a central precursor in 
excellent yields.4 Moreover, imidate ligands could further be fine-tuned when 
substituents were put on the aromatic ring of the imidate ligand precursor (Scheme 
5.5). 
O
NH
.HClO
N R*
R*-NH2
ONO N
NH2H2N
R1
R2
R3
R4
R3
R2
R1
R4
R4
R3 R2
R1 R1
R2 R3
R4
*
*
Scheme 5.5. Synthesis of imidate ligand family.  
The synthesized monodentate and bidentate ligands were tested in several 
asymmetric test reactions (Scheme 5.6). In the copper(I)-catalyzed asymmetric 
aziridinations, we obtained usually high yields (up to 90% yield) and moderate 
enantioselectivity (51% ee) with ligand 4.39. The asymmetric addition of diethylzinc to 
benzaldehyde resulted in high yields (up to 87% yield) and good enantioselectivities 
(up to 76% ee) with ligand 4.40. However, the best result was obtained in the 
asymmetric allylic alkylation with ligand 4.40: a moderate yield (53% yield) with an 
excellent selectivity (95% ee).  
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CO2Me Cu(MeCN)4PF6 / 4.39
PhINTs
CO2Me
N
Ts
4.70 4.75
up to 90% yield
up to 51% ee
H
O
+ Et2Zn
OH
*
4.40
toluene, RT
4.91 4.92
up to 87% yield
up to 76% ee
Ph Ph
OAc
Ph Ph
CH(COOMe)2
CH2(COOMe)2/BSA
BSA activator
CH2Cl2, RT, 16h
[Pd(pi−C3H5)Cl]2 /
4.40
4.101 4.102
*
NN
N
O O
4.39
N
O
O
4.40
53% yield
95% ee
Scheme 5.6. Application of bisimidate ligands in asymmetric aziridinations, 
asymmetric diethylzinc additions and asymmetric allylic alkylations.
Futhermore, we developed successfully hybrid imidate-phosphane ligands as a new 
type of P,N ligands. These ligands are easily accessible in one step via a 
condensation of a commercially available aminophosphane and an imidate ligand 
precursor. The ligands were demonstrated to be highly valuable in palladium-
catalyzed allylic substitution reactions (Scheme 5.7). Excellent performance of this 
catalyst system was observed in the allylic alkylation of 1,3-diphenyl-2-propenyl 
acetate with various nucleophiles (up to 99% yield and >99% ee). Moreover, the 
allylic alkylation of linear unhindered and cyclic substrates resulted in good 
conversions and enantioselectivities. Rarely are enantioselective catalysts successful 
in both substrate classes. Therefore, this imidate-phosphane ligand family can 
compete with a few other ligands which also provide high selectivities for both 
hindered and unhindered substrates (Table 5.1).  
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R R
OAc
+
[Pd(pi−C3H5)Cl]2 /
Ligand 4.55b
BSA / BSA activator
CH2Cl2, RT, 16h
R R
Nu
Fe
PPh2 N O
4.55b
Cl
Nu-HOAc Nu
up to 99% yield
up to >99% ee
Scheme 5.7. Pd-catalyzed asymmetric allylic alkylation with hybrid imidate-
phosphane ligand 4.55b. 
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Entry Ligand Ph Ph
CH(COOMe)2
4.98
CH(COOMe)2
4.99
CH(COOMe)2
4.100
Reference 
1 
Fe
PPh2N O
4.55b
Cl
99% yield 
99% ee 
76% yield 
74% ee 
91% yield 
83% ee 
5 
2 
S
OPAr2
CMe3
28% yield 
91% ee 
94% yield 
91% ee 
- 6 
3a 
Ph
H
N
OPh
P
P
O
O
O
O
100% conversion 
96% ee 
- 
81% ee 
- 
82% ee 
7 
4a 
OOO
N O
R
O
PO
O
Ph
100% conversion 
92% ee 
100% 
conversion 
75% ee 
- 
81% ee 
8 
5a O N
O
R
PO
O
100% conversion 
>99% ee 
100% 
conversion 
91% ee 
100% conversion 
73% ee 
9 
a  
      
O
O
t-Bu
t-Bu
t-Bu
t-Bu
O
O =
Table 5.1. Comparison of hybrid imidate-phosphane (4.55b) with the best in the 
literature existing results.  
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The cyclic imidate ligand precursor 4.18 could also be used efficiently as a synthetic 
intermediate for the synthesis of chiral oxazoline alcohol ligands 4.60 and the 
synthesis of  chiral imidazolidines 4.64 (Scheme 5.8). The chiral oxazoline alcohol 
ligands 4.60 were tested in asymmetric diethylzinc additions to benzaldehydes.10
Enantioselectivities up to 87% ee were obtained.  
OHH2N
R1 R2
* *
O
NH
OH
N
O
R1
R2
*
*NH2H2N
HN NH
O
4.18
4.60
4.584.61
4.64
.HCl
Scheme 5.8. Synthetic applications of cyclic imidate esters. 
In conclusion, we have shown that both chiral diene ligands as well as chiral imidate 
ligands can be very useful ligands for asymmetric catalysis.  
We, as well as various other groups, showed that chiral dienes can be more than 
only a proof of concept. An impressive number of papers has been published to show 
their amazing catalytic properties.11 However, it is remarkable that almost all 
examples concern rhodium- or iridium-catalyzed asymmetric reactions. Therefore, 
further research should be directed towards the search of new metals which are 
compatible with these diene ligands. This would expand the scope of the diene ligand 
family considerably.  
Despite the fact that chiral imidate ligands are still at their infancy, we have 
demonstrated in this Ph.D.-thesis that they may be very interesting ligands in the 
future. Especially the easy and straightforward synthetic access to chiral imidates is 
of prime importance. This feature can help its widespread use in asymmetric 
transition metal catalysis. Future investigations should be directed towards the 
development of new applications for these imidate ligands. Especially the hybrid 
imidate-phosphane ligands have a lot of potential and should be further explored in 
other asymmetric test reactions.  
Moreover, we showed briefly that it is possible to tune the catalytic properties of the 
imidate ligand by putting substituents on the aromatic ring of the imidate ligand 
precursor. This aspect should help to fine-tune the imidate catalyst system for a 
specific application.  
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6 
EXPERIMENTAL SECTION 
6.1 GENERAL 
All reactions were carried out under argon atmosphere in dry solvents under 
anhydrous conditions, unless otherwise stated. Solvents were dried and distilled prior 
to use. Tetrahydrofuran, dioxane and diethylether were distilled from 
sodium/benzophenone. Dichloromethane, chloroform, 1,2-dichloroethane, pyridine, 
triethylamine were distilled from calciumhydride. DMF, DMSO, MeOH, chlorobenzene 
and acetonitrile were purchased as dry solvents. When needed, solvents were 
degassed prior to use by three freeze-pump-thaw cycles. 
Analytical TLC was performed using Macherey-Nagel SIL G-25 UV254 plates. 
Visualization was performed via UV (254 nm) or via staining with potassium 
permanganate, cerium ammonium molybdate or ninhydrine. Flash chromatography 
was carried out with Rocc silicagel (0.040 – 0.063 mm).  
1H NMR and 13C NMR were recorded on a Bruker Avance 300 or a Bruker AM 500 
spectrometer as indicated, with chemical shifts reported in ppm relative to TMS, 
using the residual solvent signal as a standard. 13C NMR spectra were recorded 
using the attached proton test.  IR-spectra were recorded a Perkin-Elmer spectrum 
1000 FT-IR spectrometer with a Pike Miracle HATR module.  
EI Mass spectra were recorded with a Hewlett-Packard 5988A mass spectrometer. 
LC-MS analysis was performed on an Agilent 1100 series HPLC with quaternary 
pump, DAD and single quadrupole MS detector type VL with an API-ES source, 
using a Phenomenex Luna C18(2) column (250 x 4.6 mm, particle size 5 µm). 
Analytical chiral HPLC separations were performed on an Agilent 1100 series HPLC 
system with DAD detection. Exact molecular masses were measured on a Kratos 
MS50TC mass spectrometer. Melting points were measured with a Kofler melting 
point apparatus.  
Norbornadiene was passed through neutral alumina and subsequently distilled. 
Cyclohexenone was distilled prior to use. HSiCl3 was distilled from quinoline. 
Benzaldehyde was passed through basic alumina. All other reagents were purchased 
and used without purification, unless otherwise noted.
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6.2 SYNTHESIS OF CHIRAL DIENE LIGANDS 
6.2.1 Synthesis of (1S, 2R, 4S, 5R)-2,5-dihydroxybicyclo[2.2.1]heptane (3.6) 
HO
OH
1. HSiCl3, [PdCl(C3H5)]2,
(S)-MeO-MOP (O.1 mol % Pd), -3 °C, 3d.
2. MeOH, Et3N, Et2O.
3.H2O2.urea, KHF2, THF/MeOH.
64 %
3.6
A solution of [PdCl(-C3H5)]2 (13.7 mg, 37.4 mol) and (S)-MeO-MOP (70 mg, 149 
mol) in benzene (2 mL) and pyridine (0.1 mL) was placed in a double-jacketed 50 
mL flask, provided with a thermometer, under argon. HSiCl3 (18 mL, 179 mmol) was 
added and the solution was cooled to -3 °C. Norborn adiene (8.06 mL, 75 mmol) was 
added slowly with a syringe pump (2 mL/h). The temperature in the reaction vessel 
was kept constant at -3 °C. The reaction was stirre d for ca. 3 days, until it turned into 
a pale yellowish solid. The solvent and excess HSiCl3 were removed in vacuo at 
room temperature. The residue was dissolved in 50.0 mL of dry Et2O under argon 
and cooled to 0 °C. A mixture of dry MeOH (545.0 mL , 1.34 mol), dry Et3N (72.0 mL, 
0.552 mol) and dry Et2O (50.0 mL) was added dropwise. After the solution was 
stirred at room temperature overnight, the precipitated salts were filtered off and 
washed with Et2O. The filtrate was concentrated in vacuo to yield a brownish oil. To 
this was added KHF2 (29.17 g, 374 mmol), dry THF (80 mL), dry MeOH (80 mL) and 
H2O2.urea (52.70 g, 560 mmol). The resulting white suspension was stirred overnight 
at 60 °C.  The solids were filtered off and washed with MeOH. The filtrate was 
concentrated in vacuo to yield a white solid. This was dissolved in 150 mL sat. aq. 
NH4Cl and extracted with 6 x 500 mL CHCl3/EtOH (70/30). The combined organic 
phases were dried over Na2SO4 and evaporated. Diol 1 (>99% ee) was isolated as a 
white solid after flash chromatography over silicagel (EtOAc/pentane, 75/25), 6.08 g 
(64 % based on norbornadiene). 
Formula: C7H12O2 (128.17 g/mol).  
Rf (EtOAc/Et2O 75:25): 0.24  
1H-NMR (500 MHz, pyridine-d5):  1.58-1.59 (m, 4H), 2.02 (s, 2H), 2.42 (s, 2H), 3.94 
(t, J= 4.5 Hz, 2H), 5.94 (br s, 2H) ppm. 
13C-NMR (75.4 MHz, pyridine-d5):  31,2 (CH2), 37.7 (CH2), 44.2 (CH), 73.5 (CH) 
ppm. 
IR (KBr, thin film): 3233, 2960, 2931, 2889, 1351, 1088, 993, 744 cm-1. 
EI-MS m/z (rel. intensity %): 110 (M+-H2O, 17), 92 (8), 81 (21), 66 (100), 55 (38), 41 
(45). 
Melting Point (°C) : 162 °C. 
Optical rotation: [α]20
D
= + 8.8 (c 1.0, EtOH). 
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6.2.2 Synthesis of (1S,4S)-Bicyclo[2.2.1]heptane-2,5-dione (3.7) 
1) (COCl)2, DMSO, CH2Cl2, -78°C.
2) Et3N, -78°C.
82 %
HO
OH
O
O3.6 3.7
Dry CH2Cl2 (500.0 mL) was cooled to -78 °C and oxalylchloride  (18.0 mL, 189 mmol) 
was added under argon and magnetic stirring. DMSO (26.8 mL, 378 mmol) was 
added dropwise and the solution was stirred for 5 min. Diol 3.6 (6.10 g, 43 mmol) was 
dissolved in 1000 mL dry CH2Cl2 and canulated to the Swern reagent. The resulting 
solution was stirred for another 20 min. Et3N (104.0 mL, 686 mmol) was added, and 
after 1 h TLC indicated complete conversion of the diol. 1 N HCl (500 mL) was added 
and the mixture was extracted with CH2Cl2/Et2O (1/1; 4x500 mL). The combined 
organic phases were washed with sat. aq. NaHCO3 (1000 mL) and brine (1000 mL) 
and dried over MgSO4. The filtrate was concentrated in vacuo. The resulting yellow 
oil was purified by flash chromatography over silicagel (Et2O/pentane, 2/1) resulting 
in a white solid, giving 4.82 g (82 %) of diketone 3.7 (>99% ee). 
Formula: C7H8O2 (124.14 g/mol).  
Rf (Et2O/pentane 2:1): 0.23  
1H-NMR (500 MHz, CDCl3):  2.08-2.10 (m, 2H), 2.10-2.18 (ddd, J= 2, 4, 18 Hz,  2H), 
2.33-2.42 (ddd, J= 2, 4, 18 Hz,  2H) 2.97-3.00 (td, J= 1.6, 6.2 Hz, 2H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  36.4 (CH2), 39.0 (CH2), 48.6 (CH), 212.3 (C) ppm. 
IR (KBr, thin film): 2960, 1753, 1736, 1406, 1268, 1232, 1188, 1124, 1000, 963 cm-
1. 
EI-MS m/z (rel. intensity %): 124 (M+, 100), 95 (18), 82 (26), 67 (99), 55 (86), 50 (8), 
41 (34). 
Melting Point (°C) : 118-128 °C. 
Optical rotation: [α]20
D
= - 3.1 (c 1.0, CHCl3).
Chiral HPLC: Chiralcel OJ-H kolom, solvent: n-hexane/EtOH (90:10), flow rate= 1 
mL/min, T= 35°C, retention times: 14.9 min for (1 R, 4R)-3.7, 16.2 min for (1S, 4S)-
3.7. 
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6.2.3 Synthesis of bis-triflate (S,S)-3.45 
3.7
1) KHMDS, THF, -78°C, 1h.
2) PhNTf2, -78°C, 3h.
55 -60 %
TfO
OTf
O
O 3.45
Diketone (1S,4S)-3.7 (4.0 g, 31.8 mmol) was dissolved in dry THF (220 mL) and 
cooled to -78 °C. KHMDS (166 mL, 0.5 M in toluene, 82.8 mmol) was added 
dropwise. After 1 h PhNTf2 (29.6 mL, 82.8 mmol) dissolved in 120 mL dry THF was 
added. The resulting reaction mixture was stirred for another 3 h. The reaction 
mixture was quenched with saturated aq. NH4Cl (300 mL) and extracted with pentane 
(2 x 500 mL). The combined organic phases were washed with saturated aq. NH4Cl 
(200 mL). The organic phases were dried over MgSO4 and concentrated in vacuo. 
The resulting brown oil was purified by flash chromatography over silicagel (gradient 
elution with pentane/CHCl3, 96/4 to pentane/Et2O, 95/5) resulting in a colourless oil, 
giving 7.08 g (55 %) of bis-triflate 3.45. 
Formula: C9H6F6O6S2 (388.25 g/mol).  
Rf (pentane/Et2O 95:5): 0.44  
1H-NMR (300 MHz, CDCl3):  2.62 (t, J= 1.8 Hz, 2H), 3.53 (m,  2H), 6.51 (dd (app.t), 
J= 2.4, 2.4 Hz, 2H) ppm. 
13C-NMR (75.4 MHz, CDCl3 CDCl3):  50.3 (CH), 73.1 (CH2), 118.4 (q, JC-F = 321 Hz, 
C), 123.7 (CH), 168.2 (C) ppm. 
IR (KBr, thin film): 1632, 1609, 1426, 1294, 1247, 1207, 1135, 1073, 1023, 934, 
882, 845 cm-1. 
EI-MS m/z (rel. intensity %): 388 (M+, 9), 227 (4), 149 (6), 122 (9), 105 (10), 77 (41), 
69 (100), 41 (26). 
Optical rotation: [α]20
D
= - 28 (c 1.0, CHCl3) 
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6.2.4 A typical procedure for the preparation of (S,S)-nbd*-ligands 
6.2.4.1 Synthesis of (S,S)-Bn-nbd* (3.10) 
BnMgCl, PdCl2(dppf).CH2Cl2 (2.3 mol %),
Et2O, RT, 1 h.
72 %
TfO
OTf3.45 3.10
A solution of bis-triflate (S,S)-3.45 (104.7 mg, 269.7 mol) and PdCl2(dppf).CH2Cl2
(4.7 mg, 5.79 mol) in Et2O (1.0 mL) was cooled in an ice bath . To the resulting red 
suspension was added BnMgCl (1.35 mL, 1.77 mmol, 20 w/w% in THF) under argon. 
The reaction mixture was stirred for 1 h at room temperature, quenched with brine 
(25 mL) and extracted with EtOAc (4x 50 mL). The combined organic phases were 
dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
flash chromatography over silicagel (isooctane/CHCl3, 96/4) resulting in a white solid 
which contained a significant amount of diphenylethane which was removed under 
reduced pressure (< 1 mm Hg, 1 night) resulting in pure (S,S)-Bn-nbd* (3.10) as a 
white solid, 53.0 mg (72 %). 
Formula: C21H20 (272.38 g/mol).  
Rf (isooctane/CHCl3 96:4): 0.21 
1H-NMR (500 MHz, CDCl3):  1.94 (t, J= 1.7 Hz, 2H), 3.14 (dt, J= 3.8, 1.7 Hz, 2H), 
3.49 (s, 4H), 6.02 (dt, J= 3.8, 1.6 Hz,  2H), 7.09 (d, J= 7.2 Hz, 4H), 7.18 (tt, J= 7.2, 
1.2 Hz,  2H), 7.26 (t, J= 7.2 Hz, 4H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  38.0 (CH2), 53.1 (CH), 71.4 (CH2), 125.9 (CH), 128.1 
(CH), 129.0 (CH), 134.3 (CH), 139.1 (C), 156.9 (C) ppm. 
IR (KBr, thin film): 2970, 2950, 2929, 2878, 1600, 1492, 1451, 1306, 1183, 1069, 
1026, 948, 856, 780, 752, 737, 708 cm-1. 
EI-MS m/z (rel. intensity %): 272 (M+, 9), 181 (34), 165 (21), 156 (34), 141 (17), 128 
(22), 115 (39), 103 (8), 91 (88), 84 (29), 65 (30), 49 (71), 40 (100). 
APCI-MS: 273 [M+H]+.
Melting Point (°C) : 67 °C. 
Optical rotation: [α]20
D
= - 180 (c 1.07, CHCl3). 
HRMS (EI): calcd for C21H20: 272.1565; found 272.1569. 
Formula: C14H14 (182.26 g/mol).  
Rf (isooctane/CHCl3 96:4): 0.27 
1H-NMR (500 MHz, CDCl3):  2.95 (s, 4H), 7.23 (m, 6H), 7.31 (m, 4H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  37.98 (CH2), 125.94 (CH), 128.36 (CH), 128.48 (CH), 
141.81 (C) ppm. 
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IR (KBr, thin film): 3058, 3026, 2944, 1600, 1491, 1450, 1063, 1027, 750, 698, 517 
cm-1. 
EI-MS m/z (rel. intensity %): 182 (M+, 21), 91 (100), 77 (3), 65 (20), 51 (7), 41 (2). 
Melting Point (°C) : 51-52 °C. 
6.2.4.2 Synthesis of (S,S)-i-Bu-nbd* (3.56) 
i-Bu-MgBr, PdCl2(dppf).CH2Cl2 (2.3 mol %),
Et2O, kt, 1 h.
33 %
TfO
OTf3.45 3.56
The reaction was performed on bis-triflate (S,S)-3.45 (501.3 mg, 1.29 mmol) using a 
i-BuMgCl (4.5 mL, 8.99 mmol, 2 M in Et2O) solution. After 1 h the reaction was 
quenched with H2O and extracted with pentane. The combined organic phases were 
dried on MgSO4 and carefully concentrated in vacuo. Purification by flash 
chromatography over silicagel (pentane) resulted in pure (S,S)-i-Bu-nbd* (3.56) as a 
colourless oil, 86.7 mg (33 %). 
Formula: C15H24 (204.35 g/mol).  
Rf (isooctane): 0.56 
1H-NMR (500 MHz, CDCl3):  0.81 (d, J= 6.6 Hz, 6H), 0.87 (d, J= 6.6, 6H), 1.71-1.80 
(septet, J= 6.6 Hz, 2H), 1.94 (t, J= 1.6 Hz,  2H), 2.03-2.08 (dq, J= 1.5, 6.8 Hz, 4H), 
3.17 (dt, J= 3.9, 1.6 Hz,  2H), 6.12 (td, J= 1.5, 3.9 Hz, 2H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  22.6 (CH3), 22.8 (CH3), 26.6 (CH), 41.0 (CH2), 53.4 
(CH), 71.9 (CH2), 133.5 (CH), 157.9 (C) ppm. 
IR (KBr, thin film): 3062, 2955, 2930, 2900, 2867, 2830, 1464, 1383, 1366, 1298, 
1185, 1167, 780 cm-1. 
EI-MS m/z (rel. intensity %): 204 (M+, 49), 161 (27), 147 (25), 122 (48), 117 (20), 
105 (60), 91 (51), 80 (100), 66 (44), 43 (77). 
APCI-MS: 205 [M+H]+.
Optical rotation: [α]20
D
= - 103 (c 1.14, CHCl3). 
HRMS (EI): calcd for C15H24: 204.1878; found 204.1873. 
6.2.4.3 Synthesis of (S,S)-c-Hex-nbd* (3.57). 
3.45 3.57
c-Hex-MgCl, PdCl2(dppf).CH2Cl2 (2.3 mol %),
Et2O, kt, 1 h.
72 %
TfO
OTf
The reaction was performed on bis-triflate (S,S)-3.45 (101.0 mg, 257.6 µmol) using a 
c-HexMgCl (0.9 mL, 177 µmol, 2 M in Et2O) solution. After 1 h the reaction was 
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quenched with H2O and extracted with pentane. The combined organic phase were 
dried on MgSO4 and concentrated in vacuo. Purification by flash chromatography 
over silicagel (pentane) resulted in pure (S,S)-c-Hex-nbd* (3.57) as a colourless oil, 
51.0 mg (77 %). 
Formula: C19H28 (256.43 g/mol).  
Rf (isooctane): 0.55 
1H-NMR (500 MHz, CDCl3):  0.95-1.04 (m, 2H), 1.05-1.20 (m, 4H), 1.22-1.32 (m, 
4H), 1.62-1.79 (m,  10H), 1.84 (t, J= 1.6 Hz, 2H), 2.08 (m, 2H), 3.26 (dt, J= 3.9, 1.6 
Hz, 2H), 6.02 (td, J= 1.6, 3.9 Hz, 2H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  26.2 (CH2), 26.5 (CH2), 31.1 (CH2), 31.2 (CH2), 39.8 
(CH), 51.7 (CH), 71.1 (CH2), 130.7 (CH), 164.1 (C) ppm. 
IR (KBr, thin film): 3059, 2960, 2923, 2850, 1448, 1276, 1184, 890, 806, 788 cm-1. 
EI-MS m/z (rel. intensity %): 256 (M+, 43), 189 (15), 173 (33), 148 (51), 131 (21), 
117 (24), 105 (34), 91 (58), 79 (38), 55 (69), 41 (100). 
APCI-MS: 257 [M+H]+.
Optical rotation: [α]20
D
= - 58 (c 0.96, CHCl3). 
HRMS (EI): calcd for C19H28: 256.2191; found 256.2190. 
6.2.4.4 Synthesis of (S,S)-Allyl-nbd* (3.58). 
3.45 3.58
AllylMgCl, PdCl2(dppf).CH2Cl2 (2.3 mol %),
Et2O, kt, 30 min.
41 %
TfO
OTf
The reaction was performed on bis-triflate (S,S)-3.45 (508.5 mg; 1.31 mmol) using an 
allylMgBr solution (8.85 mL, 8.99 mmol, 1 M in Et2O) . After 30 min the reaction was 
quenched with H2O and extracted with pentane. The combined organic phases were 
dried over MgSO4 and carefully concentrated in vacuo. Purification by flash 
chromatography over silicagel (pentane) resulted in pure (S,S)-allyl-nbd* (3.58) as a 
colourless oil, 92.5 mg (41 %).
Formula: C13H16 (172.27 g/mol).  
Rf (isooctane): 0.55 
1H-NMR (500 MHz, CDCl3):  1.97 (t, J= 1.6 Hz, 2H), 2.93 (m, 4H), 3.22 (dt, J= 4.0, 
1.6 Hz, 2H), 5.01 (ddt, J= 10.0, 1.2, 1.2 Hz, 2H), 5.04 (ddd, J= 17.0, 1.6, 3.4 Hz, 2H), 
5.79 (tdd, J= 3.5, 10.0, 17.0 Hz, 2H), 6.18 (td, J= 1.7, 4.0 Hz, 2H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  36.0 (CH2), 53.3 (CH), 71.8 (CH2), 115.7 (CH2), 133.5 
(CH), 135.7 (CH), 157.0 (C) ppm. 
IR (KBr, thin film): 3076, 2972, 2932, 2866, 1640, 1607, 1427, 1301, 1263, 1185, 
993, 912, 786 cm-1. 
EI-MS m/z (rel. intensity %): 172 (M+, 5), 131 (45), 115 (28), 106 (18), 91 (100), 78 
(62), 65 (18), 51 (18), 41 (18). 
APCI-MS: 173 [M+H]+.
Optical rotation: [α]20
D
= - 151.1 (c 1.06, CHCl3). 
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HRMS (EI): calcd for C13H16: 172.1252; found 172.1259. 
6.2.5 Synthesis of [RhCl ((S,S)-allyl-nbd*)]2 (3.62) 
[RhCl(C2H4)2]2, CHCl3
91 %
Rh
Cl
23.62
3.58
(S,S)-Allyl-nbd* (3.58) (16.9 mg, 98.1 mol) and [RhCl(C2H4)2]2 (17.9 mg, 92.0 mol 
Rh) were dissolved in CHCl3 (5 mL) and stirred for 3 h under argon. Purification by 
flash chromatography over silicagel (hexane/CH2Cl2, 60:40) resulted in pure 
[RhCl((S,S)-allyl-nbd*)]2 (3.62) as a yellowish oil, 25.9 mg (91 %).
Formula: C26H32Cl2Rh2 (621.25 g/mol).  
Rf (hexane/CH2Cl2 60:40): 0.48 
1H-NMR (300 MHz, CDCl3):  1.18 (s, 4H), 2.45 (dd, J= 6.9, 14.6 Hz, 4H), 2.94 (dd, 
J= 7.0, 14.6 Hz, 4H), 3.57 (m, 4H), 3.60 (m, 4H), 5.17 (dd, J= 1.0, 10.0 Hz, 4H), 5.27 
(dd, J= 1.2, 17.0 Hz, 4H), 6.37 (tdd, J= 3.2, 10.0, 17.0 Hz, 4H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  38.5 (CH2), 47.4 (d, JC-Rh= 10.6 Hz, CH), 53.1 (d, JC-
Rh= 3.0 Hz, CH), 59.5 (d, JC-Rh= 7.5 Hz, CH2), 69.4 (d, JC-Rh= 11.3 Hz, C), 116.6 
(CH2), 135.4 (CH) ppm. 
IR (KBr, thin film): 3071, 2988, 2911, 1634, 1422, 1307, 1234, 1170, 991, 913 cm-1. 
EI-MS m/z (rel. intensity %): 620 (M+, 44), 584 (9), 548 (26), 412 (100), 372 (41), 
346 (12), 308 (9), 273 (56), 218 (41), 205 (33), 168 (15), 115 (20), 103 (24), 77 (20), 
49 (22). 
ES-MS: 584.9 ([RhOH((S,S)-allyl-nbd*)]2 + H
+), 275 (Rh+(S,S)-allyl-nbd*).
Optical rotation: [α]20
D
= + 3.4 (c 0.90, CHCl3). 
HRMS (EI): calcd for C26H32Cl2Rh2: 619.9991; found 620.0003. 
6.2.6 Synthesis of trisylhydrazon (3.63) 
trisylhydrazide, THF
70 %
N
N
O
O
H
N S
O
O
H
NS
O
O
3.7 3.63
Diketone 3.72 (100 mg, 0.806 mmol) and trisylhydrazide (481 mg, 1.612 mmol) are 
dissolved in 5 mL dry THF and stirred for 24 h at room temperature. Evaporation of 
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the reaction mixture and purification via flash chromatography over silicagel 
(hexane/EtOAc, 80:20 + 1% Et3N) resulted in pure trisylhydrazon (3.63) as a white 
powder, 384.0 mg (70 %). 
Formula: C37H56N4O4S2 (684.99 g/mol).  
Rf (hex/EtOAc 80:20): 0.24 
1H-NMR (300 MHz, CDCl3):  1.29-1.33 (d, J= 6.8 Hz, 18H), 1.33-1.36 (d, J= 6.8 Hz, 
18H), 1.77 (s, 2H), 2.07-2.13 (d, J= 16.7 Hz, 2H), 2.30-2.40 (dd, J= 3.0, 16.7 Hz, 2H), 
3.0 (septet, J= 6.8 Hz, 2H), 3.2 (d, J = 3.0 Hz, 2H), 4.26 (septet, J= 6.8 Hz, 4H), 7.13 
(br s, 2H), 7.26 (s, 2H), 7.36 (s, 2H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  23.6 (CH3), 24.7 (CH3), 24.8 (CH3), 29.9 (CH), 32.6 
(CH2), 34.2 (CH), 39.1 (CH2), 43.9 (CH), 123.9 (CH), 131.1 (C), 151.3 (C), 153.4 (C), 
161.8 (C) ppm. 
IR (KBr, thin film): 3204, 2959, 2869, 1599, 1563, 1462, 1426, 1383, 1363, 1326, 
1164, 1153, 1103, 1030, 995, 940, 904, 722, 660, 563 cm-1. 
APCI-MS: 685.3 [M+H]+. 
Optical rotation: [α]20
D
= - 68.7 (c 1.0, CHCl3). 
Melting Point (°C) : decomposition.
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6.3 SYNTHESIS OF CHIRAL IMIDATE LIGANDS 
6.3.1 Synthesis of 1,3-dihydro-iminobenzofuran hydrochloride (4.18) 
1. NaBH4, EtOH, -78°C to 0°C in 35 min.
2. HCl in dry Et2O
92 %
CN
H
O
O
NH
HCl.
4.184.30
2-Cyanobenzaldehyde 4.30 (7.0 g, 53.4 mmol) was dissolved in absolute ethanol 
(420 mL) and cooled to -78°C. NaBH 4 (2.02 g, 53.4 mmol) was added and the 
reaction mixture was allowed to warm to 0°C in 30 m in. The reaction mixture was 
poured into H2O and extracted with CH2Cl2 (3 x 1000 mL). The organic phases were 
dried over Na2SO4 and concentrated in vacuo. The resulting orange oil was dissolved 
in dry CH2Cl2 (165 mL) and dry HCl in Et2O (65 mL) was added. The resulting 
suspension was filtrated and the white crystals were washed with dry THF. This 
resulted in 8.3 g (92 %) of imidate hydrochloride 4.18.  
Formula: C8H8ClNO (169.61 g/mol).  
Rf (CH2Cl2/MeOH, 90/10): 0.53 
1H-NMR (300 MHz, CD3OD):  5.99 (s, 2H), 7.76 (t, J= 7.8 Hz, 1H), 7.84 (d, J= 7.8 
Hz, 1H), 7.98 (t, J= 7.8 Hz, 1H), 8.33 (d, J= 7.8 Hz, 1H) ppm. 
13C-NMR (75.4 MHz, CD3OD): 81.0 (CH2), 123.9 (CH), 124.6 (C), 126.5 (CH), 131.1 
(CH), 138.1 (CH), 148.9 (C), 178.4 (C) ppm. 
IR (HATR): 3422, 3357, 3062, 3036, 2924, 2806, 2717, 2628, 1676, 1617, 1592, 
1560, 1486, 1446, 1330, 1318, 1222, 1080, 938, 794, 739 cm-1. 
EI-MS m/z (rel. intensity %): 133 ((M+-HCl), 50), 104 (100), 89 (15), 77 (44), 63 (14), 
51 (20),  43 (7). ES-MS: 134 [M-Cl-]+. 
Melting Point (°C) : decomposition. 
HRMS (EI): calcd for C8H7NO: 133.0528; found 133.0533. 
6.3.2 Synthesis of (1R, 2R)-N,N'-bis-(3H-isobenzofuran-1-ylidene)-
cyclohexane-1, 2-diamine (4.39). 
H2N NH2
N N
O OEt3N (13 equiv), CH2Cl2
85 %
O
NH
HCl.
4.18
(2.6 equiv)
+
4.39
4.33
A suspension of (1R, 2R)-(-)-diaminocyclohexane (4.33) (119 mg, 1.04 mmol) and 
imidate 4.18 (450 mg, 2.65 mmol) in dry CH2Cl2 (5 mL) was cooled in an ice bath. 
Et3N (1 mL, 13.6 mmol) was added and the resulting suspension was refluxed for 
24h. The reaction mixture was passed through a short pad of silicagel and eluted with 
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EtOAc. Evaporation in vacuo and purification by flash chromatography over silicagel 
(toluene/Et2O, 6/4, + 1% Et3N) resulted in 4.39 as a white solid, 308 mg (85 %).
Formula: C22H22N2O2 (346.42 g/mol).  
Rf (toluene/Et2O, 6/4, + 1% Et3N): 0.23 
1H-NMR (500 MHz, CDCl3):  1.47 (m, 2H) 1.60 (m, J= 1.9, 10.7 Hz, 2 H), 1.80 (m, 
J= 1.9 Hz, 2H), 1.92 (m, J= 3.9, 10.7 Hz, 2H), 3.98 (dd, J= 3.9, 4.7 Hz, 2H), 5.16 (d, 
J= 14.3 Hz, 2H), 5.23 (d, J= 14.3 Hz, 2H), 7.23 (td, J= 0.7, 7.5 Hz, 2 H), 7.3 (dt, J=
0.7, 7.5 Hz, 2H), 7.38 (dt, J= 0.9, 7.5 Hz, 2H), 7.76 (d, J= 7.5 Hz, 2H) ppm. 
13C-NMR (75.4 MHz, CDCl3): 24.9 (CH2), 32.5 (CH2), 61.0 (CH), 71.7 (CH2), 121.1 
(CH), 123.4 (CH), 128.0 (CH), 130.6 (CH), 130.9 (C), 143.1 (C), 158.9 (C) ppm. 
IR (HATR): 3040, 2927, 2873, 2854, 1689, 1614, 1468, 1448, 1360, 1288, 1227, 
1093, 1015, 951, 863, 775, 726, 702, 670 cm-1. 
EI-MS m/z (rel. intensity %): 346 (M+, 22), 213 (22), 186 (10), 160 (30), 146 (20), 
118 (70), 104 (46), 90 (100), 63 (15), 41 (12). 
ES-MS: 347 [M+H]+.
Melting Point (°C) : 146°C. 
Optical rotation: [α]20
D
= + 84.8 (c 1.12, CHCl3). 
HRMS (EI): calcd for C22H22N2O2: 346.1681; found 346.1680. 
6.3.3 Synthesis of (R)-(+)-N,N’-bis-(3H-isobenzofuran-1-ylidene)-1,1’-
binaphthyl-2,2’-diamine (4.40). 
Et3N (13 equiv), CH2Cl2
71 %
O
NH
HCl.
4.18
(2.6 equiv)
+
NH2
NH2
4.34
N
N
O
O
4.40
A suspension of (R)-(+)-1,1’-binaphthyl-2,2’-diamine (4.34) (99 mg, 0.35 mmol) and 
imidate 4.18 (179 mg, 1.06 mmol) in MeOH (5 mL) was cooled in an ice bath. Et3N 
(0.32 mL, 2.3 mmol) was added and the resulting suspension was refluxed for 5 
days. Evaporation in vacuo and purification by flash chromatography over silicagel 
(toluene/EtOAc, 7/3, + 1% Et3N) followed by a recrystallization in hexane/CH2Cl2
resulted in 4.40 as a white solid, 127.8 mg (71 %).
Formula: C36H24N2O2 (516.59 g/mol).  
Rf (toluene/EtOAc 7/3 + 1% Et3N): 0.50 
1H-NMR (300 MHz, CDCl3):  4.07 (d, J= 14.6 Hz, 2H), 4.84 (d, J= 14.6 Hz, 2H), 
7.10-7.56 (m, 16H), 7.85 (m, 4H) ppm. 
13C-NMR (75.4 MHz, CDCl3): 71.8 (CH2), 120.8 (CH), 122.9 (CH), 123.9 (CH), 124.6 
(CH), 125.6 (CH), 126.5 (C), 126.9 (CH), 127.5 (CH), 127.6 (CH), 128.4 (CH), 130.5 
(C), 130.7, 131.4 (CH), 133.8 (C), 143.2 (C), 144.3 (C), 158.3 (C) ppm. 
IR (HATR): 3050, 2357, 1687, 1614, 1589, 1502, 1466, 1361, 1291, 1262, 1206, 
1408, 1004, 942, 826, 770, 727 cm-1. 
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EI-MS m/z (rel. intensity %): 516 (M+, 16), 382 (29), 284 (12), 266 (18), 149 (32), 
118 (31), 90 (83), 45 (100). 
ES-MS: 517 [M+H]+.
Melting Point (°C) : 216-218°C. 
Optical rotation: [α]20
D
= + 596.6 (c 1.01, CHCl3). 
HRMS (EI): calcd for C36H24N2O2: 516.1838; found 516.1837.
6.3.4 Synthesis of (1S, 2S, 4S, 5S)-bis-(3H-isobenzofuran-1-ylidene)-
bicyclo[2.2.1]heptane-2,5-diamine  (4.41). 
H2N
NH2
N
N
O
O
Et3N (13 equiv), CH2Cl2
56 %
O
NH
HCl.
4.18
(2.6 equiv)
+
4.35 4.41
A suspension of (1S, 4S)-DIANANE (4.35)1 (410 mg, 3.26 mmol) and imidate 4.18 
(1.60 g, 9.46 mmol) in dry CH2Cl2 (30 mL) was cooled in an ice bath. Et3N (2.5 mL, 
18 mmol) was added and the resulting suspension was stirred for 16h at room 
temperature. Evaporation in vacuo and purification by flash chromatography over 
silicagel (toluene/Et2O, 6/4, 1% Et3N) resulted in a white solid. This contained 90% of 
3c and 10% of  endo-exo bisimidaat. Recrystallization in CH2Cl2/hexane afforded 
4.41 as a pure product, 654.3 mg (56 %). 
Formula: C23H22N2O2 (358.43 g/mol).  
Rf (toluene/Et2O, 6/4, + 1% Et3N): 0.24 
1H-NMR (500 MHz, CDCl3):  1.59 (s, 2H), 1.93 (m, 2H), 1.95 (m, 2H), 2.38 (s, 2H), 
4.18 (m, 2H), 5.29 (s, 4H), 7.31 (d, J= 7.6 Hz, 2H), 7.35 (t, J= 7.6 Hz, 2H), 7.44 (t, J=
7.6 Hz, 2H), 7.87 (d, J= 7.6 Hz, 2H) ppm. 
13C-NMR (75.4 MHz, CDCl3): 29.8 (CH2), 38.1 (CH2), 43.2 (CH), 58.2 (CH), 72.1 
(CH2), 121.1 (CH), 123.8 (CH), 128.5 (CH), 130.6 (C), 131.0 (CH), 143.0 (C), 160.0 
(C) ppm. 
IR (HATR): 3023, 2963, 2860, 2368, 2324, 1679, 1468, 1447, 1362, 1337, 1286, 
1062, 1042, 1002, 936, 850, 780, 723 cm-1. 
EI-MS m/z (rel. intensity %): 358 (M+, 9), 317 (9), 239 (9), 225 (24), 198 (24), 184 
(32), 159 (23), 134 (27), 118 (69), 90 (100). 
ES-MS: 359 [M+H]+.
Melting Point (°C) : 108°C. 
Optical rotation: [α]20
D
= - 54.6 (c 1.24, CHCl3). 
HRMS (EI): calcd for C23H22N2O2: 358.1681; found 358.1682. 
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6.3.5 Synthesis of (4S, 5S)-4,5-di[(3H-isobenzofuran-1-ylidene)aminomethyl]-
2,2-dimethyl-1,3-dioxolane  (4.42). 
Et3N (13 equiv), CH2Cl2
92 %
O
NH
HCl.
4.18
(2.6 equiv)
+
OO
N NO O
4.42
OO
NH2 NH2
4.36
A suspension of (4S, 5S)-4,5-di(aminomethyl)-2,2-dimethyl-1,3-dioxolane (4.36) 
(105.0 mg, 0.66 mmol) and imidate 4.18 (307 mg, 1.81 mmol) in CH2Cl2 was cooled 
in an ice bath. Et3N (0.48 mL, 3.4 mmol) was added and the reaction mixture was 
stirred for 16h at room temperature. Evaporation in vacuo and recrystrallization from 
EtOAc resulted in 4.42 as a white solid, 236.6 mg (92 %). 
Formula: C23H24N2O4 (392.45 g/mol).  
Rf (CH2Cl2/MeOH 9/1): 0.76  
1H-NMR (300 MHz, CDCl3):  1.49 (s, 6H), 3.81 (m, 4 H), 4.24 (t, J= 3.5 Hz, 2H), 
5.25 (s, 4 H), ), 7.31 (d, J= 7.5 Hz, 2 H), 7.37 (t, J= 7.5 Hz, 2H), 7.46 (dt, J= 1.0, 7.5 
Hz, 2H), 7.83 (d, J= 7.5 Hz, 2H) ppm. 
13C-NMR (75.4 MHz, CDCl3): 27.3 (CH3), 49.8 (CH2), 72.1 (CH2), 79.8 (CH), 109.1 
(C), 121.2 (CH), 123.7 (CH), 128.3 (CH), 130.4 (C), 131.1 (CH),  143.2 (C), 160.7 (C) 
ppm. 
IR (HATR): 2903, 1692, 1367, 1293, 1251, 1166, 1073, 998, 724, 664 cm-1. 
EI-MS m/z (rel. intensity %): 392 (M+, <1), 377 (2), 260 (5), 246 (17), 201 (29), 188 
(46), 160 (17), 146 (100), 118 (28), 91 (58). 
ES-MS: 393 [M+H]+.
Melting Point (°C) : 204°C. 
Optical rotation: [α]20
D
= - 47.0 (c 1.00, CHCl3). 
HRMS (EI): calcd for C23H24N2O4: 392.1736; found 392.1737. 
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6.3.6 Synthesis of (1R, 8R)-N,N’-Bis-(3H-isobenzofuran-1-ylidene)-1,2,3,6,7,8-
hexahydro-as-indacene-1,8-diamine (4.19). 
Et3N (13 equiv), CH2Cl2
93 %
O
NH
HCl.
4.18
(2.6 equiv)
+
4.19
4.17
N
N
O
O
NH3Cl
NH3Cl
(1R, 8R)-1,2,3,6,7,8-hexahydro-as-indacene-1,8-diamine hydrochloride (4.17)2 (10.9 
mg, 0.0417 mmol) and imidate 4.18 (20.3 mg, 0.1197 mmol) was suspended in dry 
CH2Cl2 (0.75 mL) and cooled in an ice bath. Et3N (32 µL, 0.230 mmol) was added 
and the resulting suspension was stirred for 24 h at room temperature. The reaction 
mixture was passed through a short pad of silicagel and eluted with EtOAc. 
Evaporation in vacuo and purification by flash chromatography over silicagel 
(cyclohexane/EtOAc, 2/1) resulted in 4.19 as a white solid, 16.3 mg (93 %). 
Formula: C28H24N2O2 (420.50 g/mol).  
Rf (hexane/EtOAc 2/1): 0.19  
1H-NMR (300 MHz, C6D6):  2.20 (dddd, J= 8.0, 8.5, 8.5, 12.1 Hz, 2H), 2.64 (dddd, 
J= 2.2, 8.0, 8.5, 12.1 Hz, 2H), 2.86 (ddd, J= 8.5, 8.5, 15.0 Hz, 2H), 3.01 (ddd, J= 2.2, 
8.5, 15.0 Hz, 2H), 3.44 (d, J= 14.2 Hz, 2H), 4.28 (d, J=14.2 Hz, 2H), 6.23 (t, J= 8.0 
Hz, 2H), 6.37-6.45 (m, 2H), 6.85-6.98 (m, 4H), 7.18 (s, 2H), 7.94-8.01 (m, 2H) ppm. 
13C-NMR (75.4 MHz, C6D6):  31.4 (CH2), 34.7 (CH2), 60.8 (CH), 71.0 (CH2), 120.7 
(CH), 123.5 (CH), 123.9 (CH), 127.8 (CH), 130.2 (CH), 131.9 (C), 142.2 (C), 143.5 
(C), 143.7 (C), 158.2 (C) ppm. 
IR (HATR): 2952, 2936, 2874, 2844, 1695, 1468, 1364, 1338, 1290, 1228, 1152, 
1078, 1025, 1016, 775, 726 cm-1. 
EI-MS m/z (rel. intensity %): 421 (M+, <1), 287 (100), 258 (11), 154 (20), 90 (21). 
ES-MS: 421 [M+H]+.
Melting Point (°C) : 184-186 °C. 
Optical rotation: [α]20
D
= - 157.3 (c 0.56, CHCl3). 
HRMS (EI): calcd for C28H24N2O2: 420.1838; found 420.1830. 
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6.3.7 Synthesis of (1R, 2R)- trans- 1-(3H-isobenzofuran-1-ylideneamino)-indan-
2-ol (4.43). 
Et3N (3 equiv), CH2Cl2
91 %
O
NH
HCl.
4.18
(1.3 equiv)
+
4.37
N
OH
O
4.43
NH2
OH
A suspension of (1R, 2R)-(-)-trans-1-amino-2-indanol (4.37) (100.0 mg, 0.67 mmol) 
and imidate 4.18 (125.0 mg, 0.74 mmol) in CH2Cl2 was cooled in an ice bath. Et3N 
(0.28 mL, 2.0 mmol) was added and the reaction mixture was stirred for 48h at room 
temperature. Evaporation in vacuo and recrystrallization from CH2Cl2 resulted in 4.43
as a white solid, 161 mg (91 %).
Formula: C17H15NO2 (265.31 g/mol).  
Rf (CH2Cl2/MeOH 9/1): 0.58  
1H-NMR (300 MHz, DMSO):  2.74 (dd, J= 7.0, 15.6 Hz, 1H), 3.18 (dd, J= 7.0, 15.6 
Hz, 1H), 4.33 (m, J= 5.6, 7.0 Hz, 1H), 5.12 (d, J= 5.6 Hz, 1H), 5.16 (d, J= 5.2 Hz, 
1H), 5.44 (d, J= 14.9 Hz, 1H), 5.50 (d, J= 14.9 Hz, 1H), 7.05-7.20 (m, 4H), 7.44-7.49 
(m, 1H), 7.56-7.63 (m, 2H), 7.70 (d, J= 7.6Hz, 1H) ppm. 
13C-NMR + HSQC (75.4 MHz, DMSO):  39.3 (CH2), 68.3 (CH), 72.1 (CH2), 79.5 
(CH), 122.2 (CH), 122.8 (CH), 124.3 (CH), 124.5 (CH), 126.4 (CH), 127.1 (CH), 
128.4 (CH), 129.7 (C), 131.5 (CH), 140.2 (C), 143.2 (C), 143.8 (C), 160.1 (C) ppm. 
IR (HATR): 3189, 1680, 1467, 1419, 1369, 1298, 1225, 1200, 1084, 1028, 998, 777, 
747, 730, 703, 675 cm-1. 
EI-MS m/z (rel. intensity %): 265 (M+, 20), 247 (4), 237 (17), 218 (5), 146 (15), 134 
(23), 118 (100), 104 (50), 90 (97), 63 (19), 49 (43). 
ES-MS: 266 [M+H]+.
Melting Point (°C) : 236 °C. 
Optical rotation: [α]20
D
= - 304.8 (c 0.81, DMSO). 
HRMS (EI): calcd for C17H15 NO2: 265.1103; found 265.1107. 
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6.3.8 Synthesis of (R)-indan-1-yl-(3H-isobenzofuran-1-ylidene)-amine (4.44). 
Et3N (3 equiv), CH2Cl2
91 %
O
NH
HCl.
4.18
(1.3 equiv)
+
4.38
N
O
4.44
NH2
A suspension of (R)-(-)-1-indanylamine (4.38) (100 mg, 0.75 mmol) and imidate 4.18
(178.0 mg, 1.05 mmol) in dry CH2Cl2 (5 mL) was cooled in an ice bath. Et3N (0.31 
mL, 2.25 mmol) was added and the resulting suspension was stirred for 24h at room 
temperature. Evaporation in vacuo and purification by flash chromatography over 
silicagel (toluene/Et2O, 6/4, + 1% Et3N) resulted in 4.44 as a white solid, 138 mg (74 
%). 
Formula: C17H15NO (249.31 g/mol).  
Rf (CH2Cl2/MeOH 9/1): 0.79  
1H-NMR (300 MHz, CDCl3)  2.09-2.21 (m, J= 7.5, 8.7, 12.5 Hz, 1H), 2.59-2.64 (m, 
J= 3.2, 7.5, 12.5 Hz, 1H), 2.93-3.04 (m, J= 15.7 Hz, 1H), 3.11-3.20 (ddd, J= 3.2, 8.8, 
15.7 Hz, 1H), 5.42 (s, 2H), 5.57 (dd, J= 7.5, 7.5 Hz, 1H), 7.20-7.45 (m, 5H), 7.48 (d, 
J= 7.5 Hz, 1H), 7.55 (t, J=7.5 Hz, 1H), 7.96 (d, J= 7.5 Hz, 1H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  30.8 (CH2), 34.6 (CH2), 61.2 (CH), 72.0 (CH2), 121.2 
(CH), 123.6 (CH), 124.2 (CH), 124.4 (CH), 126.2 (CH), 126.8 (CH), 128.3 (CH), 
130.5 (C), 131.1 (CH), 143.1 (C), 143.4 (C), 145.8 (C), 160.1 (C) ppm. 
IR (HATR): 3018, 2957, 2931, 2859, 1689, 1470, 1456, 1361, 1331, 1289, 1073, 
1024, 1015, 1002, 781, 776, 766, 740, 726, 700, 670 cm-1. 
EI-MS m/z (rel. intensity %): 249 (M+, 20), 234 (11), 220 (13), 134 (100), 118 (64), 
90 (80), 76 (16), 63 (27), 51 (21). 
ES-MS: 250 [M+H]+.
Melting Point (°C) : 79-80 °C. 
Optical rotation: [α]20
D
= + 123.5 (c 0.78, CHCl3). 
HRMS (EI): calcd for C17H15NO: 249.1154; found 249.1154. 
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6.3.9 Synthesis of Cu(4.39)2PF6. 
Cu(MeCN)4PF6, CH3CN
100 %
N
O
N N
O O
N
O
Cu
P
F
F F
F
F
F
Cu(4.39)2PF6
N N
O O
4.39
N,N'-Bis-(3H-isobenzofuran-1-ylidene)-cyclohexane-(1R, 2R)-diamine (4.39) (31.0 
mg, 89.5 mol) and Cu(MeCN)4PF6 (29.4 mg, 78.9 mol) were dissolved in 
acetonitrile (2 mL). The resulting yellow suspension was filtrated and evaporated in 
vacuo. The resulting yellow solids were recrystallized from benzene. This resulted in 
pure Cu(3a)2PF6 as a yellow solid, 40.3 mg (quantitative yield). 
Formula: C44H44CuF6N4O4P (901.35 g/mol).  
1H-NMR (300 MHz, CD3CN):  1.20 (m, 8H), 1.68 (m, 4H), 2.31 (d, J= 10.4 Hz, 4H), 
3.20 (br s, 4H), 4.83 (d, J= 15.4 Hz, 4H), 5.23 (d, J= 15.4 Hz, 4H), 7.42 (m, 8H), 7.58 
(t, J= 7.5 Hz, 4H), 8.27 (d, J= 7.5 Hz, 4H) ppm. 
13C-NMR (75.4 MHz, CD3CN):  26.0 (CH2), 31.7 (CH2), 64.0 (CH), 75.2 (CH2), 122.8 
(CH), 125.4 (CH), 129.3 (CH), 130.0 (C), 133.5 (CH), 144.8(C), 167.0 (C) ppm. 
IR (HATR): 2937, 2861, 1644, 1470, 1452, 1364, 1298, 1102, 1095, 1040, 1020, 
998, 953, 832, 776, 726, 673 cm-1. 
ES-MS: 755 [Cu(3a)2]
+, 450 [Cu(3a) CH3CN]
+, 409 [Cu(3a)]+, 347 [3a +H]+.
Melting Point (°C) : decomposition. 
Optical rotation: [α]20
D
= - 387.3 (c 0.79, CH3CN). 
6.3.10 Synthesis of 2-bromo-6-methylbenzonitrile (4.45c) 
t-butylnitrite (1.5 equiv) , CuBr2 (1.17 equiv),
acetonitrile, T= Treflux, 1h
46% yield for 4.45c
41% yield for 4.45d
NH2
CN
4.50
Br
CN
4.45c
Br
CN
4.45d
Br
+
2-amino-6-methylbenzonitrile 4.50 (10.18 g, 77.0 mmol) was added slowly over 5 min 
to a suspension of t-butyl nitrite (13.5 mL, 114.0 mmol) and anhydrous copper (II) 
bromide (20.28 g, 90 mmol) in 300 mL anhydrous acetonitrile. The resulting 
suspension was heated at 65°C. After 1h the black r eaction mixture was cooled to 
room temperature, poured out into 800 mL 1N HCl solution and extracted with 
CH2Cl2 (3x 800 mL). The combined organic phases were dried over MgSO4 and 
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concentrated in vacuo. The resulting brown solids were purified by flash 
chromatography over silicagel (hexane/EtOAc, 97/3) resulting in pure 4.45c (6.84 g, 
46%). Formation of 2,5-dibromo-6-methylbenzonitrile 4.45d (8.58 g, 41%) was also 
observed. 
For 4.45c: 
Formula: C8H6BrN (196.04 g/mol). 
Rf (hexane/EtOAc 9/1): 0.27 
1H-NMR (300 MHz, CDCl3):  2.57 (s, 3H), 7.25 (d, J= 7.7Hz, 1H), 7.31 (t, J= 7.7Hz, 
1H), 7.48 (d, J= 7.7Hz, 1H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  21.2 (CH3), 116.2 (C), 116.4 (C), 125.5 (C), 128.8 
(CH), 130.3 (CH), 133.2 (CH), 144.7 (C) ppm. 
IR (HATR): 3074, 2924, 2228, 1590, 1556, 1491, 1452, 1381, 1272, 1202, 1175, 
1137, 1035, 998, 924, 843, 783, 719 cm-1. 
EI-MS m/z (rel. intensity %): 197 (M+, 36), 195 (M+, 39), 116 (87), 89 (45), 75 (12), 
63 (31), 49 (100). 
Melting Point (°C) : 91 °C. 
HRMS (EI): calcd for C8H6
79BrN: 194.9684; found 194.9691. 
For 4.45d: 
Formula: C8H5Br2N (274.94 g/mol). 
Rf (hexane/EtOAc 9/1): 0.38 
1H-NMR (300 MHz, CDCl3):  2.67 (s, 3H), 7.36 (d, J= 8.7Hz, 1H), 7.59 (d, J= 8.7Hz, 
1H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  22.5 (CH3), 115.9 (C), 117.6 (C), 124.1 (C), 124.5 
(C), 131.4 (CH), 137.2 (CH), 144.0 (C) ppm. 
IR (HATR): 3098, 3065, 2953, 2923, 2853, 2226, 1567, 1431, 1389, 1379, 1264, 
1210, 1196, 1136, 1006, 852, 814 cm-1. 
EI-MS m/z (rel. intensity %): 275 (M+, 31), 194 (25), 114 (32), 84 (45), 49 (100). 
Melting Point (°C) : 119 °C. 
HRMS (EI): calcd for C8H5
79Br2N: 272.8789; found 272.8792. 
6.3.11  A typical procedure for the preparation of the substituted 2-
(bromomethyl)benzonitriles (4.46) 
6.3.11.1 Synthesis of 2-chloro-6-(bromomethyl)benzonitrile (4.46a) 
NBS (1.1 equiv), 
benzoylperoxide (3 mol%), CCl4
82 %
Cl
CN
4.45a
Cl
CN
Br
4.46a
A solution of 2-chloro-6-methylbenzonitrile 4.45a (4.83 g, 31.9 mmol), NBS (6.24 g, 
35.1 mmol) and benzoylperoxide (232.0 mg, 0.96 mmol) in CCl4 (100 mL) was 
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refluxed for 7 h. Afterwards, the solids are filtered off and the filtrate was 
concentrated in vacuo. The crude product was purified by flash chromatography over 
silicagel (pentane/ Et2O, 90/10) resulting in pure 4.46a, 4.35 g (82%). No formation of 
the dibromo product 4.47a was observed. 
Formula: C8H5BrClN (230.49 g/mol).  
Rf (pentane/Et2O 9/1): 0.18  
1H-NMR (300 MHz, CDCl3):  4.60 (s, 2H), 7.43-7.54 (m, 3H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  28.9 (CH2), 113.4 (C), 113.9 (C), 128.5 (CH), 129.7 
(CH), 133.7 (CH), 137.7 (C), 143.4 (C) ppm. 
IR (HATR): 3070, 3025, 2227, 1588, 1567, 1455, 1443, 1264, 1219, 1203, 1180, 
1155, 1117, 988, 905, 796, 780, 737, 628, 609 cm-1. 
EI-MS m/z (rel. intensity %): 231 (M+, 10), 229 (M+, 8), 152 (33), 150 (100), 123 
(27), 114 (22), 81 (18), 79 (18), 63 (21), 50 (14).
Melting Point (°C) : 83 °C. 
HRMS (EI): calcd for C8H5N
35Cl79Br: 228.9294; found 228.9307. 
6.3.11.2 2-(bromomethyl)-4-chlorobenzonitrile (4.46b) 
NBS (1.1 equiv), 
benzoylperoxide (3 mol%), CCl4
57 %
CN
4.45b
CN
Br
4.46b
Cl Cl
The reaction was performed on 4-chloro-2-methylbenzonitrile 4.45b (2.0 g, 13.2 
mmol) according to the typical procedure. The crude product was purified by flash 
chromatography over silicagel (pentane/Et2O, 96/4) resulting in pure 4.46b, 1.74 g 
(57%). Formation of the dibromo product 4.47b was also observed, 0.97 g (24%). 
Formula: C8H5BrClN (230.49 g/mol).  
Rf (pentane/Et2O 9/1): 0.29  
1H-NMR (300 MHz, CDCl3):  4.57 (s, 2H), 7.39 (dd, J= 2.0, 8.3Hz, 1H), 7.55 (d, J= 
2.0Hz, 1H), 7.59 (d, J= 8.3Hz, 1H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  28.2 (CH2), 110.8 (C), 116.0 (C), 129.4 (CH), 130.8 
(CH), 134.2 (CH), 139.7 (C), 142.8 (C) ppm. 
IR (HATR): 3080, 3035, 2224, 1592, 1564, 1480, 1438, 1404, 1284, 1230, 1222, 
1180, 1105, 1080, 900, 882, 827, 742, 726, 630, 618 cm-1. 
EI-MS m/z (rel. intensity %): 233 (M+, 25), 231 (M+, 100), 229 (M+, 77), 203 (9), 152 
(6), 150 (18), 114 (66), 87 (31), 63 (35). 
Melting Point (°C) : 78 °C. 
HRMS (EI): calcd for C8H5N
35Cl79Br: 228.9294; found 228.9287. 
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6.3.11.3 2-(bromomethyl)-3,6-dibromobenzonitrile (4.46d) 
NBS (3.0 equiv), 
benzoylperoxide (3 mol%), CCl4
35 %
CN
4.45b
CN
Br
Br
Br Br
Br
4.46d
A solution of 2,5-dibromo-6-methylbenzonitrile 4.45d (7.00 g, 25.5 mmol), NBS 
(13.62 g, 76.5 mmol) and benzoylperoxide (204.0 mg, 0.84 mmol) in CCl4 (71 mL) 
was refluxed for 16 h. Afterwards, the solids are filtered off and the filtrate was 
concentrated in vacuo. The crude product was purified by flash chromatography over 
silicagel (hexane/ Et2O, 95/5) resulting in pure 4.46d, 3.12 g (35%). Only a marginal 
formation of the dibromo product 4.47d was observed. 
Formula: C8H4Br3N (353.84 g/mol).  
Rf (hexane/EtOAc 95/5): 0.19  
1H-NMR (300 MHz, CDCl3):  4.76 (s, 2H), 7.48 (d, J= 8.6Hz, 1H), 7.65 (d, J= 8.6Hz, 
1H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  29.8 (CH2), 114.7 (C), 117.7 (C), 124.0 (C), 125.4 
(C), 133.9 (CH), 138.2 (CH), 142.6 (C) ppm. 
IR (HATR): 3055, 3040, 2922, 2852, 2233, 1559, 1434, 1393, 1277, 1225, 1198, 
1156, 1148, 1122, 1101, 896, 827, 806, 798, 753, 740 cm-1. 
EI-MS m/z (rel. intensity %): 353 (8), 274 (100), 195 (29), 193 (29), 114 (83), 88 
(50), 63 (44), 49 (82). 
Melting Point (°C) : 163-165°C. 
6.3.12  A typical procedure for the preparation of the substituted 2-
(dibromomethyl)benzonitriles (4.47) 
2-(dibromomethyl)benzonitriles (4.47) were synthesized according to a literature 
procedure.3
6.3.12.1 Synthesis of 2-chloro-6-(dibromomethyl)benzonitrile (4.47a). 
NBS (3.0 equiv), 
benzoylperoxide (3 mol%), CCl4
94 %
Cl
CN
4.45a
Cl
CN
Br
4.47a Br
A solution of 2-chloro-6-methylbenzonitrile 4.45a (9.91 g, 65.4 mmol), NBS (35.22 g, 
197.9 mmol) and benzoylperoxide (534.0 mg, 2.2 mmol) in CCl4 (100 mL) was 
refluxed overnight. Afterwards, the solids are filtered off and the filtrate was 
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concentrated in vacuo. The crude product was purified by flash chromatography over 
silicagel (hexane/ EtOAc, 95/5) resulting in pure 4.47a, 19.04 g (94%). 
Formula: C8H4Br2ClN (309.39 g/mol).  
Rf (hexane/EtOAc 95/5): 0.20  
1H-NMR (300 MHz, CDCl3):  6.96 (s, 1H), 7.49 (dd, J= 0.8, 8.1Hz, 1H), 7.62 (t, J= 
8.1 Hz, 1H), 7.94 (dd, J= 0.8, 8.1Hz, 1H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  35.0 (CH), 109.5 (C), 113.1 (C), 128.0 (CH), 130.6 
(CH), 134.1 (CH), 136.9 (C), 146.3 (C) ppm. 
IR (HATR): 3076, 3008, 2232, 1589, 1567, 1454, 1439, 1292, 1251, 1238, 1174, 
1140, 1134, 891, 796, 779, 735, 651, 633 cm-1. 
EI-MS m/z (rel. intensity %): 309 (M+, 2), 232 (25), 230 (100), 228 (74), 149 (14), 
114 (39), 87 (17), 74 (9), 63 (16), 50 (13). 
Melting Point (°C) : 120 °C. 
HRMS (EI): calcd for C8H4N
35Cl79Br2: 306.8399; found 306.8386. 
6.3.12.2 Synthesis of 2-(dibromomethyl)-4-chlorobenzonitrile (4.47b). 
NBS (3.0 equiv), 
benzoylperoxide (3 mol%), CCl4
96 %
CN
4.45a
CN
Br
4.47b Br
Cl Cl
The reaction was performed on 4-chloro-2-methylbenzonitrile 4.45a (9.80 g, 64.6 
mmol) according to the typical procedure. The crude product was purified by flash 
chromatography over silicagel (hexane/ EtOAc, 95/5) resulting in pure 4.47b, 19.55 g 
(96%). 
Formula: C8H4Br2ClN (309.39 g/mol).  
Rf (hexane/EtOAc 95/5): 0.24  
1H-NMR (300 MHz, CDCl3):  6.92 (s, 1H), 7.41 (dd, J= 2.0, 8.4Hz, 1H), 7.55 (d, J= 
8.4Hz, 1H), 8.00 (d, J= 2.0, 1H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  34.3 (CH), 106.9 (C), 115.2 (C), 130.4 (CH), 130.6 
(CH), 133.5 (CH), 140.5 (C), 145.9 (C) ppm. 
IR (HATR): 3080, 3058, 3028, 3004, 2359, 2227, 1589, 1556, 1481, 1462, 1404, 
1304, 1279, 1206, 1170, 1138, 1114, 1081, 902, 820, 742, 689, 649, 622 cm-1. 
EI-MS m/z (rel. intensity %): 309 (M+, 2), 232 (25), 230 (100), 228 (73), 149 (16), 
114 (47), 87 (20), 74 (10), 63 (20), 50 (15). 
Melting Point (°C) : 120 °C. 
HRMS (EI): calcd for C8H4N
35Cl79Br2: 306.8399; found 306.8386. 
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6.3.12.3 Synthesis of 2-bromo-6-(dibromomethyl)benzonitrile (4.47c). 
NBS (3.0 equiv), 
benzoylperoxide (3 mol%), CCl4
46 % for 4.47c
44 % for 4.46c
Br
CN
4.45c
Br
CN
Br
4.47c Br
Br
CN
Br
4.46c
+
The reaction was performed on 2-bromo-6-methylbenzonitrile 4.45c (1.0 g, 5.1 mmol) 
according to the typical procedure. The crude product was purified by flash 
chromatography over silicagel (hexane/ EtOAc, 95/5) resulting in pure 4.47c, 825.0 
mg (46%). Formation of the monobrominated product 4.46c was also observed, 
616.7 mg (44%). 
For 4.47c: 
Formula: C8H4Br3N (353.84 g/mol). 
Rf (hexane/EtOAc 95/5): 0.24 
1H-NMR (300 MHz, CDCl3):  6.98 (s, 1H), 7.54 (J= 7.9Hz, 1H), 7.66 (d, J= 7.9 Hz, 
1H), 7.99 (d, J= 7.9Hz, 1H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  35.2 (CH), 111.8 (C), 114.3 (C), 125.3 (C), 128.6 
(CH), 133.9 (CH), 134.3 (CH), 146.7 (C) ppm. 
IR (HATR): 3072, 3010, 2228, 1586, 1557, 1449, 1434, 1319, 1289, 1244, 1233, 
1198, 1174, 1144, 1118, 868, 792, 732, 648 cm-1. 
EI-MS m/z (rel. intensity %): 355 (M+, <5), 353 (M+, <5), 274 (100), 114 (62), 88 
(25), 63 (25). 
Melting Point (°C) : 116 °C. 
HRMS (EI): calcd for C8H4
79Br3N: 350.7894; found 350.7886. 
For 4.46c: 
Formula: C8H5Br2N (274.94 g/mol). 
Rf (hexane/EtOAc 95/5): 0.12 
1H-NMR (300 MHz, CDCl3):  4.62 (s, 2H), 7.43 (t, J= 7.8Hz, 1H), 7.49 (d, J= 7.8 Hz, 
1H), 7.63 (d, J= 7.8Hz, 1H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  29.2 (CH2), 115.1 (C), 115.8 (C), 126.3 (C), 129.0 
(CH), 132.9 (CH), 133.8 (CH), 143.7 (C) ppm. 
IR (HATR): 3079, 3066, 3029, 2977, 2953, 2925, 2872, 2232, 1718, 1581, 1559, 
1446, 1438, 1312, 1285, 1260, 1222, 1201, 1177, 1150, 1110, 894, 857, 798, 767, 
739, 621 cm-1. 
EI-MS m/z (rel. intensity %): 275 (M+, 9), 196 (98), 194 (100), 115 (52), 88 (24), 79 
(15), 62 (22), 49 (18). 
Melting Point (°C) : 126 °C. 
HRMS (EI): calcd for C8H5
79Br2N: 272.8789; found 272.8778. 
Chapter 6. Experimental section 
159
6.3.13  A typical procedure for the preparation of the substituted 2-
formylbenzonitriles (4.48) 
2-formylbenzonitriles (4.48) were synthesized according to a literature procedure.3
6.3.13.1 Synthesis of 2-chloro-6-formylbenzonitrile (4.48a) 
AgNO3 (4.0 equiv), CH3CN, H2O
90 %
Cl
CN
4.47a
Cl
CN
H
4.48a OBr
Br
To a solution of 4.47a (18.0 g, 58.2 mmol) in CH3CN (60 mL) was added a solution of 
AgNO3 (39.5 g, 233 mmol) in H2O (32 mL). The resulting yellow suspension was 
refluxed during 20 min. The solids were filtered off and washed with CH2Cl2 (150 
mL). The combined filtrate was washed with H2O (25 mL), dried over Na2SO4 and 
concentrated in vacuo. The crude product was purified by flash chromatography over 
silicagel (hexane/EtOAc, 2/1) resulting in pure 4.48a, 8.67 g (90%). 
Formula: C8H4ClNO (165.58 g/mol).  
Rf (hexane/EtOAc 2/1): 0.36  
1H-NMR (300 MHz, CDCl3):  7.72 (t, J= 7.9Hz, 1H), 7.79 (dd, J= 1.2, 7.9Hz, 1H), 
7.94 (dd, J= 1.2, 7.9Hz, 1H), 10.31 (s, 1H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  112.9 (C), 114.4 (C), 127.5 (CH), 133.8 (CH), 134.9 
(CH), 138.5 (C), 139.0 (C), 187.6 (CH) ppm. 
IR (HATR): 3069, 2865, 2221, 1697, 1584, 1566, 1443, 1395, 1291, 1224, 1195, 
1182, 1155, 922, 798, 781, 726, 675 cm-1. 
EI-MS m/z (rel. intensity %): 167 (5); 165 (15), 139 (33), 137 (100), 110 (24), 101 
(44), 84 (13),  75 (79),  61 (23), 50 (45). 
Melting Point (°C) : 140 °C. 
HRMS (EI): calcd for C8H4NO
35Cl: 164.9981; found 164.9969. 
6.3.13.2 Synthesis of 2-formyl-4-chlorobenzonitrile (4.48b) 
AgNO3 (4.0 equiv), CH3CN, H2O
83 %
CN
4.47b
CN
H
4.48b OBr
Br
Cl Cl
The reaction was performed on 4.47b (18.07 g, 58.4 mmol) according to the typical 
procedure. The crude product was purified by flash chromatography over silicagel 
(hexane/EtOAc, 9/1) resulting in pure 4.48b, 8.04 g (83%). 
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Formula: C8H4ClNO (165.58 g/mol).  
Rf (pentane/EtOAc 85/15): 0.32  
1H-NMR (300 MHz, CDCl3):  7.71 (dd, J= 2.0, 8.3Hz, 1H), 7.77 (d, J= 8.3Hz, 1H), 
8.00 (d, J= 2.0Hz, 1H), 10.31 (s, 1H) ppm. 
13C-NMR (75.4 MHz, C6D6):  111.9 (C), 115.2 (C), 129.2 (CH), 133.3 (CH), 134.6 
(CH), 138.0 (C), 139.3 (C), 186.2 (CH) ppm. 
IR (HATR): 3101, 3069, 2871, 2226, 1698, 1584, 1558, 1485, 1376, 1294, 1203, 
1119, 1099, 897, 839, 744, 702, 620 cm-1. 
EI-MS m/z (rel. intensity %): 167 (10); 165 (29), 139 (33), 137 (100), 110 (26), 102 
(44), 100 (33), 75 (55), 61 (16), 50 (39). 
Melting Point (°C) : 119 °C. 
HRMS (EI): calcd for C8H4NO
35Cl: 164.9981; found 164.9988. 
6.3.13.3 Synthesis of 2-bromo-6-formylbenzonitrile (4.48c) 
AgNO3 (4.0 equiv), CH3CN, H2O
76 %
Br
CN
4.47c
Br
CN
H
4.48c OBr
Br
The reaction was performed on 4.47c (1.35 g, 3.8 mmol) according to the typical 
procedure. The crude product was purified by flash chromatography over silicagel 
(hexane/EtOAc, 8/2) resulting in pure 4.48c, 603.0 mg (76%). 
Formula: C8H4BrNO (210.03 g/mol).  
Rf (hexane/EtOAc 2/1): 0.33 
1H-NMR (300 MHz, CDCl3):  7.64 (t, J= 7.9Hz, 1H), 7.95 (d, J= 7.9Hz, 1H), 7.98 (d, 
J= 7.9 Hz, 1H), 10.29 (s, 1H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  114.1 (C), 116.9 (C), 127.6 (C), 127.9 (CH), 133.9 
(CH), 138.0 (CH), 187.7 (CH) ppm. 
IR (HATR): 3078, 2921, 2854, 1698, 1641, 1579, 1557, 1436, 1390, 1279, 1219, 
1176, 1134, 892, 847, 786, 722, 666 cm-1. 
EI-MS m/z (rel. intensity %): 211 (M+, 12), 209 (M+, 13), 183 (93), 181 (94), 102 
(100), 84 (11), 75 (93), 61 (12), 50 (53). 
Melting Point (°C) : 124 °C. 
HRMS (EI): calcd for C8H4
79BrNO: 208.9476; found 208.9474. 
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6.3.14 A typical procedure for the preparation of the substituted imidate esters. 
(4.49) 
6.3.14.1 Synthesis of 7-chloro-1,3-dihydro-iminoisobenzofuran hydrochloride 
(4.49a). 
1. NaBH4, EtOH, -78°C to 0°C in 35 min.
2. HCl in dry Et2O
94 %
CN
H
O
O
NH
HCl.
4.49a4.48a
Cl Cl
2-Cyanobenzaldehyde 4.48a (2 g, 12.1 mmol) was dissolved in absolute ethanol 
(120 mL) and cooled to -78°C. NaBH 4 (456.8 mg, 12.1 mmol) was added and the 
reaction mixture was allowed to warm to 0°C in 30 m in. The reaction mixture was 
poured into H2O and extracted with CH2Cl2 (3 x 500 mL). The organic phases were 
dried over Na2SO4 and concentrated in vacuo. The resulting white solid was 
dissolved in dry CH2Cl2 (40 mL) and dry HCl in Et2O (15 mL) was added. The 
resulting suspension was filtrated and the white crystals were washed with dry THF. 
This resulted in 2.3 g (94 %) of imidate hydrochloride 4.49a.  
Formula: C8H7Cl2NO (204.05 g/mol).  
Rf (CH2Cl2/MeOH 90/10): 0.64  
1H-NMR (300 MHz, DMSO-d6)  5.93 (s, 2H), 7.78 (d, J= 7.8Hz, 1H), 7.80 (d, J= 
7.8Hz, 1H), 7.94 (t, J= 7.8Hz, 1H) ppm. 
13C-NMR (75.4 MHz, DMSO-d6):  78.0 (CH2), 121.1 (C), 121.8 (CH), 130.3 (CH), 
130.5 (C), 137.9 (CH), 150.3 (C), 173.6 (C) ppm. 
IR (HATR): 3053, 2936, 2861, 2706, 2628, 2545, 2436, 1662, 1610, 1582, 1524, 
1474, 1430, 1408, 1322, 1306, 1228, 1196, 1156, 1132, 1060, 1042, 919, 857, 792, 
763, 727, 654 cm-1. 
EI-MS m/z (rel. intensity %): 169 (M+,11), 167 (M+, 33), 140 (33), 138 (100), 111 
(10), 102 (47), 89 (74), 75 (69), 63 (42), 50 (50), 43 (19). 
ES-MS: 168 [M-Cl-]+. 
Melting Point (°C) : decomposition. 
HRMS (EI): calcd for C8H6NO
35Cl: 167.0138; found 167.0153. 
Chapter 6. Experimental section 
162
6.3.14.2 Synthesis of 5-chloro-1,3-dihydro-iminoisobenzofuran hydrochloride 
(4.49b). 
1. NaBH4, EtOH, -78°C to 0°C in 35 min.
2. HCl in dry Et2O
96 %
CN
H
O
O
NH
HCl.
4.49b4.48b
Cl Cl
The reaction was performed on 2-formyl-5-chlorobenzonitrile (4.48b) (2.0 g, 12.1 
mmol) according to the typical procedure resulting in 2.38 g (96 %) of imidate ester 
hydrochloride (4.49b). 
Formula: C8H7Cl2NO (204.05 g/mol).  
Rf (CH2Cl2/MeOH 90/10): 0.61  
1H-NMR (300 MHz, CD3OD)  5.94 (s, 2H), 7.79 (dd, J= 0.9, 8.5Hz, 1H), 7.88 (d, J= 
0.9Hz, 1H), 8.20 (d, J= 8.5Hz, 1H) ppm. 
13C-NMR (75.4 MHz, CD3OD):  80.5 (CH2), 123.7 (C), 124.4 (CH), 127.8 (CH), 
131.8 (CH), 144.7 (C), 150.7 (C), 177.6 (C) ppm. 
IR (HATR): 2801, 1671, 1643, 1613, 1586, 1545, 1464, 1447, 1417, 1310, 1290, 
1212, 1173, 1119, 1082, 1067, 943, 894, 864, 855, 834, 790, 774, 752, 660 cm-1. 
EI-MS m/z (rel. intensity %): 169 (M+, 16), 167 (M+, 48), 140 (33),  138 (100), 132 
(20), 111 (20), 102 (44), 89 (21), 75 (60), 63 (36), 50 (86), 43 (21). 
ES-MS: 168 [M-Cl-]+. 
Melting Point (°C) : decomposition. 
HRMS (EI): calcd for C8H6NO
35Cl: 167.0138; found 167.0143. 
6.3.14.3 Synthesis of 7-bromo-1,3-dihydro-iminoisobenzofuran hydrochloride 
(4.49c). 
1. NaBH4, EtOH, -78°C to 0°C in 35 min.
2. HCl in dry Et2O
69 %
CN
H
O
O
NH
HCl.
4.49c4.48c
Br Br
The reaction was performed on 2-bromo-6-formylbenzonitrile (4.48c) (500.0 mg, 2.4 
mmol) according to the typical procedure resulting in 403.1 g (69 %) of imidate ester 
hydrochloride (4.49c). 
Formula: C8H7BrClNO (248,50 g/mol).  
Rf (CH2Cl2/MeOH 90/10): 0.73  
1H-NMR (300 MHz, DMSO-d6):  5.90 (s, 2H), 7.84-7.88 (m, 2H), 7.94-7.99 (m, 1H) 
ppm. 
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13C-NMR (75.4 MHz, DMSO-d6):  77.6 (CH2), 118.6 (C), 122.3 (CH), 122.6 (C), 
133.8 (CH), 137.8 (CH), 150.6 (C), 174.3 (C) ppm. 
IR (HATR): 3328, 3154, 2670, 1682, 1602, 1577, 1514, 1467, 1444, 1404, 1319, 
1295, 1226, 1191, 1150, 1124, 1058, 1046, 934, 895, 794, 745, 724, 660 cm-1. 
EI-MS m/z (rel. intensity %): 213 ([M-Cl]+, 71), 211 ([M-Cl]+, 66), 184 (98), 182 
(100), 157 (13), 132 (9), 102 (60), 89 (36), 75 (67), 63 (52), 51 (55). 
Melting Point (°C) : decomposition. 
HRMS (EI): calcd for C8H7
79Br35ClNO: 246.9400; found 246.9386. 
6.3.15  Synthesis of N,N'-bis-(7-chloro-3H-isobenzofuran-1-ylidene)-
cyclohexane-(1R, 2R)-diamine (4.52) 
H2N NH2
N N
O OEt3N (13 equiv), CH2Cl2
44 %
O
NH
HCl.
4.49a
(2.6 equiv)
+
4.52
4.33
Cl
Cl Cl
A suspension of (1R, 2R)-(-)-diaminocyclohexane 4.33 (71.5 mg, 0.63 mmol) and 
imidate 4.49a (325 mg, 1.59 mmol) in dry CH2Cl2 (3 mL) was cooled in an ice bath. 
Et3N (1.1 mL, 7.97 mmol) was added and the resulting suspension was refluxed for 
24h. The reaction mixture was passed through a short pad of silica gel and eluted 
with EtOAc. Evaporation in vacuo and purification by flash chromatography over 
silica gel (toluene/Et2O, 6/4, + 1% Et3N) resulted in (4.52) as a white solid, 114 mg 
(44 %).
Formula: C22H20Cl2N2O2 (415.31 g/mol).  
Rf (CH2Cl2/MeOH 90/10): 0.61  
1H-NMR (300 MHz, CDCl3)  1.47-1.71 (m, 4H), 1.79-1.85 (m, 2H), 1.98-2.02 (m, 
2H), 4.04 (dd, J= 3.7, 4.9 Hz, 2H), 5.21 (s, 4H), 7.15-7.17 (m, 2H), 7.29-7.30 (m, 4H) 
ppm. 
13C-NMR (75.4 MHz, CDCl3): 24.6 (CH2), 31.9 (CH2), 61.4 (CH), 70.4 (CH2), 119.6 
(CH), 127.3 (C), 129.9 (CH), 130.9 (C), 131.1 (C), 145.9 (C), 155.7 (C) ppm. 
IR (HATR): 2928, 2871, 2855, 1681, 1606, 1585, 1462, 1361, 1307, 1244, 1221, 
1176, 1145, 1092, 1021, 913, 772, 729, 661 cm-1. 
EI-MS m/z (rel. intensity %): 414 (M+, 15), 379 (13), 247 (15), 206 (13), 168 (51), 
152 (86), 126 (28), 124 (64), 89 (100). 
Melting Point (°C) : 62°C. 
Optical rotation: [α]20
D
= - 26.1 (c 0.95, CHCl3). 
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6.3.16 Synthesis of N,N'-bis-(5-chloro-3H-isobenzofuran-1-ylidene)-
cyclohexane-(1R, 2R)-diamine (4.53) 
H2N NH2
N N
O OEt3N (13 equiv), CH2Cl2
75 %
O
NH
HCl.
4.49b
(2.6 equiv)
+
4.53
4.33
Cl
Cl Cl
A suspension of (1R, 2R)-(-)-diaminocyclohexane 4.33 (70.0 mg, 0.61 mmol) and 
imidate 4.49b (325 mg, 1.59 mmol) in dry CH2Cl2 (3 mL) was cooled in an ice bath. 
Et3N (1.1 mL, 7.97 mmol) was added and the resulting suspension was refluxed for 
24h. The reaction mixture was passed through a short pad of silica gel and eluted 
with EtOAc. Evaporation in vacuo and purification by flash chromatography over 
silica gel (toluene/Et2O, 6/4, + 1% Et3N) resulted in (4.52) as a white solid, 190.8 mg 
(75 %). 
Formula: C22H20Cl2N2O2 (415.31 g/mol).  
Rf (hexane/EtOAc 2/1): 0.21  
1H-NMR (300 MHz, CDCl3)  1.40-1.47 (m, 2H), 1.50-1.61 (m, 2H), 1.77-1.80 (m, 
2H), 1.87-1.91 (m, 2H), 3.91 (dd, J= 3.7, 5.1Hz, 2H), 5.12 (d, J= 14.5Hz, 2H), 5.20 (d, 
J= 14.5Hz, 2H), 7.22-7.24 (m, 2H), 7.26-7.27 (m, 2H), 7.28-7.29 (m, 2H) ppm. 
13C-NMR (75.4 MHz, CDCl3): 24.8 (CH2), 32.3 (CH2), 61.1 (CH), 71.0 (CH2), 121.5 
(CH), 124.4 (CH), 128.6 (CH), 129.4 (C), 136.8 (C), 144.6 (C), 157.6 (C) ppm. 
IR (HATR): 2936, 2876, 1690, 1611, 1469, 1453, 1423, 1350, 1334, 1304, 1281, 
1260, 1220, 1190, 1158, 1088, 1058, 1026, 1007, 978, 886, 867, 838, 781, 740, 713, 
700, 671, 659 cm-1. 
EI-MS m/z (rel. intensity %): 414 (M+, 16), 247 (17), 234 (7), 206 (14), 194 (24), 168 
(36), 152 (74), 124 (62), 89 (100). 
Melting Point (°C) : 212°C. 
Optical rotation: [α]20
D
= + 60.1 (c 1.08, CHCl3). 
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6.3.17 Synthesis of (Rp)-1-[(1S)-(1-(3H-isobenzofuran-1-ylideneamino)-ethyl)]-2-
(diphenylphosphino) ferrocene (4.55a) 
Fe
PPh2 N O
Fe
PPh2 NH2
4.54 4.55a
+ O. HCl
NH
Et3N (3 equiv), CH2Cl2, Treflux
97 %
4.18
(1.3 equiv)
A suspension of (Rp)-1-[(1S)-(1-aminoethyl)]-2-(diphenylphosphino) ferrocene 4.54
(70.0 mg, 0.17 mmol) and imidate 4.18 (44 mg, 0.26 mmol) in dry CH2Cl2 (2 mL) was 
cooled in an ice bath. Et3N (80.0 L, 0.57 mmol) was added and the resulting 
suspension was refluxed for 48h. Evaporation in vacuo and purification by flash 
chromatography over silica gel (hexane/EtOAc, 7/3) resulted in 4.55a as a brownish 
oil, 87.0 mg (97 %). 
Formula: C32H28FeNOP (529.39 g/mol).  
Rf (hexane/EtOAc 70/30): 0.20  
1H-NMR (300 MHz, CDCl3)  1.62 (d, J= 6.6 Hz, 3H), 3.62-3.65 (m, 1H), 4.08 (s, 5H), 
4.26-4.28 (m, 1H), 4.65 (m, 1H), 4.83 (d, J= 14.2Hz, 1H), 5.10 (d, J= 14.2Hz, 1H), 
5.36-5.43 (m, 1H), 6.59-6.64 (m, 1H), 6.72-6.77 (m, 2H), 6.97-7.02 (m, 2H), 7.06-7.16 
(m, 2H), 7.27-7.33 (m, 5H), 7.45-7.51 (m, 2H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  20.7 (CH3), 49.6 (d, JCP= 8.8Hz, CH)), 68.7 (d, JCP= 
4.0Hz, CH), 68.8 (CH), 69.5 (5xCH), 71.3 (d, JCP= 4.5Hz, CH), 71.8 (CH2), 75.3 (d, 
JCP= 6.6Hz, C), 98.3 (d, JCP= 23.9Hz, C), 120.5 (CH), 123.6 (CH), 126.8 (CH), 127.0 
(d, JCP= 6.3Hz, CH), 127.4 (CH), 127.9 (d, JCP= 7.7Hz, CH), 128.8 (CH), 129.8 (C), 
130.4 (CH), 132.0 (d, JCP= 18.6Hz, CH), 135.2 (d, JCP= 20.9Hz, CH), 137.6 (d, JCP= 
8.6Hz, C), 139.2 (d, JCP= 9.4Hz, C), 142.8 (C), 158.0 (C) ppm. 
31P-NMR (121.4 MHz, CDCl3): - 22.5 ppm. 
IR (HATR): 3050, 2972, 2931, 2873, 1681, 1469, 1451, 1433, 1363, 1290, 1243, 
1167, 1106, 1081, 1044, 1017, 1000, 819, 747, 728, 697 cm-1. 
EI-MS m/z (rel. intensity %): 529 (M+, 8), 396 (19), 275 (8), 212 (9), 183 (17), 165 
(15), 133 (11), 121 (100), 77 (17), 56 (30). 
ES-MS: 530 [M+H]+.
Optical rotation: [α]20
D
= - 338.8 (c 0.64, CHCl3). 
HRMS (EI): calcd for C32H28FeNOP: 529.1258; found 529.1257.  
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6.3.18 Synthesis of (Rp)-1-[(1S)-(1-(7-chloro-3H-isobenzofuran-1-ylideneamino)-
ethyl)]-2-(diphenyl phosphino)ferrocene (4.55b) 
Fe
PPh2 N O
Fe
PPh2 NH2
4.54 4.55b
+ O . HCl
NH
Et3N (3 equiv), CH2Cl2, Treflux
61 %
4.49a
(1.3 equiv)
Cl
Cl
A suspension of (Rp)-1-[(1S)-(1-aminoethyl)]-2-(diphenylphosphino) ferrocene 4.54
(100.0 mg, 0.24 mmol) and imidate 4.49a (64.2 mg, 0.31 mmol) in dry CH2Cl2 (2.5 
mL) was cooled in an ice bath. Et3N (102.0 L, 0.73 mmol) was added and the 
resulting suspension was refluxed for 48h. Evaporation in vacuo and purification by 
flash chromatography over silica gel (hexane/EtOAc, 85/15) resulted in 4.55b as a 
brownish oil, 80.9 mg (61 %).
Formula: C32H27ClFeNOP (563.83 g/mol).  
Rf (hexane/EtOAc 80/20): 0.38 
1H-NMR (300 MHz, CDCl3)  1.64 (d, J= 6.6Hz, 3H), 3.62 (m, 1H), 4.08 (s, 5H), 4.27 
(m, 1H), 4.65 (m, 1H), 4.72 (d, J= 14.3Hz, 1H) 5.01 (d, J= 14.3Hz, 1H), 5.33-5.41 (m, 
1H), 6.54-6.59 (m, 1H), 6.75-6.80 (m, 2H), 6.93-7.02 (m, 3H), 7.14-7.21 (m, 2H), 
7.30-7.35 (m, 3H), 7.45-7.52 (m, 2H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  21.1 (CH3), 50.0 (d, JCP= 8.8Hz, CH), 68.8 (d, JCP= 
3.9Hz, CH), 68.9 (CH), 69.5 (5 x CH), 70.4 (CH2), 71.0 (d, JCP= 4.3Hz, CH), 75.1 (d, 
JCP= 6.1Hz, C), 99.0 (d, JCP= 24.2Hz, C), 118.9 (CH), 126.6 (CH), 126.7 (C), 127.0 
(d, JCP= 6.1Hz, CH), 127.9 (d, JCP= 7.7Hz, CH), 128.8 (CH), 129.5 (CH), 130.8 (CH), 
131.2 (C), 131.9 (d, JCP= 18.3Hz, CH), 135.3 (d, JCP= 21.0Hz, CH), 137.7 (d, JCP= 
8.8Hz, C), 139.2 (d, JCP= 9.9Hz, C), 145.6 (C), 154.5 (C) ppm. 
31P-NMR (121.4 MHz, CDCl3): - 22.0 ppm. 
IR (HATR): 3054, 2972, 2931, 1678, 1606, 1585, 1478, 1462, 1433, 1361, 1306, 
1265, 1244, 1220, 1167, 1106, 1078, 1040, 1026, 1000, 915, 818, 774, 738, 698, 
668 cm-1. 
EI-MS m/z (rel. intensity %): 563 (M+, 7), 396 (100), 331 (21), 288 (21), 252 (17), 
226 (6), 183 (20), 167 (32), 138 (60), 102 (31), 75 (24), 56 (52). 
ES-MS: 564 [M+H]+.
Optical rotation: [α]20
D
= - 367.6° ( c 0.70, CHCl3). 
HRMS (EI): calcd for C32H27NOP
35ClFe: 563.0868; found 563.0857.
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6.3.19 Synthesis of (Rp)-1-[(1S)-(1-(5-chloro-3H-isobenzofuran-1-ylideneamino)-
ethyl)]-2-(diphenyl phosphino)ferrocene (4.55c) 
Fe
PPh2 N O
Fe
PPh2 NH2
4.54 4.55c
+ O. HCl
NH
Et3N (3 equiv), CH2Cl2, Treflux
99 %
4.49b
(1.3 equiv)
Cl
Cl
A suspension of (Rp)-1-[(1S)-(1-aminoethyl)]-2-(diphenylphosphino) ferrocene 4.54
(200.0 mg, 0.48 mmol) and imidate 4.49b (128.4 mg, 0.63 mmol) in dry CH2Cl2 (2.5 
mL) was cooled in an ice bath. Et3N (102.0 L, 0.73 mmol) was added and the 
resulting suspension was refluxed for 48h. Evaporation in vacuo and purification by 
flash chromatography over silica gel (hexane/EtOAc, 85/15) resulted in 4.55c as a 
brownish oil, 266.2 mg (99 %).
Formula: C32H27ClFeNOP (563.83 g/mol).  
Rf (hexane/EtOAc 80/20): 0.22  
1H-NMR (300 MHz, CDCl3)  1.63 (d, J= 6.6Hz, 3H), 3.66 (m, 1H), 4.11 (s, 5H), 4.30 
(s, 1H), 4.67 (m, 1H), 4.83 (d, J= 14.4Hz, 1H) 5.09 (d, J= 14.4Hz, 1H), 5.37-5.44 (m, 
1H), 6.70-6.75 (m, 1H), 6.80-6.84 (m, 2H), 6.99-7.04 (m, 2H), 7.09-7.28 (m, 3H), 
7.34-7.35 (m, 3H), 7.47-7.53 (m, 2H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  20.5 (CH3), 49.8 (d, JCP= 8.8Hz, CH), 68.7 (d, JCP= 
4.0Hz, CH), 68.9 (CH), 69.5 (5 x CH), 71.1 (CH2), 71.4 (d, JCP= 4.4Hz, CH), 75.3 (d, 
JCP= 6.6Hz, C), 98.2 (d, JCP= 23.7Hz, C), 120.9 (CH), 124.7 (CH), 126.9 (CH), 127.1 
(d, JCP= 6.2Hz, CH), 127.9 (d, JCP= 7.7Hz, CH), 128.03 (CH), 128.7 (C), 128.8 (CH), 
132.0 (d, JCP= 18.6Hz, CH), 135.2 (d, JCP= 20.9Hz, CH), 136.5 (C), 137.5 (d, JCP= 
8.7Hz, C), 139.3 (d, JCP= 9.8Hz, C), 144.4 (C), 156.5 (C). 
31P-NMR (121.4 MHz, CDCl3): - 22.6 ppm. 
IR (HATR): 3067, 2969, 2931, 2871, 2358, 2341, 1689, 1613, 1473, 1456, 1432, 
1354, 1304, 1265, 1242, 1222, 1192, 1167, 1106, 1080, 1042, 1018, 879, 822, 742, 
697, 668 cm-1. 
EI-MS m/z (rel. intensity %): 563 (M+, 5), 396 (100), 331 (20), 288 (20), 252 (15), 
226 (6), 183 (18), 167 (39), 138 (68), 102 (27), 75 (24), 56 (45). 
ES-MS: 564 [M+H]+.
Optical rotation: [α]20
D
= - 338.1 (c 0.64, CHCl3). 
HRMS (EI): calcd for C32H27NOP
35ClFe: 563.0868; found 563.0888. 
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6.3.20 Synthesis of (Rp)-1-[(1S)-(1-(7-bromo-3H-isobenzofuran-1-ylideneamino)-
ethyl)]-2-(diphenyl phosphino)ferrocene (4.55d) 
Fe
PPh2 N O
Fe
PPh2 NH2
4.54 4.55d
+ O . HCl
NH
Et3N (3 equiv), CH2Cl2, Treflux
51 %
4.49c
(1.3 equiv)
Br
Br
A suspension of (Rp)-1-[(1S)-(1-aminoethyl)]-2-(diphenylphosphino) ferrocene 4.54
(98.0 mg, 0.24 mmol) and imidate 4.49c (77.0 mg, 0.31 mmol) in dry CH2Cl2 (2.5 mL) 
was cooled in an ice bath. Et3N (102.0 L, 0.73 mmol) was added and the resulting 
suspension was refluxed for 48h. Evaporation in vacuo and purification by flash 
chromatography over silica gel (hexane/EtOAc, 85/15) resulted in 4.55c as a 
brownish oil, 74.5 mg (51 %).
Formula: C32H27BrFeNOP (608.29 g/mol).  
Rf (hexane/EtOAc 70/30): 0.47 
1H-NMR (300 MHz, CDCl3)  1.64 (d, J= 6.6Hz, 3H), 3.61 (m, 1H), 4.09 (s, 5H), 4.27 
(m, 1H), 4.65-4.70 (m, 2H), 4.99 (d, J= 14.3Hz, 1H), 5.31-5.39 (m, 1H), 6.53-6.58 (m, 
1H), 6.75-6.81 (m, 2H), 6.97-7.02 (m, 3H), 7.08-7.13 (m, 1H), 7.31-7.51 (m, 6H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  21.3 (CH3), 49.8 (d, JCP= 8.7Hz, CH), 68.8 (d, JCP= 
4.0Hz, CH), 68.9 (CH), 69.5 (5 x CH), 70.1 (CH2), 71.0 (d, JCP= 4.4Hz, CH), 75.0 (d, 
JCP= 6.1Hz, C), 99.1 (d, JCP= 23.9Hz, C), 119.2 (C), 119.6 (CH), 126.5 (CH), 127.1 
(d, JCP= 6.2Hz, CH), 127.9 (d, JCP= 7.7Hz, CH), 128.2 (C), 128.9 (CH), 130.9 (CH), 
131.9 (d, JCP= 18.3Hz, CH), 132.9 (CH), 135.3 (d, JCP= 21.0Hz, CH), 137.8 (d, JCP= 
8.9Hz, C),  139.2 (d, JCP= 10.0Hz, C), 145.7 (C), 154.4 (C) ppm. 
31P-NMR (121.4 MHz, CDCl3): - 22.0 ppm. 
IR (HATR): 3052, 2971, 2930, 1680, 1580, 1478, 1458, 1433, 1361, 1321, 1303, 
1266, 1244, 1217, 1106, 1079, 1039, 1000, 892, 819, 774, 741, 696, 668 cm-1. 
EI-MS m/z (rel. intensity %): 607 (M+, 5), 396 (100), 331 (22), 319 (10), 288 (22), 
252 (18), 211 (20), 182 (34), 165 (27), 121 (57), 102 (27), 56 (55). 
ES-MS: 607.9 [M+H]+.
Optical rotation: [α]20
D
= - 322.2° ( c 0.99, CHCl3). 
HRMS (EI): calcd for C32H27NOP
79BrFe: 607.0363; found 607.0382.
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6.4 SYNTHESIS OF CHIRAL OXAZOLINE-ALCOHOL LIGANDS 
6.4.1 A typical procedure for the preparation of chiral oxazoline-alcohol 
ligands (4.60) 
6.4.1.1 Synthesis of 2-(2’-hydroxymethyl)phenyl-(3aS,8aR)-3a,8a-dihydro-8H-
indeno[1,2-d]oxazoline (4.60a) 
HO
O
N
4.60a
Et3N (3 equiv), CH2Cl2
100 %
O
NH
HCl.
4.18
(1.1 equiv)
+
4.58a
NH2
OH
A suspension of (1S, 2R)-(-)-cis-1-amino-2-indanol 4.58a (788.0 mg, 5.28 mmol) and 
imidate ester 4.18 (1.0 g, 5.90 mmol) in CH2Cl2 (40 mL) was cooled in an ice bath. 
Et3N (2.24 mL, 16.1 mmol) was added and the reaction mixture was stirred for 48h at 
room temperature. Evaporation in vacuo, purification by flash chromatography over 
silicagel (hexane/EtOAc, 2/1) and finally recrystrallization from hexane/CH2Cl2
resulted in 4.60a as a white solid, 1.40 g (quant.). 
Formula: C17H15NO2 (265.31 g/mol).  
Rf (hexane/EtOAc 2/1): 0.20 
1H-NMR (300 MHz, CDCl3)  3.42 (d, J=17.8Hz, 1H), 3.56 (dd, J= 6.6, 17.8Hz, 1H), 
4.61 (d, J= 5.0Hz, 1H), 4.64 (d, J= 5.0Hz, 1H), 5.52 (m, 1H), 5.83 (d, J= 7.8Hz, 1H), 
6.56 (m, 1H), 7.27-7.47 (m, 6H), 7.51-7.57 (m, 1H), 7.86-7.92 (m, 1H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  39.6 (CH2), 64.6 (CH2) 76.6 (CH), 83.0 (CH), 125.3 
(CH), 125.4 (CH), 126.5 (C), 127.6 (CH), 127.7 (CH), 128.7 (CH), 130.2 (CH), 130.5 
(CH), 131.6 (CH), 139.4 (C), 141.7 (C), 142.2 (C), 164.2 (C) ppm. 
IR (HATR): 3202, 2931, 1633, 1599, 1577, 1461, 1445, 1421, 1353, 1293, 1237, 
1205, 1169, 1137, 1061, 1018, 998, 968, 956, 858, 785, 778, 755, 709, 691 cm-1. 
EI-MS m/z (rel. intensity %): 265 (M+, 11), 133 (27), 116 (100), 115 (46), 89 (13), 77 
(36), 51 (12). 
ES-MS: 266 [M+H]+.
Optical rotation: [α]20
D
= - 178.5 (c 1.02, CHCl3). 
Melting Point (°C) : 162°C. 
HRMS (EI): calcd for C17H15NO2: 265.1103; found 265.1104.  
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6.4.1.2 Synthesis of (S)-2-(2’-hydroxymethyl)phenyl-4-tert-butyloxazoline 
(4.60b) 
HO
O
N
4.60b
Et3N (3 equiv), CH2Cl2
100 %
O
NH
HCl.
4.18
(1.1 equiv)
+
4.58b
H2N OH
The reaction was performed on (S)-tert-leucinol 4.58b (95.0 mg, 0.81 mmol) 
according to the typical procedure. The crude product was purified by flash 
chromatography over silicagel (CH2Cl2/MeOH, 98/2) resulting in pure 4.60b, 189.0 
mg (quant.). 
Formula: C14H19NO2 (233.31 g/mol).  
Rf (CH2Cl2/MeOH 98/2): 0.46 
1H-NMR (300 MHz, CDCl3)  0.97 (s, 9H), 4.15 (dd, J= 8.0, 10.1Hz, 1H), 4.25 (dd, J= 
8.0, 8.5Hz, 1H), 4.39 (dd, J= 8.5, 10.1Hz, 1H), 4.60 (d, J= 12.3Hz, 1H), 4.73 (d, J= 
12.3Hz, 1H), 6.82 (br s, 1H), 7.32-7.47 (m, 3H), 7.85 (m, 1H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  25.8 (CH3), 33.7 (C), 64.7 (CH2), 68.4 (CH2), 76.1 
(CH), 126.6 (C), 127.6 (CH), 130.0 (CH), 130.3 (CH), 131.4 (CH), 142.2 (C), 163.7 
(C) ppm. 
IR (HATR): 3236, 2960, 2905, 2868, 1638, 1573, 1478, 1449, 1396, 1364, 1342, 
1312, 1304, 1262, 1214, 1201, 1138, 1076, 1050, 1024, 971, 948, 785, 746, 700 cm-
1. 
EI-MS m/z (rel. intensity %): 233 (M+, 44), 204 (12), 176 (72), 158 (50), 146 (15), 
133 (100), 130 (20), 119 (32), 105 (58), 91 (36), 77 (62), 69 (26), 57 (41), 41 (80). 
ES-MS: 234 [M+H]+.
Optical rotation: [α]20
D
= - 26.6 (c 0.94, CHCl3). 
HRMS (EI): calcd for C14H19N2O2: 233.1416; found 233.1414.  
6.4.1.3 Synthesis of (S)-2-(2’-hydroxymethyl)phenyl-4-i-propyloxazoline 
(4.60c) 
HO
O
N
4.60c
Et3N (3 equiv), CH2Cl2
100 %
O
NH
HCl.
4.18
(1.1 equiv)
+
4.58c
H2N OH
The reaction was performed on (L)-valinol 4.48c (116.8 mg, 1.13 mmol) according to 
the typical procedure. The crude product was purified by flash chromatography over 
silicagel (hexane/EtOAc, 70/30) resulting in pure 4.60c, 248.0 mg (quant.). 
Formula: C13H17NO2 (219.28 g/mol).  
Rf (hexane/EtOAc 70/30): 0.26 
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1H-NMR (300 MHz, CDCl3)  0.96 (d, J= 6.7Hz, 3H), 1.03 (d, J= 6.7Hz, 3H), 1.83 
(sept, J= 6.7Hz, 1H), 4.11-4.21 (m, 2H), 4.41-4.50 (m, 1H), 4.62 (dd, J= 6.0, 12.3Hz, 
1H), 4.69 (dd, J= 4.8, 12.3Hz, 1H), 6.78 (dd, J= 4.8, 6.0Hz, 1H), 7.32-7.46 (m, 3H), 
7.86 (m, 1H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  18.6 (CH3), 18.7 (CH3), 33.0 (CH), 64.7 (CH2), 70.2 
(CH2), 72.6 (CH), 126.7 (C), 127.7 (CH), 130.1 (CH), 130.4 (CH), 131.5 (CH), 142.2 
(C), 163.8 (C) ppm. 
IR (HATR): 3221, 2960, 2900, 2868, 1637, 1598, 1573, 1466, 1446, 1349, 1322, 
1310, 1254, 1198, 1061, 1047, 1024, 963, 946, 781, 750, 711 cm-1. 
EI-MS m/z (rel. intensity %): 219 (M+, 40), 190 (10), 188 (6), 176 (32), 158 (21), 146 
(9), 133 (100), 119 (19), 105 (54), 91 (26), 77 (47), 65 (6), 51 (16), 41 (39). 
ES-MS: 220 [M+H]+.
Optical rotation: [α]20
D
= - 42.9 (c 0.99, CHCl3). 
HRMS (EI): calcd for C13H17NO2: 219.1259; found 219.1259.  
6.4.1.4 2-(2’-hydroxymethyl-6’-chloro)phenyl-(3aS,8aR)-3a,8a-dihydro-8H-
indeno[1,2-d]oxazoline (4.60d) 
HO
O
N
4.60d
Et3N (3 equiv), CH2Cl2
83%
O
NH
HCl.
4.49a
(1.1 equiv)
+
4.58a
NH2
OH
Cl
Cl
A suspension of (1S, 2R)-(-)-cis-1-amino-2-indanol 4.58a (100.0 mg, 0.67 mmol) and 
imidate ester 4.49a (150.0 mg, 0.74 mmol) in CH2Cl2 (5 mL) was cooled in an ice 
bath. Et3N (0.28 mL, 2.0 mmol) was added and the reaction mixture was stirred for 
48h at room temperature. Evaporation in vacuo, purification by flash chromatography 
over silicagel (CH2Cl2/MeOH, 98/2) and finally recrystrallization from hexane/CH2Cl2
resulted in 4.60d as a white solid, 165.1 mg (83%). 
Formula: C17H14ClNO2 (299.75 g/mol).  
Rf (CH2Cl2/MeOH 9/1): 0.68 
1H-NMR (300 MHz, CDCl3)  3.41-3.49 (dd, J= 1.8, 17.9Hz, 1H), 3.50-3.60 (dd, J= 
6.1, 17.9Hz, 1H), 4.14-4.20 (dd, J= 6.2, 12.5Hz, 1H), 4.25-4.33 (dd, J= 8.1, 12.5Hz, 
1H), 4.69 (dd, J= 6.2, 8.1Hz , 1H), 5.60 (ddd, J= 1.8, 6.1, 7.7Hz, 1H), 5.77 (d, J= 7.7 
Hz, 1H), 7.23-7.37 (m, 6H), 7.52-7.57 (m, 1H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  39.3 (CH2), 63.5 (CH2), 76.1 (CH), 84.2 (CH), 125.2 
(CH), 125.3 (CH), 127.3 (C), 127.7 (CH), 128.7 (CH), 129.4 (CH), 131.4 (CH), 133.8 
(C), 139.3 (C), 141.3 (C), 143.3 (C), 163.1 (C) ppm. 
IR (HATR): 3179, 1652, 1478, 1458, 1444, 1420, 1358, 1328, 1292, 1240, 1176, 
1150, 1098, 1078, 1049, 991, 853, 777, 758, 730, 714, 642 cm-1. 
EI-MS m/z (rel. intensity %): 301 (M+, 2), 299 (M+, 7), 167 (12), 131 (10), 116 (100), 
104 (19), 77 (32), 63 (11). 
ES-MS: 300 [M+H]+.
Optical rotation: [α]20
D
= - 209.5 (c 0.93, CHCl3). 
Melting Point (°C) : 158°C. 
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HRMS (EI): calcd for C17H14NO2
35Cl: 299.0713; found 299.0719.  
6.4.1.5 2-(2’-hydroxymethyl-4’-chloro)phenyl-(3aS,8aR)-3a,8a-dihydro-8H-
indeno[1,2-d]oxazoline (4.60e) 
HO
O
N
4.60e
Et3N (3 equiv), CH2Cl2
66%
O
NH
HCl.
4.49b
(1.1 equiv)
+
4.58a
NH2
OH
Cl
Cl
A suspension of (1S, 2R)-(-)-cis-1-amino-2-indanol 4.58a (100.0 mg, 0.67 mmol) and 
imidate ester 4.49b (150.0 mg, 0.74 mmol) in CH2Cl2 (5 mL) was cooled in an ice 
bath. Et3N (0.28 mL, 2.0 mmol) was added and the reaction mixture was stirred for 
48h at room temperature. Evaporation in vacuo, purification by flash chromatography 
over silicagel (CH2Cl2/MeOH, 99/1) and finally recrystrallization from hexane/CH2Cl2
resulted in 4.60e as white needles, 131.2 mg (66%). 
Formula: C17H14ClNO2 (299.75 g/mol).  
Rf (CH2Cl2/MeOH 9/1): 0.80 
1H-NMR (300 MHz, CDCl3)  3.38 (dd, J= 1.3, 17.9Hz, 1H), 3.53 (dd, J= 6.5, 17.9Hz, 
1H), 4.53 (dd, J= 7.3, 12.5Hz, 1H), 4.58 (dd, J= 7.4, 12.5Hz, 1H), 5.49 (ddd, J= 1.3, 
6.5, 7.9Hz, 1H), 5.79 (d, J= 7.9Hz, 1H), 6.47 (dd, J= 7.3, 7.5Hz, 1H), 7.27-7.33 (m, 
5H), 7.47-7.51 (m, 1H), 7.79 (d, J= 8.3 Hz, 1H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  39.6 (CH2), 64.2 (CH2), 76.6 (CH), 83.1 (CH), 124.9 
(C), 125.4 (2x CH), 127.7 (CH), 127.8 (CH), 128.8 (CH), 130.5 (CH), 131.6 (CH), 
137.5 (C), 139.4 (C), 141.5 (C), 143.9 (C), 163.5 (C) ppm. 
IR (HATR): 3340, 1621, 1595, 1564, 1482, 1456, 1444, 1428, 1400, 1348, 1306, 
1292, 1278, 1246, 1229, 1199, 1142, 1103, 1040, 1031, 992, 895, 862, 824, 764, 
754, 742, 712, 677 cm-1. 
EI-MS m/z (rel. intensity %): 301 (M+, 2), 299 (M+, 6), 167 (8), 139 (9), 116 (100), 
103 (11), 89 (8), 77 (20), 63 (4). 
ES-MS: 300 [M+H]+.
Optical rotation: [α]20
D
= - 156.4 (c 0.98, CHCl3). 
Melting Point (°C) : 147°C. 
HRMS (EI): calcd for C17H14NO2
35Cl: 299.0713; found 299.0717.  
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6.4.2 Synthesis of 2-(2’-bromophenyl)-(3aS,8aR)-3a,8a-dihydro-8H-indeno[1,2-
d]oxazoline (4.93) 
Br
O
N
4.93
ZnCl2,chlorobenzene, Treflux
30%
+
4.58a
NH2
OH
CN
Br
(1 equiv)
4.93 was synthesized according to a literature procedure.4 A mixture of (1S, 2R)-(-)-
cis-1-amino-2-indanol 4.58a (500.0 mg, 3.35 mmol), 2-bromobenzonitrile (610.0 mg, 
3.35 mmol) and anhydrous ZnCl2 (23.0 mg, 0.17 mmol) in anhydrous chlorobenzene 
(2 mL) was refluxed for 24h. After removal of the solvent in vacuo, the crude product 
was purified via flash chromatography over silicagel (hexane/EtOAc, 8/2) giving 4.93 
as a colourless oil, 314.2 mg (30%).
Formula: C16H12BrNO (314.18 g/mol).  
Rf (hexane/EtOAc 8/2): 0.19 
1H-NMR (300 MHz, CDCl3)  3.41 (dd, J= 1.9, 17.9Hz, 1H), 3.51 (dd, J= 6.4, 17.9Hz, 
1H), 5.52 (ddd, J= 1.9, 6.4, 8.0Hz, 1H), 5.77 (d, J= 8.0Hz, 1H), 7.21-7.31 (m, 5H), 
7.54-7.64 (m, 3H) ppm. 
13C-NMR (75.4 MHz, CDCl3):  39.7 (CH2), 77.2 (CH), 83.6 (CH), 121.8 (C), 125.3 
(CH), 125.7 (CH), 127.0 (CH), 127.5 (CH), 128.5 (CH), 129.8 (C), 131.5 (CH), 131.6 
(CH), 133.7 (CH), 139.7 (C), 141.7 (C), 163.5 (C) ppm. 
IR (HATR): 3065, 3024, 2951, 2918, 2851, 1630, 1619, 1588, 1476, 1458, 1425, 
1353, 1316, 1295, 1234, 1212, 1166, 1097, 1081, 1023, 992, 749, 726, 707, 684, 
676, 641 cm-1. 
EI-MS m/z (rel. intensity %): 315 (M+,7), 313 (M+,7), 183 (6), 155 (4), 131 (12), 115 
(26), 104 (100), 89 (14), 77 (40), 63 (14), 50 (25). 
ES-MS: 314 and 316 [M+H]+.
Optical rotation: [α]20
D
= - 164.7 (c 1.09, CHCl3). 
HRMS (EI): calcd for C16H12NO
79Br: 313.0102; found 313.0117.  
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6.4.3 Synthesis of 2-(2’-diphenylhydroxymethyl)phenyl-(3aS,8aR)-3a,8a-
dihydro-8H-indeno[1,2-d]oxazoline (4.94) 
Br
O
N
4.93
i) n-BuLi (1.1 equiv), Et2O, -78°C;
ii) benzophenone (1.15 equiv), 
    -40°C to RT overnight
65%
HO
O
N
4.94
4.94 was synthesized according to a literature procedure.5 A solution of 4.93 (101.7 
mg, 0.33 mmol) in freshly distilled Et2O (2.5 mL) was cooled to -78°C and treated 
dropwise with n-BuLi (0.150 mL, 0.37 mmol, 2.5 M in n-hexane). After being stirred 
for 1h at -40°C, benzophenone (71.0 mg, 0.38 mmol) was added in one portion and 
stirred overnight at room temperature. The reaction mixture was poured into H2O (25 
mL) and extracted with EtOAc (3 x 25 mL). The organic phases were dried over 
Na2SO4 and concentrated in vacuo. The crude product was purified by flash 
chromatography over silicagel (hexane/EtOAc, 8/2) resulting in 4.94  as a white solid, 
88.0 mg (65%).
Formula: C29H23NO2 (417.50 g/mol).  
Rf (hexane/EtOAc 8/2): 0.14 
1H-NMR (300 MHz, CDCl3)  3.17 (d, J= 3.8Hz, 2H), 4.10 (br s, 1H), 4.63 (m, 1H), 
5.51 (d, J= 4.9Hz, 1H), 6.95-7.05 (m, 2H), 7.16-7.62 (m, 15H), 7.90-7.93 (m, 1H) 
ppm. 
13C-NMR (75.4 MHz, CDCl3):  39.7 (CH2), 63.8 (CH), 73.6 (CH), 94.2 (C), 123.8 
(CH), 124.1 (CH), 125.2 (2x CH), 126.4 (CH), 126.8 (2x CH), 127.5 (CH), 127.6 (2x 
CH), 128.2 (CH), 128.3 (2x CH), 128.4 (3x CH), 129.0 (CH), 130.0 (C), 131.9 (CH), 
141.4 (C), 141.6 (C), 142.0 (C), 142.1 (C), 148.6 (C), 159.9 (C) ppm. 
IR (HATR): 3460, 3070, 3021, 2948, 2914, 1690, 1600, 1492, 1466, 1448, 1428, 
1379, 1336, 1313, 1298, 1288, 1257, 1218, 1184, 1157, 1120, 1054, 1043, 984, 959, 
944, 930, 866, 760, 754, 746, 718, 695, 679, 656, 632 cm-1. 
EI-MS m/z (rel. intensity %): 417 (M+, 4), 270 (100), 241 (36), 239 (47), 209 (21), 
193 (16), 165 (51), 148 (23), 130 (66), 118 (51), 91 (50), 77 (93), 51 (41), 41 (9). 
ES-MS: 418 [M+H]+.
Optical rotation: [α]20
D
= + 268.4 (c 0.94, CHCl3). 
Melting Point (°C) : 210°C. 
HRMS (EI): calcd for C29H23O2N: 417.1729; found 417.1729.  
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6.5 SYNTHESIS OF  CHIRAL IMIDAZOLIDINE (4.64) 
Et3N (5.5 equiv), CH2Cl2
98%NH2H2N
O
NH
+
4.61 4.18
HN NH
O
4.64
(2.9 equiv)
A suspension of (1R, 2R)-(+)-diphenylethylenediamine 4.61 (100 mg, 0.47 mmol) and 
imidate 4.18 (232 mg, 1.36 mmol) in dry CH2Cl2 (5 mL) was cooled in an ice bath. 
Et3N (0.36 mL, 2.6 mmol) was added and the resulting suspension was stirred at 
roomtemperature for 24h. The reaction mixture was passed through a short pad of 
silicagel and eluted with EtOAc. Evaporation in vacuo and purification by flash 
chromatography over silicagel (toluene/EtOAc, 8/2, + 1% Et3N) resulted in 4.64 as a 
white solid, 152.1 mg (98 %).
Formula: C22H20N2O (328.41 g/mol).  
Rf (toluene/EtOAc, 8/2, + 1% Et3N): 0.28 
1H-NMR (300 MHz, CDCl3):  4.55 (d, J= 12.1Hz, 1H), 4.75 (d, J= 12.1Hz, 1H), 4.90 
(s, 2H), 7.20-7.44 (m, 13H), 7.68 (d, J= 7.5Hz, 1H) ppm. 
13C-NMR (75.4 MHz, CDCl3): 64.7 (CH2), 74.6 (CH), 126.5 (CH), 127.9 (CH), 128.0 
(CH), 128.5 (CH), 128.9 (CH), 129.3 (C), 131.0 (CH), 131.4 (CH), 141.9 (C), 142.6 
(C), 164.0 (C) ppm. 
IR (HATR): 3253, 3025, 2865, 1612, 1590, 1568, 1500, 1444, 1326, 1299, 1282, 
1201, 1150, 1090, 1065, 1017, 964, 920, 830, 800, 755, 698, 647 cm-1. 
EI-MS m/z (rel. intensity %): 328 (M+, 24), 207 (19), 180 (32), 165 (13), 149 (5), 118 
(100), 84 (58), 49 (87). 
ES-MS: 329 [M+H]+.
Melting Point (°C) : 153°C. 
Optical rotation: [α]20
D
= - 14.2 (c 1.0, CHCl3). 
HRMS (EI): calcd for C22H20N2O: 328.1576; found 328.1559. 
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6.6 SYNTHESIS OF  CHIRAL AMIDINE LIGANDS  
4.15 and 4.90 were synthesized according to a literature procedure.6
6.6.1 Synthesis of [1R,2R- (1(E), 2(E))]-N,N’-bis(dimethylaminomethylene)-
1,2-cyclohexanediamine (4.15) 
H2N NH2
N N100 %
(8.6 equiv)
+
4.33
N OMe
OMe
Me2N NMe2
4.15
A mixture of (1R, 2R)-(-)-diaminocyclohexane (4.33) (500 mg, 4.38 mmol) and N,N-
dimethylformamide dimethylacetal (5 mL, 37.6 mmol) was stirred at room 
temperature for 5h. The volatiles were removed in vacuo, resulting in 4.15 as a 
transparent oil, 0.983 g (quant.). 
Formula: C12H24N4 (224.34 g/mol).  
1H-NMR (300 MHz, CDCl3):  1.20-1.74 (m, 8H), 2.71 (s, 14H), 7.14 (s, 2H) ppm. 
13C-NMR (75.4 MHz, CDCl3): 25.5 (CH2), 34.9 (CH2), 37.4 (CH3), 70.1 (CH), 155.4 
(CH) ppm. 
IR (HATR): 2921, 2852, 1643, 1484, 1446, 1434, 1366, 1257, 1138, 1102, 1081, 
1042, 941, 852, 844, 730 cm-1. 
EI-MS m/z (rel. intensity %): 224 (M+, 8), 180 (52), 154 (17), 125 (14), 111 (18), 100 
(19), 98 (25), 83 (15), 72 (66), 57 (25), 44 (100).
Optical rotation: [α]20
D
= - 192.4 (c 1.0, CHCl3). 
6.6.2 Synthesis of [1R,2R- (1(E), 2(E))]-N,N’-bis(dimethylaminomethylene)-
1,2-diphenylethylenediamine (4.90) 
H2N NH2
N N32 %
(32 equiv)
+
4.61
N OMe
OMe
Me2N NMe2
4.90
A solution of (1R, 2R)-(+)-diphenylethylenediamine 4.61 (500 mg, 2.36 mmol) and 
N,N-dimethylformamide dimethylacetal (10 mL, 75.2 mmol) was stirred at 50°C for 
5h. The volatiles were removed in vacuo and the solids were recrystallized from n-
hexane/EtOAc resulting in 4.90 as a white solid, 245.1 mg (32 %). 
Formula: C20H26N4 (322.45 g/mol).  
Chapter 6. Experimental section 
177
1H-NMR (300 MHz, CDCl3):  2.82 (s, 12H), 4.12 (s, 2H), 7.03-7.14 (m, 10H), 7.29 (s, 
2H) ppm. 
13C-NMR (75.4 MHz, CDCl3): 37.0 (CH3), 77.5 (CH), 125.9 (CH), 126.5 (CH), 127.4 
(CH), 128.1 (CH), 128.6 (CH), 144.0 (CH), 155.3 (CH) ppm. 
IR (HATR): 3026, 2903, 2870, 2833, 2797, 1642, 1602, 1489, 1451, 1435, 1400, 
1371, 1257, 1107, 1073, 1055, 1028, 907, 886, 844, 775, 758, 700, 628, 621 cm-1. 
EI-MS m/z (rel. intensity %): 323 (M+, <1), 161 (100), 91 (24), 44 (42). 
Optical rotation: [α]20
D
= - 132 (c 1.0, CHCl3). 
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6.7 APPLICATION OF THE SYNTHESIZED LIGANDS 
6.7.1 General procedure for the asymmetric 1,4-addition of phenylboronic acid 
to cyclic enones 3.70a and 3.70b. 
O
+   PhB(OH)2
n
(2 equiv)
O
n
Ph
(S)-3.71a-b3.70a-b
n=1 (a), 0 (b)
[RhOH(C2H4)2]2 / ligand
(3mol % Rh)
dioxane/1.5 M aq H2O 
(10:1)
(S,S)-nbd* (3.10) (2.7 mg, 9.9 mol) and [RhCl(C2H4)2]2 (1.8 mg, 9.0 mol) were 
dissolved in dioxane (1 mL) and stirred for 15 min at room temperature under argon. 
To this reaction mixture was added KOH (0.1 mL, 1.5 M, 0.15 mmol) in 
deoxygenated H2O and the solution was stirred for another 15 min. Subsequently, 
phenylboronic acid (73.1 mg, 0.6 mmol) and 2-cyclohexenone (3.70a) (29 l, 0.3 
mmol) were added and stirred at 30 °C for 1.5 h. Th e reaction mixture was passed 
through a short pad of silicagel and eluted with EtOAc. Evaporation in vacuo and 
purification by flash chromatography over silicagel (hexane/Et2O, 85/15) resulted in 
(S)-3.71a as a colorless oil, 49.6 mg (95 %, 96% ee). 
O
(S)-3.71a
Formula: C12H14O (174.24 g/mol) 
Rf (hexane/EtOAc 2/1): 0.45 
1H-NMR (300 MHz, CDCl3):  1.70-1.94 (m, 2H), 2.05-2.20 (m, 2H), 2.31-2.52 (m, 
2H), 2.55 (m, J = 13.8 Hz, 1H), 2.61 (dddd, J = 2.0, 2.0, 4.5, 13.8 Hz, 1H), 3.02 
(dddd, J = 3.5, 4.5, 11.6, 11.6 Hz, 1H), 7.19-7.26 (m, 3H), 7.29-7.31 (m, 2H) ppm. 
13C-NMR (125.7 MHz, CDCl3):  25.6 (CH2), 32.8 (CH2), 41.2 (CH2), 44.8 (CH), 49.0 
(CH2), 126.6 (CH), 126.7 (CH), 128,7 (CH), 144.4 (C), 211,1 (C) ppm. 
IR (KBr, film): 3061, 3028, 2938, 2865, 1712, 163, 1496, 1451, 1420, 756, 700 cm-1
EI-MS m/z (rel. intensity %): 174 (M+, 54), 131 (51), 117 (59), 104 (71), 84 (46), 78 
(32), 65 (15), 49 (100), 42 (69). 
Optical rotation: [α]20
D
= - 20.3 (c 1.0, CHCl3, 96% ee).  
Literature results: 1) [ ]27
D
α = - 18.6 (c 1.045, CHCl3, 95% ee, S)
7
    2) [ ]20
D
α = - 21 (c 0.96, CHCl3, 97% ee, S)
8
CHIRAL HPLC: Chiralpak AS-H column, solvent: n-hexane/i-PrOH (98:2), flow rate= 
1 mL/min, T= 35°C, retention times: 18.3 min for ( S)-3.71a, 21.4 min for (R)-3.71a.  
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O
(S)-3.71b
Formula: C11H12O (160.21 g/mol) 
Rf (pentane/Et2O 85/15): 0.17 
1H-NMR (300 MHz, CDCl3):  1.92-2.08 (m, 1H), 2.23-2.54 (m, 4H), 2.68 (dddd, J = 
1.6, 1.6, 7.5, 18.3 Hz, 1H), 3.43 (dddd, J = 6.2, 7.5, 11.3, 11.3 Hz, 1H), 7.22-7.29 (m, 
3H), 7.31-7.39 (m, 2H) ppm. 
13C-NMR (125.7 MHz, CDCl3):  31.2 (CH2), 38.9 (CH2), 42.2 (CH), 45.8 (CH2), 126.7 
(CH), 128.7 (CH), 143.1 (C), 218.5 (C) ppm. 
IR (KBr, film): 3028, 2963, 1741, 1602, 1495, 1452, 1403,1136, 763, 700 cm-1
Optical rotation: [ ]20
D
α = - 88.1 (c 1.0, CHCl3, 90% ee).  
Literature results: 1) [ ]20
D
α = - 92 (c 0.82, CHCl3, 97% ee, S)
8 
    2) [ ]20
D
α = + 81.2 (c 1.12, CHCl3, 83% ee, R)
2
CHIRAL HPLC: Chiralpak AS-H column, solvent: n-hexane/i-PrOH (98:2), flow rate= 
1 mL/min, T= 35°C, retention times: 19.9 min for ( S)-3.71b, 21.7 min for (R)-3.71b. 
6.7.2 General procedure for the racemic 1,4-addition of phenylboronic acid to 
–acetamido acrylic ester. 
CO2Me
NHAc +   PhB(OH)2
      (4 equiv)
[Rh] (3 mol%)
CO2Me
NHAcPh
NaF (3 equiv)
dioxane/H2O (10:1)
T= 100°C, 24h
+
CO2Me
NHAcPh
3.72 3.73 3.77
Methyl 2-acetamidoacrylate 3.72 (71.6 mg, 0.5 mmol), [Rh(COD)Cl]2 (7.4 mg, 0.015 
mmol), phenylboronic acid (243.9 mg, 2 mmol) and NaF (63.0 mg, 1.5 mmol) were 
dissolved in dioxane (1.5 mL) and stirred for 30 min at room temperature. H2O (150 
l) was added and the resulting reaction mixture was heated to 100°C under argon in 
a sealed tube. After 26h, full conversion was observed via TLC. The reaction mixture 
was passed through a short pad of silicagel and eluted with EtOAc. Evaporation in 
vacuo and purification by flash chromatography over silicagel (hexane/EtOAc, 50/50) 
resulted in a mixture of 3.73 and 3.77, 84.5 mg (77%; 82% of 3.73 and 18% of 3.77). 
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6.7.3 General procedure for the asymmetric 1,4-addition of phenylboronic acid 
to –acetamido acrylic ester. 
CO2Me
NHAc +   PhB(OH)2
      (4 equiv)
[Rh] / ligand 3.10 (3 mol%)
CO2Me
NHAcPh
NaF (3 equiv)
dioxane/H2O (10:1)
T= 100°C, 24h
+
CO2Me
NHAcPh
3.72 3.73 3.77
*
[Rh(C2H4)2Cl]2 (2.9 mg, 7.5 µmol) and (S,S)-Bn-nbd* (3.10) (4.5 mg, 16.5 µmol) were 
dissolved in degassed dioxane (0.75 mL) and degassed H2O (75 l) and stirred for 
30 min at room temperature. After addition of methyl 2-acetamidoacrylate 3.72 (35.8 
mg, 0.25 mmol), phenylboronic acid (122 mg, 1 mmol) and NaF (31.5 mg, 0.75 
mmol), the resulting reaction mixture was stirred for 24h at 100°C in a sealed tube. 
The reaction mixture was passed through a short pad of silicagel and eluted with 
EtOAc. Evaporation in vacuo and purification by flash chromatography over silicagel 
(hexane/EtOAc, 50/50) resulted in a mixture of 3.73 and 3.77, 22.0 mg (40%; 30% 
(rac) of 3.73 and 70% of 3.77). 
CO2Me
NHAcPh
3.73
*
Formula: C12H15NO3 (221.25 g/mol) 
Rf (hexane/EtOAc 50/50): 0.15 
1H-NMR (300 MHz, CDCl3):  1.98 (s, 3H), 3.09 (dd, J= 5.7, 13.8, 1H), 3.16 (dd, J= 
6.0, 13.8, 1H), 3.72 (s, 3H), 4.88 (m, 1H), 5.95 (br d, J= 6.4), 7.07-7.10 (m, 2H), 7.21-
7.32 (m, 3H) ppm. 
ES-MS: 222 [M+H]+.
CO2Me
NHAcPh
3.77
Formula: C12H13NO3 (219.24 g/mol) 
Rf (hexane/EtOAc 50/50): 0.15 
1H-NMR (300 MHz, CDCl3):  2.11 (s, 3H), 3.84 (s, 3H), 7.12 (br s, 1H), 7.21-7.63 
(m, 6H) ppm. 
ES-MS: 220 [M+H]+.
HPLC: Phenomenex Luna C18(2) column, solvent: H2O/acetonitrile with gradient 
elution (0 to 100% acetonitrile in 15 min), flow rate= 1 mL/min, T= 35°C, retention 
times: 12.68 min for 3.77 and 12.97 min for 3.73. 
Chapter 6. Experimental section 
181
CHIRAL GC: Chirasil-Val Column (30 m x 0.25 mm x 0.25 m); temperature 
program: 150°C for 11 min, increasing to 190°C (40° C/min); retention times: 9.11 min 
for R-3.73, 9.38 min for S-3.73 and 14.60 min for 3.77. 
6.7.4 General procedure for the racemic 1,2-addition of phenylboronic acid to 
p-trifluoromethylbenzaldehyde (3.89) catalyzed by 
[Rh(norbornadiene)Cl]2. 
+   PhB(OH)2
(3 x 2 equiv)
[RhCl(nbd)]2
(3mol % Rh)
dioxane/1.5 M aq H2O 
(10:3)F3C
O
H
F3C
OH
3.89 3.90
[Rh(norbornadiene)Cl]2 (6.9 mg, 0.015 mmol), phenylboronic acid (121.9 mg, 1 
mmol) and p-trifluoromethylbenzaldehyde (3.89) (68 l, 0.5 mmol) were dissolved 
dioxane (1.5 mL). Aq KOH (1.5M, deoxygenated, 450 l) was added and the 
resulting reaction mixture was stirred under argon at 50 °C. After 2 h, more 
phenylboronic acid (121.9 mg, 1 mmol) was added, followed by another portion 
(121.9 mg, 1 mmol) after 4 h.  After 6 h the conversion of the aldehyde was complete. 
The reaction mixture was passed through a short pad of silicagel and eluted with 
EtOAc. Evaporation in vacuo and purification by flash chromatography over silicagel 
(hexane/EtOAc, 90/10) resulted in 3.90 as a white solid, 97 mg (78%). 
6.7.5 General procedure for the asymmetric 1,2-addition of phenylboronic acid 
to p-trifluoromethylbenzaldehyde (3.89). 
+   PhB(OH)2
(2 equiv)
[RhCl(C2H4)2]2/ ligand
(3mol % Rh)
dioxane/1.5 M aq H2O 
(10:3)F3C
O
H
F3C
OH
3.89 (R)-3.90
[Rh(C2H4)2Cl]2 (1.5 mg, 7.5 µmol) and (S,S)-i-Bu-nbd* (3.56) (1.6 mg, 7.8 µmol) were 
dissolved in dioxane (0.75 mL) and stirred for 15 min under argon. To this reaction 
mixture was added aqueous  KOH (225 µl, 1.5 M, 0.34 mmol) in deoxygenated H2O 
and the solution was stirred for another 15 min. The reaction mixture was cooled in 
an ice bath and phenylboronic acid (61.0 mg, 0.5 mmol) and p-
trifluoromethylbenzaldehyde (3.89) (34 µl, 0.25 mmol) were added and stirred for 1 h. 
The reaction mixture was passed through a short pad of silicagel and eluted with 
EtOAc. Evaporation in vacuo and purification by flash chromatography over silicagel 
(hexane/EtOAc, 90/10) resulted in (R)-3.90 as a white solid, 62.5 mg (99 %, 37% ee).
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F3C
OH
(R)-3.90
Formula: C14H11F3O (252.23 g/mol) 
Rf (pentane/EtOAc 85/15): 0.36 
1H-NMR (300 MHz, CDCl3):  2.2 (br s, 1H), 5.78 (s, 1H), 7.16-7.27 (m, 5H), 7.41 (d, 
J= 8.5 Hz, 2H), 7.49 (d, J= 8.5 Hz, 2H) ppm. 
13C-NMR (125.7 MHz, CDCl3):  75.8 (CH), 125.4 (q, JC-F= 273.0 Hz, C), 126.0 (C), 
126.7 (CH), 126.7 (CH), 128.1 (CH), 128.8 (CH), 143.2 (C), 147.5 (C) ppm. 
IR (KBr, film): 3346, 3065, 3032, 1620, 1495, 1454, 1326, 1165, 1124, 1067, 1016, 
700, 669 cm-1
EI-MS m/z (rel. intensiteit %): 252 (M+, 100), 233 (20), 173 (62), 165 (21), 145 (29), 
127 (32), 105 (66), 79 (47), 77 (46), 51 (33), 41 (4). 
CHIRAL HPLC: Chiralcel OJ-H column, solvent: n-hexane/EtOH (98:2), flow rate= 1 
mL/min, T= 35°C, retention times: 23.6 min for ( R)-3.90, 26.5 min for (S)-3.90. 
6.7.6 General procedure for the copper(I)-catalyzed asymmetric aziridination. 
CO2Me
Cu(MeCN)4PF6 (10 mol%)
ligand (11 mol%)
+   PhINTs
CO2Me
N
Ts
4.70
(1 mmol) (2S, 3R) - 4.75
(0.2 mmol)
4 mol. sieves / CH2Cl2
T= -40°C
Bisimidate (4.39) (7.6 mg, 0.022 mmol) and Cu(MeCN)4PF6 (7.5 mg, 0.020 mmol) 
were dissolved in CH2Cl2 (2 mL) and stirred for 45 min at room temperature under 
argon. To this reaction mixture was added 4Å molecular sieves (100 mg) and methyl 
cinnamate 4.70 (162 mg, 1.0 mmol).  The resulting suspension was cooled to -40°C. 
Subsequently, PhINTs (74.6 mg, 0.2 mmol) was added and stirred for 21h. The 
reaction mixture was passed through a short pad of silicagel and eluted with EtOAc. 
Evaporation in vacuo and purification by flash chromatography over silicagel 
(gradient elution with hexane/EtOAc, 90/10 to hexane/EtOAc, 80/20) resulted in 4.75, 
59.3 mg (90%, 45% ee).
CO2Me
N
Ts
(2S, 3R) - 4.75
Formula: C17H17NO4S (331.39 g/mol) 
Rf (hexane/EtOAc 2/1): 0.30 
1H-NMR (300 MHz, CDCl3):  2.40 (s, 3H), 3.51 (d, J= 3.9Hz, 1H), 3.84 (s, 3H), 4.42 
(d, J= 3.9Hz, 1H), 7.21-7.32 (m, 7H), 7.77 (d, J= 8.3Hz, 2H) ppm. 
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13C-NMR (75.5 MHz, CDCl3):  21.6 (CH3), 46.8 (CH), 47.7 (CH), 53.1 (CH3), 127.4 
(CH), 127.5 (CH), 128.6 (CH), 128.9 (CH), 129.5 (CH), 132.6 (C), 137.1 (C), 144.3 
(C), 166.2 (C) ppm. 
Optical rotation: [ ]20
D
α = - 21.2 (c 0.78, CHCl3, 51% ee).  
Literature results: 1) [ ]28
D
α = - 18.3 (c 0.18, CH2Cl2, 83% ee, (2S,3R))
9 
    2) [ ]25
D
α = + 33.1 (c 1.00, CH2Cl2, 94% ee, (2R,3S))
10
CHIRAL HPLC: Chiralcel OD-H column, solvent: n-hexane/EtOH (90:10), flow rate= 
1 mL/min, T= 35°C, retention times: 10.7 min for (2 R, 3S)-4.75 and 16.4 min for (2S, 
3R)- 4.75. 
CO2t-Bu
N
Ts
(2S, 3R) - 4.76
Formula: C20H23NO4S (373.49 g/mol) 
Rf (hexane/EtOAc 2/1): 0.46 
1H-NMR (300 MHz, CDCl3):  1.54 (s, 9H), 2.41 (s, 3H), 3.41 (d, J= 4.0Hz, 1H), 4.38 
(d, J= 4.0Hz, 1H), 7.20-7.33 (m, 7H), 7.80 (d, J= 8.3Hz, 2H) ppm. 
CHIRAL HPLC: Chiralpak AD-H column, solvent: n-hexane/EtOH (90:10), flow rate= 
1 mL/min, T= 35°C, retention times: 11.9 min for (2 R, 3S)-4.76 and 13.8 min for (2S, 
3R)- 4.76. 
O
NC
NTs4.77
Formula: C19H18N2O3S (354.42 g/mol) 
Rf (hexane/EtOAc 2/1): 0.29 
1H-NMR (300 MHz, CDCl3):  1.25 (s, 3H), 1.30 (s, 3H), 2.43 (s, 3H), 3.37 (d, J= 
7.3Hz, 1H), 3.87 (d, J= 7.3Hz, 1H), 6.80 (d, J= 8.5Hz, 1H), 7.32 (d, J= 8.2Hz, 2H), 
7.46 (dd, J= 2.1, 8.5Hz, 1H), 7.55 (d, J= 2.1Hz, 1H), 7.81 (d, J= 8.2Hz, 2H) ppm. 
13C-NMR (75.5 MHz, CDCl3):  21.6 (CH3), 23.8 (CH3), 25.8 (CH3), 38.7 (CH), 49.4 
(CH), 73.2 (C), 104.7 (C), 118.5 (C), 119.3 (C), 119.3 (CH), 127.9 (CH), 129.8 (CH), 
133.2 (CH), 134.2 (CH), 134.5 (C), 145.1 (C), 156.3 (C) ppm. 
Optical rotation: [ ]20
D
α = - 14.2 (c 1.0, CHCl3, 8% ee).  
Literature results: 1) [ ]25
D
α = - 115.7 (c 1.65, CHCl3, 70% ee, (3S,4S))
2
CHIRAL HPLC: Chiralcel OD-H column, solvent: n-hexane/EtOH (95:5), flow rate= 1 
mL/min, T= 35°C, retention times: 21.8 min for (3 S,4S)-4.77 and 24.2 min for 
(3R,4R)- 4.77. 
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6.7.7 General procedure for the asymmetric addition of Et2Zn to aldehyde. 
ligand (10 mol %)
toluene , 0°C
H
O
+      Et2Zn
        (1.5 equiv)
OH
*
4.91 4.92
Ligand (4.60a) (13.1 mg, 0.049 mmol) was dissolved in toluene (2 mL). Et2Zn (0.75 
mL, 0.75 mmol, 1 M in hexane) was added and the resulting yellow solution was 
stirred for 20 min at room temperature under argon atmosphere. Next, the reaction 
was cooled to 0°C and benzaldehyde 4.91 was added (50 L, 0.49 mmol). The 
reaction was stirred for another 48h. After quenching with 1 mL saturated NH4Cl 
solution, the reaction was added to 25 mL H2O and extracted with EtOAc (3 x 25 
mL). The combined organic phases were dried on Na2SO4 and evaporated in vacuo. 
Purification by flash chromatography over silicagel (pentane/EtOAc, 90/10) resulted 
in 4.92, 46.3 mg (69%, 85% ee). 
OH
4.92
Formula: C9H12O (136.19 g/mol) 
Rf (pentane/EtOAc 80/20 ): 0.44 
1H-NMR (300 MHz, CDCl3):  0.82 (t, J= 7.4Hz, 3H), 1.56-1.82 (m, 2H), 2.09 (br s, 
1H), 4.48 (t, J= 6.6Hz, 1H), 7.24 (s, 5H)  ppm. 
13C-NMR (75.5 MHz, CDCl3):  10.1 (CH3), 31.9 (CH2), 76.0 (CH), 126.0 (CH), 127.5 
(CH), 128.4 (CH), 144.6 (C) ppm. 
EI-MS m/z (rel. intensiteit %): 136 (M+, 17), 107 (96), 91 (7), 79 (100), 77 (56), 51 
(23). 
Optical rotation: [ ]20
D
α = + 37.8 (c 1.06, CHCl3, 75% ee).  
Literature results: 1) [ ]25
D
α = + 30.2 (c 2.20, CHCl3, 96% ee, R)
11  
CHIRAL HPLC: Chiralcel OD-H column, solvent: n-hexane/EtOH (97:3), flow rate= 1 
mL/min, T= 35°C, retention times: 7.8 min for ( R)-4.92 and 9.0 min for (S)- 4.92. 
OHCl
(S)-(-)
Formula: C9H11ClO (170.64 g/mol) 
Rf (pentane/EtOAc 90/10): 0.35 
1H-NMR (300 MHz, CDCl3):  1.00 (t, J= 7.3Hz, 3H), 1.66-1.91 (m, 2H), 2.39 (br s, 
1H), 5.07 (t, J= 5.8Hz, 1H), 7.17-7.35 (m, 3H), 7.52-7.56 (m, 1H) ppm. 
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13C-NMR (75.5 MHz, CDCl3):  10.0 (CH3), 30.4 (CH2), 71.9 (CH), 127.0 (CH), 127.1 
(CH), 128.3 (CH), 129.3 (CH), 131.9 (C), 142.0 (C) ppm. 
Optical rotation: [ ]20
D
α = - 30 (c 1.0, CHCl3, 55% ee).  
Literature results: 1) [ ]20
D
α = - 48.6 (c 1.25, C6H6, 85% ee, S)
12  
CHIRAL HPLC: Chiralcel AD-H column, solvent: n-hexane/EtOH (97:3), flow rate= 1 
mL/min, T= 35°C, retention times: 7.7 min for ( R) and 8.5 min for (S). 
OH
(S)-(-)
Cl
Formula: C9H11ClO (170.64 g/mol) 
Rf (pentane/EtOAc 80/20): 0.40 
1H-NMR (300 MHz, CDCl3):  0.94 (t, J= 7.4Hz, 3H), 1.70-1.87 (m, 2H), 1.96 (br s, 
1H), 4.60 (t, J= 6.5Hz, 1H), 7.21-7.32 (m, 3H), 7.35-7.37 (m, 1H) ppm. 
13C-NMR (75.5 MHz, CDCl3):  9.9 (CH3), 31.9 (CH2), 75.3 (CH), 124.1 (CH), 126.1 
(CH), 127.6 (CH), 129.6 (CH), 134.3 (C), 146.6 (C) ppm. 
Optical rotation: [ ]20
D
α = - 26.6 (c 1.01, CHCl3, 74% ee).  
Literature results: 1) [ ]20
D
α = - 23.3 (c 1.21, C6H6, 79% ee, S)
12  
CHIRAL HPLC: Chiralcel AD-H column, solvent: n-hexane/EtOH (97:3), flow rate= 1 
mL/min, T= 35°C, retention times: 8.9 min for ( R) and 10.5 min for (S). 
OH
(S)-(-)
Cl
Formula: C9H11ClO (170.64 g/mol) 
Rf (pentane/EtOAc 90/10): 0.22 
1H-NMR (300 MHz, CDCl3):  0.91 (t, J= 7.5Hz, 3H), 1.67-1.85 (m, 2H), 2.10 (br s, 
1H), 4.58 (t, J= 6.7Hz, 1H), 7.26-7.34 (m, 4H) ppm. 
13C-NMR (75.5 MHz, CDCl3):  9.9 (CH3), 31.9 (CH2), 75.2 (CH), 127.3 (CH), 128.5 
(CH), 133.0 (C), 143.0 (C) ppm. 
Optical rotation: [ ]20
D
α = - 27.6 (c 1.06, CHCl3, 62% ee).  
Literature results: 1) [ ]20
D
α = - 23.3 (c 1.21, C6H6, 79% ee, S)
12  
    2) [ ]20
D
α = - 23.5 (c 0.82, C6H6, 93% ee, S)
13
CHIRAL HPLC: Chiralcel OB-H column, solvent: n-hexane/EtOH (97:3), flow rate= 1 
mL/min, T= 35°C, retention times: 6.5 min for ( S) and 7.8 min for (R). 
Chapter 6. Experimental section 
186
(S)-(-)
OH
Formula: C11H14O (162.23 g/mol) 
Rf (pentane/EtOAc 90/10): 0.22 
1H-NMR (300 MHz, CDCl3):  1.00 (t, J= 7.5Hz, 3H), 1.63-1.74 (m, 2H), 1.82 (br s, 
1H), 4.20-4.27 (m, 1H), 6.24 (dd, J= 6.8, 15.9Hz, 1H), 6.60 (d, J= 15.9Hz), 7.24-7.43 
(m, 5H) ppm. 
13C-NMR (75.5 MHz, CDCl3):  9.7 (CH3), 30.2 (CH2), 74.4 (CH), 126.4 (CH), 127.6 
(CH), 128.5 (CH), 130.4 (CH), 132.2 (CH), 136.7 (C) ppm. 
Optical rotation: [ ]20
D
α = - 5.5 (c 0.78, CHCl3, 61% ee).  
Literature results: 1) [ ]20
D
α = + 4.3 (c 2.1, CHCl3, 84% ee, R)
12  
    2) [ ]24
D
α = - 6.3 (c 1.73, CHCl3, 88% ee, S)
14
CHIRAL HPLC: Chiralcel OD-H column, solvent: n-hexane/EtOH (97:3), flow rate= 1 
mL/min, T= 35°C, retention times: 5.8 min for ( R) and 7.4 min for (S). 
OH
(S)-(-)
Formula: C13H14O (186.10 g/mol) 
Rf (pentane/EtOAc 90/10): 0.16 
1H-NMR (300 MHz, CDCl3):  0.94 (t, J= 7.4Hz, 3H), 1.82-1.86 (m, 3H), 4.77 (t, J= 
6.5Hz, 1H), 7.45-7.48 (m, 3H), 7.77-7.84 (m, 4H) ppm. 
13C-NMR (75.5 MHz, CDCl3):  10.1 (CH3), 31.7 (CH2), 76.1 (CH), 124.1 (CH), 124.7 
(CH), 125.7 (CH), 126.1 (CH), 127.7 (CH), 127.9 (CH), 128.2 (CH), 133.0 (C), 133.3 
(C), 141.9 (C) ppm. 
Optical rotation: [ ]20
D
α = - 32.2 (c 1.02, CHCl3, 87% ee).  
Literature results: 1) [ ]20
D
α = + 35.1 (c 2.4, CHCl3, 92% ee, R)
11  
CHIRAL HPLC: Chiralcel OD-H column, solvent: n-hexane/EtOH (97:3), flow rate= 1 
mL/min, T= 35°C, retention times: 14.7 min for ( S) and 16.0 min for (R). 
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6.7.8 General procedure for the palladium-catalyzed asymmetric allylic 
alkylation. 
[Pd(pi−C3H5)Cl]2 (5 mol %) /
Ligand (10 mol %)
CH2(COOMe)2 (3 equiv) / BSA (3 equiv)
BSA activator (5 mol %)
CH2Cl2, RT, 16h
Ph Ph
OAc
Ph Ph
CH(COOMe)2
4.101 4.102
Imidate-phosphane ligand (4.55b) (12.3 mg, 21.8 mol) and [Pd(3-C3H5)Cl]2 (2.0 
mg, 5.5 mol) were dissolved in degassed CH2Cl2 (1 mL) and stirred for 1 h at room 
temperature. Next, a solution of rac-1,3-diphenyl-3-acetoxyprop-1-ene 4.101 (55.0 
mg, 0.22 mmol) in CH2Cl2 (0.5 mL) was added and stirred for another 30 min at room 
temperature. Finally, a solution of dimethylmalonate (75 l, 0.66 mmol), BSA (160 l, 
0.66 mmol) and KOAc (1.4 mg, 10.6 mol) in CH2Cl2 (0.5 mL) was added and the 
reaction mixture was stirred for 16h at room temperature. The reaction mixture was 
passed through a short pad of silica gel and eluted with CH2Cl2. Evaporation in vacuo 
and purification by flash chromatography over silica gel (hexane/EtOAc, 90/10) 
resulted in S-4.102, 69.8 mg (99%, 99% ee). 
Ph Ph
CH(COOMe)2
(S)-4.102
Formula: C20H20O4 (324.37 g/mol) 
Rf (pentane/EtOAc 9/1): 0.24 
1H-NMR (500 MHz, CDCl3):  3.54 (s, 3H), 3.72 (s, 3H), 3.99 (d, J= 10.8Hz, 1H), 4.30 
(dd, J= 8.7, 10.8Hz, 1H),  6.36 (dd, J= 8.7, 15.7Hz, 1H), 6.51 (d, J= 15.7Hz, 1H), 
7.20-7.36 (m, 10H)  ppm. 
13C-NMR (125.7 MHz, CDCl3):  49.3 (CH), 52.5 (CH3), 52.7 (CH3), 57.7 (CH), 126.5 
(CH), 127.3 (CH), 127.7 (CH), 128.0 (CH), 128.6 (CH), 128.8 (CH), 129.2 (CH), 
131.9 (CH), 136.9 (C), 140.3 (C), 167.9 (C), 168.3 (C) ppm. 
Optical rotation: [ ]20
D
α = - 20.3 (c 0.99, CHCl3, 99% ee).  
Literature results: 1) [ ]25
D
α = - 20.6 (c 1.01, CHCl3, 98% ee, S)
15  
    2) [ ]25
D
α = - 22.0 (c 1.13, CHCl3, 98% ee, S)
16
CHIRAL HPLC: Chiralcel AD-H column, solvent: n-hexane/EtOH (70:30), flow rate= 
1 mL/min, T= 35°C, retention times: 9.2 min for ( S)-4.102 and 13.9 min for (R)- 4.102. 
Ph Ph
CH(COOEt)2
(S)-4.103
Formula: C22H24O4 (352.42 g/mol) 
Rf (pentane/EtOAc 9/1):0.35 
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1H-NMR (500 MHz, CDCl3):  1.01 (t, J= 7.1Hz, 3H), 1.21 (t, J= 7.1Hz, 3H), 3.93 (d, 
J= 10.8Hz, 1H), 3.97 (dq, J= 4.7, 7.1Hz, 1H), 3.99 (dq, J= 4.7, 7.1Hz, 1H), 4.18 (q, J= 
7.1Hz, 2H),  4.27 (dd, J= 8.7, 10.8Hz, 1H), 6.35 (dd, J= 8.7, 15.7Hz, 1H), 6.49 (d, J= 
15.7Hz, 1H), 7.18-7.36 (m, 10H)  ppm. 
13C-NMR (125.7 MHz, CDCl3):  13.9 (CH3), 14.2 (CH3), 49.3 (CH), 57.9 (CH), 61.5 
(CH2), 61.7 (CH3), 126.5 (CH), 127.2 (CH), 127.6 (CH), 128.1 (CH), 128.6 (CH), 
128.8 (CH), 129.4 (CH), 131.4 (CH), 136.9 (C), 140.4 (C), 167.5 (C), 168.0 (C) ppm. 
Optical rotation: [ ]20
D
α = - 16.6 (c 0.99, CHCl3, 99% ee).  
Literature results: 1) [ ]25
D
α = - 17.2 (c 1.02, CHCl3, 97% ee, S)
15  
CHIRAL HPLC: Chiralcel AD-H column, solvent: n-hexane/EtOH (80:20), flow rate= 
1 mL/min, T= 35°C, retention times: 6.9 min for ( S)-4.103 and 8.7 min for (R)- 4.103. 
Formula: C26H32O4 (408.53 g/mol) 
Rf (hexane/EtOAc 95/5): 0.26 
1H-NMR (500 MHz, CDCl3):  1.22 (s, 9H), 1.42 (s, 9H), 3.73 (d, J= 10.9Hz, 1H), 4.16 
(dd, J= 8.4, 10.9Hz, 1H), 6.34 (dd, J= 8.4, 15.8Hz, 1H), 6.45 (d, J= 15.8Hz, 1H), 
7.17-7.34 (m, 10H)  ppm. 
13C-NMR (125.7 MHz, CDCl3):  27.7 (CH3), 28.7 (CH3), 49.2 (CH), 59.4 (CH), 81.7 
(C), 81.9 (C), 126.4 (CH), 127.0 (CH), 127.5 (CH), 128.3 (CH), 128.6 (CH), 128.6 
(CH), 130.3 (CH), 131.3 (CH), 137.2 (C), 140.9 (C), 166.9 (C), 167.4 (C) ppm. 
Optical rotation: [ ]20
D
α = - 12.2 (c 1.0, CHCl3, 99% ee).  
Literature results: 1) [ ]25
D
α = - 9.3 (c 1.01, CHCl3, 80% ee, S)
15  
CHIRAL HPLC: Chiralcel AD-H column, solvent: n-hexane/EtOH (80:20), flow rate= 
1 mL/min, T= 35°C, retention times: 10.6 min for ( S)-4.104 and 15.4 min for (R)-
4.104. 
Ph Ph
CMe(COOMe)2
(S)-4.105
Formula: C21H22O4 (338.40 g/mol) 
Rf (hexane/EtOAc 90/10): 0.23 
1H-NMR (500 MHz, CDCl3):  1.49 (s, 3H), 3.63 (s, 3H), 3.71 (s, 3H), 4.31 (d, J= 
9.0Hz, 1H), 6.47 (d, J= 15.7Hz, 1H), 6.69 (dd, J= 9.0, 15.7Hz, 1H), 7.15-7.38 (m, 
10H)  ppm. 
13C-NMR (125.7 MHz, CDCl3):  18.8 (CH3), 52.6 (CH3), 52.6 (CH3), 54.0 (CH), 59.3 
(C), 125.4 (CH), 126.5 (CH), 127.4 (CH), 127.5 (CH), 128.4 (CH), 128.6 (CH), 129.2 
(CH), 129.6 (CH), 132.9 (CH), 137.4 (C), 139.4 (C), 171.4 (C), 171.7 (C) ppm. 
Optical rotation: [ ]20
D
α = + 61.9 (c 1.1, CH2Cl2, >99% ee).  
Literature results: 1) [ ]25
D
α = + 60.1 (c 1.20, CH2Cl2, 98% ee, S)
16  
CHIRAL NMR: The enantiomeric excess was determined by 1H NMR using Eu(hfc)3
as a resolving agent. The two signals at 3.63 (s) and 3.71 (s) are splitting up in the 
presence of Eu(hfc)3. To 11.3 mg of 4.105 in 0.7mL CDCl3 was added 18.5 mg 
Ph Ph
CH(COOt-Bu)2
(S)-4.104
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Eu(hfc)3. Integration of the signals was performed after applying a resolution 
enhancing Gaussian window function to the FID. 
Ph Ph
CH(COMe)2
(S)-4.106
Formula: C20H20O2 (292.37 g/mol) 
Rf (pentane/EtOAc 90/10): 0.26 
1H-NMR (500 MHz, CDCl3):  1.93 (s, 3H), 2.26 (s, 3H), 4.35 (m, 2H), 6.20 (ddd, J= 
2.0, 6.0, 15.0Hz, 1H), 6.44 (d, J= 15.0Hz, 1H), 7.18-7.37 (m, 10H) ppm. 
13C-NMR (125.7 MHz, CDCl3):  29.9 (CH3), 30.2 (CH3), 49.3 (CH), 74.6 (CH), 126.5 
(CH), 127.4 (CH), 127.8 (CH), 128.0 (CH), 128.7 (CH), 129.2 (CH), 129.4 (CH), 
131.8 (CH), 136.6 (C), 140.2 (C), 202.9 (C), 203.0 (C) ppm. 
Optical rotation: [ ]20
D
α = + 6.8 (c 1.0, EtOH, 94% ee).  
Literature results: 1) [ ]23
D
α = + 5.9 (c 1.30, EtOH, 93% ee, S)17  
CHIRAL HPLC: Chiralcel AD-H column, solvent: n-hexane/EtOH (99:1), flow rate= 1 
mL/min, T= 35°C, retention times: 21.1 min for ( S)-4.106 and 25.8 min for (R)- 4.106. 
CH(COOMe)2
(S)-4.108
Formula: C10H16O4 (200.23 g/mol) 
Rf (pentane/EtOAc 9/1): 0.51 
1H-NMR (500 MHz, CDCl3):  1.04 (d, J= 6.8Hz, 3H), 1.61 (dd, J= 1.5, 6.4Hz, 3H), 
2.88 (m, 1H), 3.25 (d, J= 9.1Hz, 1H), 3.68 (s, 3H), 3.71 (s, 3H), 5.33 (ddd, J= 1.5, 8.3, 
15.2Hz, 1H), 5.51 (dqd, J= 0.6, 6.4, 15.2Hz, 1H)  ppm. 
13C-NMR (125.7 MHz, CDCl3):  18.0 (CH3), 18.6 (CH3), 37.5 (CH), 52.3 (CH3), 52.5 
(CH3), 58.1 (CH), 126.5 (CH), 132.4 (CH), 169.0 (2x C) ppm. 
Optical rotation: [ ]20
D
α = - 25.1 (c 1.1, CHCl3, 83% ee).  
Literature results: 1) [ ]25
D
α = - 20.9 (c 1.26, CH2Cl2, 65% ee, S)
16  
CHIRAL NMR: The enantiomeric excess was determined by 1H NMR using (+)-
Eu(hfc)3 as a resolving agent. The signal at 1.04 (d) is splitting up in the presence of 
(+)-Eu(hfc)3. To 11.2 mg of 4.108 in 0.7mL CDCl3 was added 9.0 mg (+)-Eu(hfc)3.  
CH(COOMe)2
(R)-4.110
Formula: C11H16O4 (212.25 g/mol) 
Rf (pentane/EtOAc 90/10): 0.33 
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1H-NMR (500 MHz, CDCl3):  1.3-1.4 (m, 1H), 1.5-1.6 (m, 1H), 1.6-1.8 (m, 2H), 1.98 
(m, 2H), 2.90 (m, 1H), 3.28 (d, J= 9.5Hz, 1H), 3.71 (s, 3H), 3.72 (s, 3H), 5.51 (dd, J= 
2.0, 10.2Hz, 1H) 5.74-5.80 (m, 1H) ppm. 
13C-NMR (125.7 MHz, CDCl3):  21.0 (CH2), 25.0 (CH2), 26.7 (CH2), 35.5 (CH), 52.5 
(CH3), 57.0 (CH), 127.4 (CH), 129.8 (CH), 169.0 (C), 169.0 (C) ppm. 
Optical rotation: [ ]20
D
α = + 32.1 (c 0.91, CHCl3, 74% ee).  
Literature results: 1) [ ]25
D
α = + 32.1 (c 1.0, CH2Cl2, 64% ee, R)
18  
CHIRAL NMR: The enantiomeric excess was determined by 1H NMR using (+)-
Eu(hfc)3 as a resolving agent. The two signals at 3.71 (s) and 3.72 (s) are splitting up 
in the presence of (+)-Eu(hfc)3. To 13.4 mg of 4.110 in 0.7mL CDCl3 was added 16.6 
mg (+)-Eu(hfc)3. Integration of the signals was performed after applying a resolution 
enhancing Gaussian window function to the FID. 
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7 
NEDERLANDSE 
SAMENVATTING EN 
TOEKOMST-
PERSPECTIEVEN 
In dit werk worden twee belangrijke ligandklassen bestudeerd, nl. chirale dieen 
liganden en chirale imidaat liganden. Gemeenschappelijk aan beiden is dat hun 
gebruik in de asymmetrische katalyse tot voor kort verhinderd werd door hun 
veronderstelde instabiliteit. 
In 2003 beschreef Hayashi et al. voor het eerst het gebruik van chirale dieen 
liganden in asymmetrische katalyse. Hoewel de katalytische eigenschappen van 
deze liganden excellent waren, bleek dat de synthese ervan omslachtig was.1 In 
hoofdstuk 3, beschrijven we de ontwikkeling van een nieuwe syntheseroute voor 
deze chirale digesubstitueerde bicyclo[2.2.1]heptadienen (Scheme 7.1). Voordelen 
van deze benadering zijn enerzijds het hogere totaalrendement en anderzijds de 
mogelijkheid tot simultane introductie van de zijketens.2  
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O
O
TfO
OTf
1. KHMDS, THF, -78°C, 1u.
2. PhNTf2, -78°C, 3u.
55-60 %
R
R
O
O
O
O
O
OTf
O
O
R R
O
TfO
R
HOCH2CH2OH,
TsOH
97 %
1. LDA, THF
2. Tf2N py-2
70 %
RMgX, 
PdCl2(dppf)
97 %
2.0N HCl, THF
94 %
1. LDA, THF
2. Tf2N py-2
81 %
RMgX, 
PdCl2(dppf)
       45 %
RMgX, PdCl2(dppf)
33 - 77 %
Rendement bepaald voor R = Bn:
Hayashi:                       23 %
Onze methode:            44 %
3.7 3.45 3.10
3.8
3.9
Schema 7.1. Vergelijking van onze nieuwe methode voor de synthese van chirale 
bicyclo[2.2.1]heptadieen liganden  met de oorspronkelijke methode van Hayashi.
Via deze methode synthetiseerden we het Hayashi ligand met de benzyl zijketen en 
drie nieuwe liganden (met R= i-Bu, c-Hex and Allyl). Een NMR studie van het 
rhodium complex van (S,S)-allyl-nbd* toonde aan dat de coördinatie met het metaal 
enkel gebeurde via de norbornadieen dubbele bindingen. Dit staat in contrast met de 
bevindingen van Carreira.3
De gesynthetiseerde dieen liganden werden getest in verschillende rhodium-
gekatalyseerde asymmetrische testreacties. Er werden heel goede 
enantioselectiviteiten (tot 96% ee) behaald in de rhodium(I)-gekatalyseerde 1,4-
additie van fenylboronzuren aan cyclische enonen (schema 7.2). Een toename in 
sterische hinder van de ligand substituenten leidde niet tot een significant verschil in 
selectiviteit. De reactiesnelheid werd daarentegen wel sterk beïnvloed. 
O
+   PhB(OH)2
dioxaan/1.5 M aq H2O 
(10:1)
[RhOH(C2H4)2]2
(3mol % Rh)
n
(2 equiv)
O
n
Ph
(S)-3.71a-b3.70a-b
n=1 (a), 0 (b)
82-96% ee
44-95% rendement
R
R
Scheme 7.2. Rhodium(I)-gekatalyseerde asymmetrische 1,4-additie van PhB(OH)2
aan cyclische enonen.
In de 1,4-additie van fenylboronzuren aan -acetamido acrylester 3.72 werd ook de 
vorming van een Heck-type product 3.77 geobserveerd. Bovendien kon de 
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verhouding van het conjugaat adduct 3.73 en het Heck product 3.77 beïnvloed 
worden door een geschikte keuze van het ligand in de achiral versie (Schema 7.3). In 
de asymmetrische versie van dit type reactie met ligand 3.10 werden lage 
rendementen en enantioselectiviteiten bekomen. 
CO2Me
NHAc +   PhB(OH)2
      (4 equiv)
CO2Me
NHAcPh
*
NaF (3 equiv)
dioxaan/H2O (10:1)
+
CO2Me
NHAcPh
3.72 3.73 3.77
[Rh]
[Rh(COD)Cl]2: 82% 18%
Rh(acac)(etheen)2: 21% 79%
Schema 7.3. Rhodium(I)-gekatalyseerde 1,4-additie versus Heck reactie.
Als laatste bestudeerden we de rhodium-gekatalyseerde 1,2-additie van 
fenylboronzuren aan benzaldehyden. Deze reactie kan beschouwd worden als een 
grote uitdaging. De aanwezigheid van alkyl zijketens in het ligand bleek een cruciale 
rol te spelen voor de katalytische activiteit. Dit resulteerde in een sterk verhoogde 
reactiviteit ten opzichte van het ongesubstitueerde norbornadieen als ligand. 
Enantioselectiviteiten konden verhoogd worden van laag tot middelmatig met ligand 
3.56 (tot 48% ee) (Schema 7.4). 
3.89
F3C
O
H
B
OHHO
+
[Rh(C2H4)2Cl]2
(3 mol % Rh)
F3C
OH
(2 equiv)
solvent, additief
(R)- 3.90
3.56
tot 99% rendement
tot 48% ee
Schema 7.4. Rhodium(I)-gekatalyseerde asymmetrische 1,2-additie van PhB(OH)2
aan p-trifluoromethylbenzaldehyd.
In hoofdstuk 4 beschrijven we de ontwikkeling van chirale imidaten als een nieuwe 
ligand familie. Imidaten werden nooit eerder als liganden beschreven in de literatuur. 
Dit is waarschijnlijk te wijten aan hun vermeende instabiliteit. 
Een belangrijke factor die de bruikbaarheid van een ligand bepaalt voor 
asymmetrische synthese is het gemak waarmee het gesynthetiseerd kan worden. 
We hebben aangetoond dat deze imidaat liganden vlot gesynthetiseerd kunnen 
worden startende van een centrale precursor.4 Bovendien kunnen deze imidaat 
liganden verder geoptimaliseerd worden door het plaatsen van substituenten op de 
aromatische ring van de imidaat ligand precursor (Schema 7.5). 
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O
NH
.HClO
N R*
R*-NH2
ONO N
NH2H2N
R1
R2
R3
R4
R3
R2
R1
R4
R4
R3 R2
R1 R1
R2 R3
R4
*
*
Schema 7.5. Synthese van een imidaat ligand familie.  
De gesynthetiseerde monodentaat en bidentaat liganden werden getest in 
verschillende asymmetrische testreacties (Schema 7.6). In de koper(I)-
gekatalyseerde asymmetrische aziridinering behaalden we meestal hoge 
rendementen (tot 90% rendement) en middelmatige enantioselectiviteiten (51% ee) 
met ligand 4.39. De asymmetrische additie van diethylzink aan benzaldehyd 
resulteerde in hoge rendementen (tot 87% rendement) en goede 
enantioselectiviteiten (tot 76% ee) met ligand 4.40. Het beste resultaat werd echter 
behaald met ligand 4.40 in de asymmetrische allylische alkylatie: een middelmatig 
rendement (53% rendement) maar een excellente enantioselectiviteit (95% ee).  
CO2Me Cu(MeCN)4PF6 / 4.39
PhINTs
CO2Me
N
Ts
4.70 4.75
tot 90% rendement
tot 51% ee
H
O
+ Et2Zn
OH
*
4.40
tolueen, KT
4.91 4.92
tot 87% rendement
tot 76% ee
Ph Ph
OAc
Ph Ph
CH(COOMe)2
CH2(COOMe)2/BSA
BSA activator
CH2Cl2, KT, 16u
[Pd(pi−C3H5)Cl]2 /
4.40
4.101 4.102
*
NN
N
O O
4.39
N
O
O
4.40
53% rendement
95% ee
Schema 7.6. Toepassing van bisimidaat liganden in asymmetrische aziridineringen, 
asymmetrische diethylzink addities en asymmetrische allylische alkyleringen.
Verder hebben we ook gemengde imidaat-fosfaan liganden ontwikkeld als een nieuw 
type P,N liganden. Deze liganden zijn eenvoudig te synthetiseren in één stap via een 
Chapter 7. Nederlandse samenvatting en toekomstperspectieven 
196
condensatie van een commercieel verkrijgbaar aminofosfaan en een imidaat ligand 
precursor. De liganden bleken heel waardevol te zijn in palladium-gekatalyseerde 
allylische substitutie reacties (Schema 7.7). Schitterende resultaten werden behaald 
met dit katalysator systeem in de allylische alkylering van  1,3-difenyl-2-propenyl 
acetaat met verschillende nucleofielen (tot 99% rendement en 99% ee). Dit 
katalysatorsysteem bleek ook goede resultaten te geven in de allylische alkylatie van 
lineaire ongehinderde en cyclische substraten. Zelden zijn enantioselectieve 
katalysatoren succesvol in beide substraatklassen. Om deze reden kan deze imidaat-
fosfaan familie concurreren met enkele andere liganden die ook hoge selectiviteiten 
geven voor zowel gehinderde als ongehinderde substraten (Tabel 7.1).  
R R
OAc
+
[Pd(pi−C3H5)Cl]2 /
Ligand 4.55b
BSA / BSA activator
CH2Cl2, KT, 16u
R R
Nu
Fe
PPh2 N O
4.55b
Cl
Nu-HOAc Nu
tot 99% rendement
tot 99% ee
Schema 7.7. Pd-gekatalyseerde asymmetrische allylische alkylatie met een 
gemengd imidaat-fosfaan ligand 4.55b. 
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Entry Ligand Ph Ph
CH(COOMe)2
4.98
CH(COOMe)2
4.99
CH(COOMe)2
4.100
Referentie 
1 
Fe
PPh2N O
4.55b
Cl
99% rendement 
99% ee 
76% rendement 
74% ee 
91% rendement 
83% ee 
5 
2 
S
OPAr2
CMe3
28% rendement 
91% ee 
94% rendement 
91% ee 
- 6 
3a 
Ph
H
N
OPh
P
P
O
O
O
O
100% omzetting 
96% ee 
- 
81% ee 
- 
82% ee 
7 
4a 
OOO
N O
R
O
PO
O
Ph
100% omzetting 
92% ee 
100% omzetting 
75% ee 
- 
81% ee 
8 
5a O N
O
R
PO
O
100% omzetting 
>99% ee 
100% omzetting  
91% ee 
100% omzetting 
73% ee 
9 
a  
      
O
O
t-Bu
t-Bu
t-Bu
t-Bu
O
O =
Tabel 7.1. Vergelijking van het gemengd imidaat-fosfaan ligand (4.55b) met de beste 
resultaten uit de literatuur.  
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Het cyclisch imidaat ligand precursor kon ook efficient gebruikt worden als een 
bouwsteen voor de synthese van chirale oxazoline alcohol liganden en de synthese 
van chirale imidazolidines (Schema 7.8). De chirale oxazoline alcohol liganden 
werden getest in asymmetrische diethylzink addities aan benzaldehydes.10
Enantioselectiviteiten tot 87% ee werden behaald.  
OHH2N
R1 R2
* *
O
NH
OH
N
O
R1
R2
*
*NH2H2N
HN NH
O
Schema 7.8. Synthetische toepassingen van cyclische imidaat esters. 
We hebben in dit doctoraat aangetoond dat zowel chirale dieen liganden als chirale 
imidaat liganden zeer interessante liganden kunnen zijn voor asymmetrische 
katalyse. 
Zowel wij als andere groepen hebben aangetoond dat chirale dieen liganden meer 
zijn dan enkel een princiepsbewijs. Sinds 2003 is een indrukwekkend aantal 
publicaties verschenen die hun uitzonderlijke katalytische eigenschappen 
aantonen.11 Het is echter opmerkelijk dat bijna alle voorbeelden rhodium- en iridium-
gekatalyseerde asymmetrische reacties betreffen. Het zou bijgevolgd interessant zijn 
om verder onderzoek te wijten aan de zoektocht naar nieuwe metalen die compatibel 
zijn met deze dieen liganden. Dit zou de bruikbaarheid van deze dieen ligand familie 
aanzienlijk verruimen. 
Ondanks het feit dat het gebruik van chirale imidaat liganden tot voor kort 
onbestaande was, hebben wij in dit doctoraat aangetoond dat zij zeer interessant 
kunnen zijn in de toekomst. De eenvoudige synthese van dit ligandtype is 
opmerkelijk. Dit kenmerk kan het gebruik van imidaten als liganden in de toekomst 
sterk versnellen. In de toekomst zou het interessant zijn om nieuwe applicaties voor 
deze imidaat liganden te ontwikkelen. Zeker de gemengde imidaat-fosfaan liganden 
hebben heel wat potentieel en zouden in de toekomst verder gevaloriseerd moeten 
worden in verschillende testreacties. 
Daarnaast toonden we aan dat het mogelijk is om de katalytische eigenschappen 
van het imidaat ligand aan te passen door substituenten te plaatsen op de 
aromatische ring van het imidaat ligand precursor. Dit aspect is uiterst belangrijk 
aangezien het de mogelijkheid biedt om de imidaat katalysator verder te 
optimaliseren voor een specifieke applicatie. 
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